

CUMULATIVE
SUPPLEMENT 8
AUGUST 2002



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Department of Health and Human Services

Food and Drug Administration

Center for Drug Evaluation and Research

Office of Generic Drugs

2002

RM
301.45
.A66
2002
Aug.
suppl.

Ebsco
Subscription

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

Library Use Only

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

22ND EDITION

CUMULATIVE SUPPLEMENT 8
August 2002

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 22nd Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 22nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 23rd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
DANBURY PHARMACEUTICALS INC (DANBURY PHARMA)	WATSON LABORATORIES INC (WATSON LABS)
DURAMED PHARMACEUTICALS INC (DURAMED)	DURAMED PHARMACEUTICALS INC SUB OF BARR LABORATORIES INC (DURAMED PHARM BARR)
DERMIK LABORATORIES INC (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	DERMIK LABORATORIES DIVISION OF AVENTIS PHARMACEUTICALS INC (DERMIK LABS)
JANSSEN RESEARCH FDN (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JANSSEN RESEARCH FDN DIV JOHNSON AND JOHNSON (JANSSEN)	JANSSEN PHARMACEUTICA PRODUCTS LP (JANSSEN PHARMA)
JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT LLC (JOHNSON AND JOHNSON)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)	ORTHO MCNEIL PHARMACEUTICAL INC (ORTHO MCNEIL PHARM)
MCNEIL CONSUMER HEALTHCARE DIVISION (MCNEIL CONS)	MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS DIVISION MCNEIL PPC (MCNEIL CONS SPECLT)
MOVA PHARMACEUTICALS CORPORATION (MOVA)	CLONMEL HEALTHCARE LTD (CLONMEL HLTH)
PARKE DAVIS PHARMACEUTICALS LTD (PARKE DAVIS PHARMS)	PFIZER PHARMACEUTICALS LTD (PFIZER PHARM LTD)
THAMES PHARMACAL COMPANY INC (THAMES)	TARO PHARMACEUTICALS NORTH AMERICA INC (TARO PHARMS US)
WHITEHALL LABORATORIES INC DIV AMERICAN HOME PRODUCTS CORP (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)
WHITEHALL ROBINS HEALTHCARE (WHITEHALL LABS)	WYETH CONSUMER HEALTHCARE (WYETH CONS)

1.3 WAIVED EXCLUSIVITY

Waived exclusivity - If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.

However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity

1.4 AVAILABILITY OF THE EDITION

The 22nd Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is \$105.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the hard copy monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 22nd annual edition of the 2001 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/22bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:

<http://www.fda.gov/cder/orange/patdecl.pdf>

<http://www.fda.gov/cder/orange/patdecl.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2001) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2001</u>	<u>MAR 2002</u>	<u>JUN 2002</u>	<u>SEP 2002</u>
DRUG PRODUCTS LISTED	10166	10357	10193	
SINGLE SOURCE	2665 (26.2%)	2645 (25.5%)	2400 (23.5%)	
MULTISOURCE	7391 (72.7%)	7602 (73.4%)	7687 (75.4%)	
THERAPEUTICALLY EQUIVALENT	7105 (69.9%)	7309 (70.6%)	7402 (72.6%)	
NOT THERAPEUTICALLY EQUIVALENT	286 (2.8%)	293 (2.8%)	285 (2.8%)	
EXCEPTIONS ¹	110 (1.1%)	110 (1.1%)	106 (1.0%)	
NEW MOLECULAR ENTITIES APPROVED	10	1	5	
NUMBER OF APPLICANTS	574	574	574	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

PRESCRIPTION DRUG PRODUCT LIST - 22ND EDITION
RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - AUG 2002

1-1

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL				
SECTRAL				
AB ESP PHARMA	EQ 200MG BASE	N18917 001	DEC 28, 1984	JUL CAHN
AB +	EQ 400MG BASE	N18917 003	DEC 28, 1984	JUL CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL				
ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE				
AB VINTAGE PHARMS	325MG;50MG;40MG;30MG	N75929 001	APR 22, 2002	APR NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL				
PHENAPHEN W/ CODEINE NO. 2				
@ ROBINS AH	325MG;15MG	N84444 001		MAY DISC
SOLUTION; ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
AA + ALPHARMA	120MG/5ML;12MG/5ML	N85861 001		MAY CRLD
TYLENOL W/ CODEINE				
@ JOHNSON RW	120MG/5ML;12MG/5ML	N85057 001		MAY DISC
TABLET; ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
>A> AA ABLE	300MG;30MG	N40452 001	AUG 01, 2002	AUG NEWA
>A> AA	300MG;60MG	N40459 001	AUG 01, 2002	AUG NEWA
@ PUREPAC PHARM	300MG;60MG	N86683 001		MAY DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
AA KV PHARM	500MG/15ML;7.5MG/15ML	N40366 001	JAN 23, 2002	JAN NEWA
TABLET; ORAL				
AA + MALLINCKRODT	660MG;10MG	N40084 003	JUL 29, 1996	JUL CTNA
AA UCB	500MG;10MG	N40210 001	AUG 13, 1997	JUN CAHN
+ NORCO				
AA + WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	MAY CTNA

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL				
ACETAMINOPHEN AND PENTAZOCINE HCL				
>A> AB AMIDE PHARM	650MG;EQ 25MG BASE	N76202 001	AUG 02, 2002	AUG NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL				
DARVOCET				
@ AAIPHARMA LLC	325MG;32.5MG	N16844 001		JUN CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL				
DARVOCET-N 100				
AB + AAIPHARMA LLC	650MG;100MG	N17122 002		JUN CAHN
DARVOCET-N 50				
AB AAIPHARMA LLC	325MG;50MG	N17122 001		JUN CAHN

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

AB	NEOSAN PHARMS	400MG	N74946 001	NOV 19, 1997	JUL	CAHN
AB		800MG	N74946 002	NOV 19, 1997	JUL	CAHN

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

@ ISO TEX 100uCi/VIAL

N17835 001

JUN DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

@ MALLINCKRODT	6.67uCi/ML	N17844 003	JUN	DISC
@	100uCi/ML	N17844 002	JUN	DISC

ALBUTEROL

AEROSOL, METERED; INHALATION

PROVENTIL

BN + SCHERING	0.09MG/INH	N17559 001	JUN	CRDL
---------------	------------	------------	-----	------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROVENTIL-HFA

BX + 3M	EQ 0.09MG BASE/INH	N20503 001	AUG 15, 1996	MAR	CTEC
---------	--------------------	------------	--------------	-----	------

BX + VENTOLIN HFA	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	MAR	CTEC
-------------------	--------------------	------------	--------------	-----	------

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

AP + GD SEARLE LLC	EQ 0.5MG BASE/ML	N19353 001	DEC 29, 1986	JUL	CAHN
--------------------	------------------	------------	--------------	-----	------

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME	10 UNITS/ML	N20057 004	MAY 08, 1992	JUN	DISC
-----------	-------------	------------	--------------	-----	------

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALOPRIM

+ DSM PHARMS	EQ 500MG BASE/VIAL	N20298 001	MAY 17, 1996	JUN	CAHN
--------------	--------------------	------------	--------------	-----	------

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN;DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATESODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION

>D> MULTI-12

>D> + SABEX 2002

2 IU/ML; 20MG/ML; 12UGM/ML; 40
 IU/ML; 1UGM/ML; 3MG/ML; 80UGM/ML; 8MG/M
 L; 0.8MG/ML; 0.72MG/ML; 0.6MG/ML; 600
 IU/ML

N21163 001 MAY 18, 2000 AUG CTNA

>A> INFUVITE ADULT
 >A> + SABEX 2002 2 IU/ML;20MG/ML;12UGM/ML;40
 IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/M
 L;0.8MG/ML;0.72MG/ML;0.6MG/ML;600
 IU/ML N21163 001 MAY 18, 2000 AUG CTNA
 MULTI-12
 + SABEX 2002 2 IU/ML;20MG/ML;12UGM/ML;40
 IU/ML;1UGM/ML;3MG/ML;80UGM/ML;8MG/M
 L;0.8MG/ML;0.72MG/ML;0.6MG/ML;600
 IU/ML N21163 001 MAY 18, 2000 APR CAHN

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PHARMACIA AND UPJOHN 0.01MG/VIAL
0.02MG/VIALN21212 001 JUN 11, 2002 JUN NEWA
N21212 002 JUN 11, 2002 JUN NEWAAMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

@ MEDIMMUNE ONCOLOGY 375MG/VIAL

N20221 002 SEP 10, 1999 JUN DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN 7%

@ ABBOTT 7% (7GM/100ML)

N17673 002 JUN DISC

AMINOSYN 8.5%

@ ABBOTT 8.5% (8.5GM/100ML)

N17673 004 JUN DISC

AMINOSYN II 3.5%

@ ABBOTT 3.5% (3.5GM/100ML)

N19438 001 APR 03, 1986 JUN DISC

BRANCHAMIN 4%

@ BAXTER HLTHCARE 4% (4GM/100ML)

N18678 001 SEP 28, 1984 JUN DISC

AMLEXANOX

PASTE; DENTAL

APHTHASOL

+ GLAXOSMITHKLINE CONS 5%

N20511 001 DEC 17, 1996 JUL CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

>D> + NOVARTIS EQ 5MG BASE;20MG N20364 004 MAR 03, 1995 AUG CRLD
 >A> + EQ 5MG BASE;20MG N20364 004 MAR 03, 1995 AUG CRLD
 >A> + EQ 10MG BASE;20MG N20364 005 JUN 20, 2002 AUG NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB CLAY PARK EQ 12% BASE N75774 001 MAY 01, 2002 MAY NEWA

LAC-HYDRIN

AB + WESTWOOD SQUIBB EQ 12% BASE N20508 001 AUG 29, 1996 MAY CFTG

LOTION; TOPICAL

AMMONIUM LACTATE

AB PADDOK EQ 12% BASE N75575 001 JUN 11, 2002 JUN NEWA

AMMONIUM LACTATE

LOTION; TOPICAL
LAC-HYDRIN

AB + WESTWOOD SQUIBB EQ 12% BASE

N19155 001 APR 24, 1985 JUN CFTG

AMOXICILLIN

TABLET, CHEWABLE; ORAL

AMOXICILLIN

@ APOTHECON 125MG
@ 250MG

N64131 001 MAY 06, 1996 JUL DISC
N64131 002 MAY 06, 1996 JUL DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB GENEVA PHARMS 200MG/5ML;EQ 28.5MG BASE/5ML
AB 400MG/5ML;EQ 57MG BASE/5ML

N65066 001 JUN 05, 2002 JUN NEWA
N65066 002 JUN 05, 2002 JUN NEWA

AUGMENTIN '200'
AB GLAXOSMITHKLINE 200MG/5ML;EQ 28.5MG BASE/5ML
AUGMENTIN '400'

N50725 001 MAY 31, 1996 JUN CFTG
N50725 002 MAY 31, 1996 FEB CRLD

AB GLAXOSMITHKLINE 400MG/5ML;EQ 57MG BASE/5ML
400MG/5ML;EQ 57MG BASE/5ML

N50725 002 MAY 31, 1996 JUN CFTG
N50725 002 MAY 31, 1996 JUN CFTG

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB GENEVA PHARMS 500MG;EQ 125MG BASE
AB 875MG;EQ 125MG BASE

N65064 001 MAR 15, 2002 MAR NEWA
N65063 001 MAR 14, 2002 MAR NEWA

AUGMENTIN '500'
AB GLAXOSMITHKLINE 500MG;EQ 125MG BASE
AUGMENTIN '875'

N50564 002 AUG 06, 1984 MAR CFTG
N50720 001 FEB 13, 1996 MAR CFTG

AB + GLAXOSMITHKLINE 875MG;EQ 125MG BASE
TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB GENEVA PHARMS 200MG;EQ 28.5MG BASE
AB 400MG;EQ 57MG BASE

N65065 001 APR 18, 2002 APR NEWA
N65065 002 APR 18, 2002 APR NEWA

AUGMENTIN '200'
AB GLAXOSMITHKLINE 200MG;EQ 28.5MG BASE
AUGMENTIN '400'

N50726 001 MAY 31, 1996 APR CFTG
N50726 002 MAY 31, 1996 APR CFTG

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE;
DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

>D> SHIRE LABS 2.5MG;2.5MG;2.5MG;2.5MG

N21303 001 OCT 11, 2001 AUG CAHN

>A> SHIRE PHARM 2.5MG;2.5MG;2.5MG;2.5MG

N21303 001 OCT 11, 2001 AUG CAHN

ADDERALL XR 15

>D> SHIRE LABS 3.75MG;3.75MG;3.75MG;3.75MG
3.75MG;3.75MG;3.75MG;3.75MG

N21303 006 MAY 22, 2002 AUG CAHN
N21303 006 MAY 22, 2002 JUN NEWA

>A> SHIRE PHARM 3.75MG;3.75MG;3.75MG;3.75MG

N21303 006 MAY 22, 2002 AUG CAHN

ADDERALL XR 20

>D> SHIRE LABS 5MG;5MG;5MG;5MG
5MG;5MG;5MG;5MG

N21303 002 OCT 11, 2001 AUG CAHN
N21303 002 OCT 11, 2001 AUG CAHN

ADDERALL XR 25

>D> SHIRE LABS 6.25MG;6.25MG;6.25MG;6.25MG

N21303 004 MAY 22, 2002 AUG CAHN

>A>	SHIRE PHARM ADDERALL XR 30	6.25MG;6.25MG;6.25MG;6.25MG 6.25MG;6.25MG;6.25MG;6.25MG	N21303 004 MAY 22, 2002 JUN NEWA N21303 004 MAY 22, 2002 AUG CAHN
>D>	+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003 OCT 11, 2001 AUG CAHN
>A>	+ SHIRE PHARM ADDERALL XR 5	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003 OCT 11, 2001 AUG CAHN
>D>	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG 1.25MG;1.25MG;1.25MG;1.25MG	N21303 005 MAY 22, 2002 AUG CAHN N21303 005 MAY 22, 2002 JUN NEWA
>A>	SHIRE PHARM TABLET; ORAL ADDERALL 10	1.25MG;1.25MG;1.25MG;1.25MG	N21303 005 MAY 22, 2002 AUG CAHN
AB	SHIRE LABS ADDERALL 20	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007 FEB 13, 1996 FEB CFTG
AB	SHIRE LABS ADDERALL 30	5MG;5MG;5MG;5MG	N11522 008 FEB 13, 1996 FEB CFTG
AB	+ SHIRE LABS ADDERALL 5	7.5MG;7.5MG;7.5MG;7.5MG	N11522 010 MAY 12, 1997 FEB CFTG
AB	SHIRE LABS	1.25MG;1.25MG;1.25MG;1.25MG	N11522 009 MAY 12, 1997 FEB CFTG
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE		
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	N40422 001 FEB 11, 2002 FEB NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40422 002 FEB 11, 2002 FEB NEWA
AB		5MG;5MG;5MG;5MG	N40422 003 FEB 11, 2002 FEB NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40422 004 FEB 11, 2002 FEB NEWA
AB	COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	N40444 001 JUN 19, 2002 JUN NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	N40444 002 JUN 19, 2002 JUN NEWA
AB		5MG;5MG;5MG;5MG	N40444 003 JUN 19, 2002 JUN NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40444 004 JUN 19, 2002 JUN NEWA
AB	EON	2.5MG;2.5MG;2.5MG;2.5MG	N40439 001 JUN 14, 2002 JUN NEWA
AB		5MG;5MG;5MG;5MG	N40439 002 JUN 14, 2002 JUN NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	N40439 003 JUN 14, 2002 JUN NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+ ELAN PHARMS

5MG/ML

N50724 001 NOV 20, 1995 JAN CAHN

SUSPENSION; ORAL

FUNGIZONE

@ BRISTOL MYERS SQUIBB

100MG/ML

N50341 003 JUN DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP ESI LEDERLE

EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL

N65074 001 MAR 19, 2002 MAR NEWA

AP

EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

N65074 002 MAR 19, 2002 MAR NEWA

AP

EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL

N65076 001 MAR 19, 2002 MAR NEWA

UNASYN

AP + PFIZER

EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL

N50608 002 DEC 31, 1986 MAR CFTG

AP +

EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL

N50608 001 DEC 31, 1986 MAR CFTG

AP +

EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL

N50608 005 DEC 10, 1993 MAR CFTG

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

@ GLAXOSMITHKLINE

50MG

N21007 001 APR 15, 1999 MAY DISC

@

150MG

N21007 002 APR 15, 1999 MAY DISC

SOLUTION; ORAL

@ GLAXOSMITHKLINE

15MG/ML

N21039 001 APR 15, 1999 MAY DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SABEX 2002

80MG/VIAL;0.02MG/VIAL;400

IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14M

G/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIA

L;1.2MG/VIAL;7 IU/VIAL;2,300

IU/VIAL;0.2MG/VIAL

N21265 001 FEB 21, 2001 APR CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ AAIPHARMA

80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;

5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17

MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/V

IAL;EQ 1.2MG

BASE/VIAL;0.7MG/VIAL;7MG/VIAL

N18920 001 SEP 21, 2000 JUL CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

AP + AAIPHARMA

10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/

ML;20

IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.3

6MG/ML;0.3MG/ML;330 UNITS/ML;1

IU/ML

N08809 004 AUG 08, 1985 JUL CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON COMPOUND

+ AAIPHARMA LLC

389MG;32.4MG;32MG

N10996 006 MAR 08, 1983 JUN CAHN

DARVON COMPOUND-65

AA + AAIPHARMA LLC

389MG;32.4MG;65MG

N10996 007 MAR 08, 1983 JUN CAHN

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

@ SANOFI SYNTHELABO

325MG;EQ 12.5MG BASE

N16891 001

JUN DISC

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
 DARVON W/ ASA
 + AAIPHARMA LLC 325MG;65MG N10996 005 JUN CAHN

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL
 DARVON-N W/ ASA
 @ AAIPHARMA LLC 325MG;100MG N16829 001 JUN CAHN
 TABLET; ORAL
 @ AAIPHARMA LLC 325MG;100MG N16863 001 JUN CAHN

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR
 ATNAA
 + @ US ARMY 2.1MG/0.7ML;600MG/2ML N21175 001 JAN 17, 2002 JAN NEWA
 @ 2.1MG/0.7ML;600MG/2ML N21175 001 JAN 17, 2002 FEB NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
 OPTIVAR
 + MURO 0.05% N21127 001 MAY 22, 2000 MAY CAHN

AZITHROMYCIN DIHYDRATE

TABLET; ORAL
 ZITHROMAX
 + PFIZER EQ 500MG BASE N50784 001 MAY 24, 2002 MAY NEWA

AZTREONAM

INJECTABLE; INJECTION
 AZACTAM
 @ BRISTOL MYERS SQUIBB 500MG/VIAL N50580 001 DEC 31, 1986 JUN DISC
 @ 1GM/VIAL N50580 002 DEC 31, 1986 JUN DISC
 @ 2GM/VIAL N50580 003 DEC 31, 1986 JUN DISC

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
 BACITRACIN ZINC AND POLYMYXIN B SULFATE
 AT ALTANA 500 UNITS/GM;10,000 UNITS/GM N65022 001 FEB 27, 2002 FEB NEWA

BENDROFLUMETHIAZIDE

TABLET; ORAL
 NATURETIN-10
 @ APOTHECON 10MG N12164 003 JUN DISC
 NATURETIN-5
 + APOTHECON 5MG N12164 002 JUN CRLD

BENZONATATE

CAPSULE; ORAL
 TESSALON
 + FOREST LABS 200MG N11210 003 JUN 25, 1999 MAR NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
 >A> DUAC
 >A> + STIEFEL 5%;EQ 1% BASE

N50741 001 AUG 26, 2002 AUG NEWA

BENZTROPINE MESYLATE

TABLET; ORAL
 BENZTROPINE MESYLATE

AA	COREPHARMA	0.5MG	N72264 001	FEB 27, 1989	MAY	CAHN
AA		1MG	N72265 001	FEB 27, 1989	MAY	CAHN
AA		2MG	N72266 001	FEB 27, 1989	MAY	CAHN
>D>	AA PAR PHARM	0.5MG	N88877 001	APR 11, 1985	AUG	CRLD
>A>	AA +	0.5MG	N88877 001	APR 11, 1985	AUG	CRLD
>D>	AA	1MG	N88894 001	APR 11, 1985	AUG	CRLD
>A>	AA +	1MG	N88894 001	APR 11, 1985	AUG	CRLD
>D>	AA	2MG	N88895 001	APR 11, 1985	AUG	CRLD
>A>	AA +	2MG	N88895 001	APR 11, 1985	AUG	CRLD
COGETINTIN						
>D>	AA + MERCK	0.5MG	N09193 004		AUG	DISC
>A>	@	0.5MG	N09193 004		AUG	DISC
>D>	@	1MG	N09193 003		AUG	DISC
>A>	@	1MG	N09193 003		AUG	DISC
>D>	AA +	2MG	N09193 002		AUG	DISC
>A>	@	2MG	N09193 002		AUG	DISC

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
 PRE-PEN
 + SCHWARZ PHARMA 60UMOLAR

N50114 001 JUL CAHN

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL
 BETAMETHASONE DIPROPIONATE

>D>	AB FOUGERA	EQ 0.05% BASE	N19141 001	SEP 04, 1984	AUG	CRLD
>A>	AB +	EQ 0.05% BASE	N19141 001	SEP 04, 1984	AUG	CRLD
DIPROSONE						
>D>	AB + SCHERING	EQ 0.05% BASE	N17691 001		AUG	DISC
>A>	@	EQ 0.05% BASE	N17691 001		AUG	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A>	AB ALPHARMA US PHARM	EQ 0.05% BASE;1%	N76002 001	AUG 02, 2002	AUG	NEWA
-----	----------------------	------------------	------------	--------------	-----	------

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL
 KERLEDEX

@ LOREX	5MG;12.5MG	N19807 001	OCT 30, 1992	JUN	DISC
@	10MG;12.5MG	N19807 002	OCT 30, 1992	JUN	DISC

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

@ ALCON

EQ 0.25% BASE; 1.75%

N20619 001 APR 17, 1997 JUN DISC

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

@ ABBOTT

5MG/ML

N12418 002

JUN DISC

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

@ SANOFI SYNTHELABO

0.37MG/INH

N18770 001 DEC 28, 1984 JUN DISC

SOLUTION; INHALATION

@ SANOFI SYNTHELABO

0.2%

N19548 001 FEB 19, 1992 JUN DISC

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

>D> + ALLERGAN

0.2%

N20613 001 SEP 06, 1996 AUG DISC

>A>

0.2%

N20613 001 SEP 06, 1996 AUG DISC

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB LEK SVCS

EQ 2.5MG BASE

N74631 001 JAN 13, 1998 JAN CMFD

PARLODEL

AB + NOVARTIS

EQ 2.5MG BASE

N17962 001

JAN CFTG

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

BROMANYL

@ ALPHARMA

12.5MG/5ML; 10MG/5ML

N88343 001 AUG 15, 1984 MAY DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL KIT

@ ABBOTT

0.075%

N19978 001 SEP 03, 1992 JUN DISC

@

0.114%

N19978 002 SEP 03, 1992 JUN DISC

@

0.23%

N19978 003 SEP 03, 1992 JUN DISC

BUPIVACINE HCL PRESERVATIVE FREE

AP INTL MEDICATED

0.25%

N76012 001 JAN 09, 2002 JAN NEWA

AP

0.5%

N76012 002 JAN 09, 2002 JAN NEWA

AP

0.75%

N76012 003 JAN 09, 2002 JAN NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN SR

GLAXOSMITHKLINE

150MG

N20358 003 OCT 04, 1996 JUL CRLD

+

200MG

N20358 004 JUN 14, 2002 JUL NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL					
BUSPAR					
@ BRISTOL MYERS SQUIBB	5MG	N21190 001	DEC 20, 2000	JUN	DISC
@	7.5MG	N21190 002	DEC 20, 2000	JUN	DISC
@	10MG	N21190 003	DEC 20, 2000	JUN	DISC
@	15MG	N21190 004	DEC 20, 2000	JUN	DISC
TABLET; ORAL					
BUSPIRONE HCL					
AB EGIS	5MG	N75119 001	MAR 14, 2002	MAR	NEWA
AB	10MG	N75119 002	MAR 14, 2002	MAR	NEWA
AB GENEVA PHARMS	5MG	N75413 001	MAR 19, 2002	MAR	NEWA
AB	10MG	N75413 002	MAR 19, 2002	MAR	NEWA
AB	15MG	N75413 003	MAR 19, 2002	MAR	NEWA
AB KV PHARM	5MG	N75572 001	FEB 27, 2002	FEB	NEWA
AB	10MG	N75572 002	FEB 27, 2002	FEB	NEWA
AB	15MG	N75572 003	FEB 27, 2002	FEB	NEWA
AB MYLAN	5MG	N75272 001	MAR 01, 2002	MAR	NEWA
AB	10MG	N75272 002	MAR 01, 2002	MAR	NEWA
AB	30MG	N76008 001	JUN 28, 2001	MAY	CAHN
AB PAR PHARM	5MG	N75467 001	FEB 28, 2002	FEB	NEWA
AB	10MG	N75467 003	FEB 28, 2002	FEB	NEWA
AB	15MG	N75467 004	FEB 28, 2002	FEB	NEWA
AB PHARMEX PRODS	5MG	N75388 001	MAY 09, 2002	MAY	NEWA
AB	10MG	N75388 002	MAY 09, 2002	MAY	NEWA
AB	15MG	N75388 003	MAY 09, 2002	MAY	NEWA
AB TEVA	5MG	N75022 001	FEB 28, 2002	FEB	NEWA
AB	10MG	N75022 002	FEB 28, 2002	FEB	NEWA
AB	15MG	N75022 003	FEB 28, 2002	FEB	NEWA
AB TORPHARM	5MG	N75521 001	APR 05, 2002	APR	NEWA
AB	10MG	N75521 002	APR 05, 2002	APR	NEWA
AB	15MG	N75521 003	APR 05, 2002	APR	NEWA
AB ZENITH GOLDLINE	5MG	N75385 001	MAR 01, 2002	MAR	NEWA
AB	10MG	N75385 002	MAR 01, 2002	MAR	NEWA
AB	15MG	N75385 003	MAR 01, 2002	MAR	NEWA

BUTORPHANOL TARTRATE

SPRAY, METERED; NASAL					
BUTORPHANOL TARTRATE					
AB ROXANE	1MG/SPRAY	N75824 001	MAR 12, 2002	MAR	NEWA

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL				
ERCATAB				
+ GENEVA PHARMS	100MG;1MG	N84294 001		JUN CTEC
WIGRAINE				
@ ORGANON	100MG;1MG	N86562 001		JUN DISC

CALCIFEDIOL

CAPSULE; ORAL				
CALDEROL				
@ ORGANON	0.02MG	N18312 001		JUN DISC

@	0.05MG	N18312 002	JUN DISC
---	--------	------------	----------

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

+ BRISTOL MYERS SQUIBB 0.005%

N20273 001 DEC 29, 1993 FEB CAHN

SOLUTION; TOPICAL

+ BRISTOL MYERS SQUIBB 0.005%

N20611 001 MAR 03, 1997 FEB CAHN

CAPTOPRIL

TABLET; ORAL

CAPOTEN

AB	PAR PHARM	12.5MG	N18343 005	JAN 17, 1985	MAY	CAHN
AB		25MG	N18343 002		MAY	CAHN
	@	37.5MG	N18343 006	SEP 17, 1986	MAY	CAHN
AB		50MG	N18343 001		MAY	CAHN
	@	75MG	N18343 007	JUN 13, 1995	MAY	CAHN
AB	+	100MG	N18343 003		MAY	CAHN
	@	150MG	N18343 004	JUN 13, 1995	MAY	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBATROL

@ SHIRE LABS 100MG
@ 200MG
@ 300MGN20712 003 DEC 22, 1999 JUL DISC
N20712 001 SEP 30, 1997 JUL DISC
N20712 002 SEP 30, 1997 JUL DISC

SUSPENSION; ORAL

CARBAMAZEPINE

AB	MORTON GROVE	100MG/5ML	N75714 001	JUN 05, 2002	JUN	NEWA
AB	APOTEX	200MG	N75948 001	FEB 27, 2002	FEB	NEWA
	TABLET, CHEWABLE; ORAL		N75687 002	JUL 29, 2002	JUL	NEWA
+ TARO PHARM INDs		200MG				

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HCL

AT	NOVEX	1%	N76097 001	FEB 06, 2002	FEB	NEWA
----	-------	----	------------	--------------	-----	------

CEFACLOR

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

@ LILLY EQ 375MG BASE

N50673 001 JUN 28, 1996 JUN DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

DURICEF

@ GALEN CHEM EQ 250MG BASE

N50512 002 MAY CAHN

@ WARNER CHILCOTT EQ 250MG BASE

N50512 002 JUL CAHN

AB + EQ 500MG BASE

N50512 001 JUL CAHN

FOR SUSPENSION; ORAL

GALEN CHEM EQ 125MG BASE/5ML
EQ 250MG BASE/5MLN50527 002 MAY CAHN
N50527 003 MAY CAHN

+ WARNER CHILCOTT	EQ 500MG BASE/5ML EQ 125MG BASE/5ML EQ 250MG BASE/5ML EQ 500MG BASE/5ML	N50527 001 N50527 002 N50527 003 N50527 001	MAY CAHN JUL CAHN JUL CAHN JUL CAHN
+ TABLET; ORAL			
AB + GALEN CHEM	EQ 1GM BASE	N50528 001	MAY CAHN
AB + WARNER CHILCOTT	EQ 1GM BASE	N50528 001	JUL CAHN
<u>CEFAMANDOLE NAFATE</u>			
INJECTABLE; INJECTION			
MANDOL			
@ LILLY	EQ 10GM BASE/VIAL	N50504 004	JUN DISC
<u>CEFORANIDE</u>			
INJECTABLE; INJECTION			
PRECEF			
@ BRISTOL	500MG/VIAL	N50554 001	MAY 24, 1984 JUN DISC
@	1GM/VIAL	N50554 002	MAY 24, 1984 JUN DISC
@	2GM/VIAL	N50554 003	MAY 24, 1984 JUN DISC
@	10GM/VIAL	N50554 004	MAY 24, 1984 JUN DISC
@	20GM/VIAL	N50554 005	MAY 24, 1984 JUN DISC
<u>CEFPODOXIME PROXETIL</u>			
FOR SUSPENSION; ORAL			
CEFPODOXIME PROXETIL			
AB RANBAXY	EQ 50MG BASE/5ML	N65082 001	MAY 31, 2002 MAY NEWA
AB	EQ 100MG BASE/5ML	N65082 002	MAY 31, 2002 MAY NEWA
VANTIN			
AB PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N50675 001	AUG 07, 1992 MAY CFTG
AB +	EQ 100MG BASE/5ML	N50675 002	AUG 07, 1992 MAY CFTG
<u>CEFTIZOXIME SODIUM</u>			
INJECTABLE; INJECTION			
CEFIZOX			
@ FUJISAWA HLTHCARE	EQ 500MG BASE/VIAL	N50560 001	SEP 15, 1983 JUL DISC
<u>CEFTRIAZONE SODIUM; LIDOCAINE</u>			
INJECTABLE; INJECTION			
ROCEPHIN KIT			
@ HLR	EQ 500MG BASE/VIAL;1%	N50585 007	MAY 08, 1996 JUN DISC
@	EQ 1GM BASE/VIAL;1%	N50585 006	MAY 08, 1996 JUN DISC
<u>CEFUROXIME AXETIL</u>			
TABLET; ORAL			
CEFTIN			
AB GLAXOSMITHKLINE	EQ 125MG BASE	N50605 001	DEC 28, 1987 FEB CFTG
AB	EQ 250MG BASE	N50605 002	DEC 28, 1987 FEB CFTG
AB +	EQ 500MG BASE	N50605 003	DEC 28, 1987 FEB CFTG
CEFUROXIME AXETIL			
AB RANBAXY	EQ 125MG BASE	N65043 003	FEB 15, 2002 FEB NEWA
AB	EQ 250MG BASE	N65043 002	FEB 15, 2002 FEB NEWA
AB	EQ 500MG BASE	N65043 001	FEB 15, 2002 FEB NEWA

CELECOXIB

CAPSULE; ORAL					
CELEBREX					
>D>	+ GD SEARLE LLC	200MG	N20998 002	DEC 31, 1998	AUG CRLD
>A>		200MG	N20998 002	DEC 31, 1998	AUG CRLD
>A>	+	400MG	N20998 003	AUG 29, 2002	AUG NEWA

CEPHALEXIN

FOR SUSPENSION; ORAL					
CEPHALEXIN					
@ TEVA	EQ 125MG BASE/5ML	N62873 001	MAY 23, 1988	APR	DISC
@	EQ 250MG BASE/5ML	N62867 001	APR 15, 1988	APR	DISC
TABLET; ORAL					
TEVA	EQ 500MG BASE	N63024 001	JAN 12, 1989	JUN	CTEC
KEFLET					
@ LILLY	EQ 500MG BASE	N50440 001		JUN	DISC
@	EQ 1GM BASE	N50440 002		JUL	DISC

CEPHALOGLYCIN

CAPSULE; ORAL					
KAFOCIN					
@ LILLY	250MG	N50219 001		MAY	DISC

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION					
KEFLIN					
@ LILLY	EQ 20GM BASE/VIAL	N50482 007		JUN	DISC

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION					
CEFADYL					
APOTHECON	EQ 500MG BASE/VIAL	N62961 001	SEP 20, 1988	JUN	DISC
@	EQ 1GM BASE/VIAL	N62961 002	SEP 20, 1988	JUN	DISC
@	EQ 2GM BASE/VIAL	N62961 003	SEP 20, 1988	JUN	DISC
@	EQ 4GM BASE/VIAL	N62961 004	SEP 20, 1988	JUN	DISC

CERIVASTATIN SODIUM

TABLET; ORAL					
BAYCOL					
@ BAYER	0.2MG	N20740 003	JUN 26, 1997	JAN	DISC
@	0.3MG	N20740 004	JUN 26, 1997	JAN	DISC
@	0.4MG	N20740 005	MAY 24, 1999	JAN	DISC
@	0.8MG	N20740 006	JUL 24, 2000	JAN	DISC

CHLORAMPHENICOL

FOR SOLUTION; OPHTHALMIC					
CHLOROMYCETIN					
@ PARKADEL	25MG/VIAL	N50143 001		JUL	DISC

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

@ PARKE DAVIS

EQ 150MG BASE/5ML

N50152 001

JUN DISC

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

@ PARKADELE

12.5MG/VIAL;25MG/VIAL

N50202 001

JUL DISC

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

@ SANOFI SYNTHELABO

100MG

N11467 003

JUN DISC

@

200MG

N11467 005

JUN DISC

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

>D> CHLOROTHIAZIDE AND RESERPINE

>D> BP WEST WARD

250MG;0.125MG

N88557 001 DEC 22, 1983 AUG DISC

>A>

250MG;0.125MG

N88557 001 DEC 22, 1983 AUG DISC

>D> BP

500MG;0.125MG

N88365 001 DEC 22, 1983 AUG DISC

>A>

500MG;0.125MG

N88365 001 DEC 22, 1983 AUG DISC

>D> CHLOROTHIAZIDE-RESERPINE

>D> BP MYLAN

250MG;0.125MG

N87744 001 MAY 06, 1982 AUG DISC

>A>

250MG;0.125MG

N87744 001 MAY 06, 1982 AUG DISC

>D> BP

500MG;0.125MG

N87745 001 MAY 06, 1982 AUG DISC

>A>

500MG;0.125MG

N87745 001 MAY 06, 1982 AUG DISC

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

@ PHARMACIA AND UPJOHN

400MG

N14217 002

JUN DISC

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

@ GLAXOSMITHKLINE

30MG

N11120 016

JUN DISC

@

75MG

N11120 017

JUN DISC

@

150MG

N11120 018

JUN DISC

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ LEDERLE

100MG

N89561 001 SEP 04, 1987 MAY DISC

@

250MG

N89562 001 SEP 04, 1987 MAY DISC

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

@ LEDERLE

1%

N50404 001

JUN DISC

CHLORTHALIDONE; RESERPINE

TABLET; ORAL DEMI-REGROTON			
@ AVENTIS PHARMS	25MG;0.125MG	N15103 002	JUL DISC
REGROTON			
@ AVENTIS PHARMS	50MG;0.25MG	N15103 001	JUL DISC

CHOLESTYRAMINE

TABLET; ORAL QUESTRAN			
@ APOTHECON	EQ 800MG RESIN	N73403 002	DEC 27, 1999 JUN DISC

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION OVIDREL			
+ SERONO INC	0.25MG/VIAL	N21149 001	SEP 20, 2000 FEB CAHN

CHYMOPAPAIN

INJECTABLE; INJECTION CHYMODIACTIN			
@ ABBOTT	4,000 UNITS/VIAL	N18663 002	AUG 21, 1984 JUN DISC

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC ZOLYSE			
@ ALCON	750 UNITS/VIAL	N11903 001	JUN DISC

CICLOPIROX

SOLUTION; TOPICAL PENLAC			
+ DERMICK LABS	8%	N21022 001	DEC 17, 1999 JUN CAHN

CIMETIDINE

TABLET; ORAL CIMETIDINE			
AB LEK LJUBLJANA	300MG	N74250 002	JUN 29, 1995 FEB CMFD
AB	400MG	N74250 003	JUN 29, 1995 FEB CMFD
AB	800MG	N74250 004	JUN 29, 1995 FEB CMFD

CINOXACIN

CAPSULE; ORAL CINOBAC			
@ LILLY	250MG	N18067 001	JUN DISC
@	500MG	N18067 002	JUN DISC

CLADRIBINE

INJECTABLE; INJECTION LEUSTATIN			
+ ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993 MAR CAHN

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

@ ABBOTT

187MG/5ML

N50698 003 SEP 30, 1998 JUN DISC

CLINDAMYCIN PHOSPHATE

LOTION; TOPICAL

CLEOCIN T

AB + PHARMACIA AND UPJOHN EQ 1% BASE N50600 001 MAY 31, 1989 JAN CFTG
CLINDAMYCIN PHOSPHATEAB ALTANA EQ 1% BASE N65067 001 JAN 31, 2002 JAN NEWA
SWAB; TOPICAL

AT CLAY PARK EQ 1% BASE N65049 001 MAY 25, 2000 FEB CDFR

CLOBETASOL PROPIONATE

GEL; TOPICAL

EMBELINE

AB HEALTHPOINT 0.05% N76141 001 APR 12, 2002 APR NEWA

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

@ NOVARTIS

100MG

N19500 001 DEC 15, 1986 JUN DISC

CLONAZEPAM

TABLET; ORAL

KLONOPIN

@ ROCHE 0.125MG

@ 0.25MG

N17533 005 APR 09, 1997 JUN DISC

N17533 006 APR 09, 1997 JUN DISC

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

@ ROCHE 0.125MG

N20813 001 DEC 23, 1997 JUN DISC

@ 0.25MG

N20813 002 DEC 23, 1997 JUN DISC

@ 0.5MG

N20813 003 DEC 23, 1997 JUN DISC

@ 1MG

N20813 004 DEC 23, 1997 JUN DISC

@ 2MG

N20813 005 DEC 23, 1997 JUN DISC

CLOZAPINE

TABLET; ORAL

CLOZARIL

AB NOVARTIS 25MG N19758 001 SEP 26, 1989 MAY CRLD

AB + 100MG N19758 002 SEP 26, 1989 MAY CRLD

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

BP + WATSON LABS 0.5MG;500MG N84279 001 JUN CRLD

COLBENEMID

@ MERCK 0.5MG;500MG

N12383 001 JUN DISC

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL

@ SANKYO

375MG

N21141 001 MAY 26, 2000 JUN DISC

CORTICOTROPIN

INJECTABLE; INJECTION

CORTICOTROPIN

>D>	BC	ORGANICS LAGRANGE	40 UNITS/ML	N10831 001	AUG CRLD
>A>	+		40 UNITS/ML	N10831 001	AUG CRLD
		H.P. ACTHAR GEL			
		@ QUESTCOR PHARMS	40 UNITS/ML	N08372 006	JUL DISC

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTONE

@ MERCK

25MG/ML

N07110 002

JUN DISC

@

50MG/ML

N07110 003

JUN DISC

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	NOVEX	10MG/ML	N75333 001 APR 30, 2002 APR NEWA
----	-------	---------	----------------------------------

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58

N/A; N/A

DICOPAC KIT

@ AMERSHAM HLTH

N/A;N/A;N/A

N17406 001

FEB DISC

CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

@ MALLINCKRODT

0.1MG;0.5uCi;60MG

N16635 001

JUN DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

FLEXERIL

@ MCNEIL CONS SPECLT

5MG

N17821 001

JUN CAHN

AB	+	10MG	N17821 002
----	---	------	------------

JUN CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

AP	BAXTER HLTHCARE	100MG/VIAL	N88371 001 JUL 03, 1986 JUN CAHN
AP		200MG/VIAL	N88372 001 JUL 03, 1986 JUN CAHN
AP		500MG/VIAL	N88373 001 JUL 03, 1986 JUN CAHN
AP		1GM/VIAL	N88374 001 SEP 24, 1986 JUN CAHN

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	ABBOTT	25MG	N65003 001 MAY 12, 2000 MAY CTEC
-----	--------	------	----------------------------------

BX		50MG	N65003 002	MAY 12, 2000	MAY	CTEC
AB1		100MG	N65003 003	MAY 12, 2000	MAY	CTEC
AB1	EON	25MG	N65017 002	JAN 13, 2000	MAY	CTEC
AB1		100MG	N65017 001	JAN 13, 2000	MAY	CTEC
AB1	SIDMAK LABS	25MG	N65044 002	DEC 20, 2000	MAY	CTEC
AB1		100MG	N65044 001	DEC 20, 2000	MAY	CTEC
AB2	TORPHARM	25MG	N65040 001	MAY 09, 2002	MAY	CTEC
AB2		100MG	N65040 002	MAY 09, 2002	MAY	NEWA
	NEORAL					
AB1	NOVARTIS	25MG	N50715 001	JUL 14, 1995	MAY	CTEC
AB1 +		100MG	N50715 002	JUL 14, 1995	MAY	CTEC
	SANDIMMUNE					
AB2	NOVARTIS	25MG	N50625 001	MAR 02, 1990	MAY	CTEC
AB2 +		100MG	N50625 002	MAR 02, 1990	MAY	CTEC
	SOLUTION; ORAL					
	CYCLOSPORINE					
AB	ABBOTT	100MG/ML	N65025 001	MAR 03, 2000	JAN	CMFD
<u>CYTARABINE</u>						
	INJECTABLE; INJECTION					
	CYTARABINE					
>D>	AP FAULDING	2GM/VIAL	N75383 001	NOV 22, 1999	AUG	CPOT
>A>	+	100MG/ML	N75383 001	NOV 22, 1999	AUG	CPOT
<u>DALFOPRISTIN; QUINUPRISTIN</u>						
	INJECTABLE; IV (INFUSION)					
	SYNERCID					
+ AVENTIS		350MG/VIAL;150MG/VIAL	N50748 001	SEP 21, 1999	JUN	CRLD
@		420MG/VIAL;180MG/VIAL	N50748 002	AUG 24, 2000	JUN	DISC
<u>DANAPAROID SODIUM</u>						
	INJECTABLE; INJECTION					
	ORGARAN					
@ ORGANON		750 UNITS/0.6ML	N20430 001	DEC 24, 1996	JUN	DISC
<u>DEFEROXAMINE MESYLATE</u>						
	INJECTABLE; INJECTION					
	DESFERAL					
+ NOVARTIS		2GM/VIAL	N16267 002	MAY 25, 2000	FEB	CPOT
<u>DEMECARIUM BROMIDE</u>						
	SOLUTION/DROPS; OPHTHALMIC					
	HUMORSOL					
@ MERCK		0.125%	N11860 002		JUN	DISC
@		0.25%	N11860 001		JUN	DISC
<u>DEMECTOCYCLINE HYDROCHLORIDE</u>						
	TABLET; ORAL					
	DECLOMYCIN					
@ LEDERLE		75MG	N50261 001		JUN	DISC

DESLOTRATADINE

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

+ SCHERING

5MG

N21312 001 JUN 26, 2002 JUN NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL

CONCENTRAID

@ FERRING

0.01%

N19776 001 DEC 26, 1990 JUN DISC

SPRAY, METERED; NASAL

DDAVP

@ AVENTIS

0.01MG/SPRAY

N17922 002 FEB 06, 1989 MAY DISC

DESMOPRESSIN ACETATE

AB + BAUSCH AND LOMB

0.01MG/SPRAY

N74830 001 JAN 25, 1999 MAY CRLD

DESOGESTREL; ETHINYLL ESTRADIOL

TABLET; ORAL-28

KARIVA

AB BARR

0.15MG;0.02MG;0.01MG

N75863 001 APR 05, 2002 APR NEWA

MIRCETTE

AB + ORGANON

0.15MG;0.02MG;0.01MG

N20713 001 APR 22, 1998 APR CFTG

DESONIDE

LOTION; TOPICAL

DESONIDE

AB ALTANA

0.05%

N75860 001 MAR 19, 2002 MAR NEWA

DESOWEN

AB + GALDERMA LABS LP

0.05%

N72354 001 JAN 24, 1992 MAR CFTG

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

@ ALTANA

0.25%

N73440 001 APR 01, 1998 MAY DISC

DEXAMETHASONE

AEROSOL; TOPICAL

DECASPRAY

@ MERCK

0.04%

N12731 002

JUN DISC

TABLET; ORAL

DEXAMETHASONE

>D> BP WATSON LABS

0.25MG

N85455 001

AUG DISC

>A> @

0.25MG

N85455 001

AUG DISC

>D> BP

0.5MG

N85458 001

AUG DISC

>A> @

0.5MG

N85458 001

AUG DISC

>D> BP

1.5MG

N85456 001

AUG DISC

>A> @

1.5MG

N85456 001

AUG DISC

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

@ MERCK

EQ 8MG BASE/ML

N16675 001

APR DISC

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DEXAMETHASONE ACETATE

© STERIS

EQ 8MG BASE/ML

N84315 001

APR DISC

©

EQ 16MG BASE/ML

N87711 001

MAY 24, 1982 APR DISC

DEXAMETHASONE SODIUM PHOSPHATE

OINTMENT; OPHTHALMIC

MAXIDEX

© ALCON

EQ 0.05% PHOSPHATE

N83342 001

JUN DISC

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

© MERCK

EQ 4MG PHOSPHATE/ML;10MG/ML

N13334 002

JUN DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB + GLAXOSMITHKLINE

5MG

N17078 001

JAN CFTG

AB +

10MG

N17078 002

JAN CFTG

AB +

15MG

N17078 003

JAN CFTG

DEXTROAMPHETAMINE SULFATE

AB BARR

5MG

N76137 001

JAN 18, 2002 JAN NEWA

AB

10MG

N76137 002

JAN 18, 2002 JAN NEWA

AB

15MG

N76137 003

JAN 18, 2002 JAN NEWA

TABLET; ORAL

AA MALLINCKRODT

5MG

N40436 001

JAN 29, 2002 JAN NEWA

AA

10MG

N40436 002

JAN 29, 2002 JAN NEWA

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

DIATRIZOATE MEGLUMINE

© BRACCO

76%

N10040 017

JUN DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOVIST

© BRACCO

34.3%;35%

N10040 020

JUN DISC

RENOVIST II

© BRACCO

28.5%;29.1%

N10040 019

JUN DISC

DIATRIZOATE SODIUM

INJECTABLE; INJECTION

HYPAQUE

© AMERSHAM HLTH

25%

N09561 003

JUN DISC

SOLUTION; ORAL, RECTAL

© AMERSHAM HLTH

40%

N11386 003

JUL DISC

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

© AMERSHAM HLTH

20%

N09561 002

JUN DISC

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

@ BAKER NORTON

50MG

N17425 001

JUN DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

AB MUTUAL PHARM

50MG

N75470 001 FEB 21, 2002 FEB NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ BIORGLAN PHARMA 3%

N21005 001 OCT 16, 2000 JUL CAHN

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB ALPHAPHARM

50MG

N75281 002 FEB 12, 2002 FEB NEWA

AB 75MG

N75281 003 FEB 12, 2002 FEB NEWA

TABLET, EXTENDED RELEASE; ORAL

AB PUREPAC PHARM

100MG

N75910 001 JAN 07, 2002 JAN NEWA

DICUMAROL

TABLET; ORAL

DICUMAROL

@ ABBOTT

25MG

N05545 003

JUN DISC

DIENESTROL

CREAM; VAGINAL

DIENESTROL

+ ORTHO MCNEIL

0.01%

N06110 005

JUN CAHN

DIGOXIN

TABLET; ORAL

DIGOXIN

AB STEVENS J

0.125MG

N76268 001 JUL 26, 2002 JUL NEWA

AB 0.25MG

N76268 002 JUL 26, 2002 JUL NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

XCEL PHARMS

1MG/ML

N05929 001

JUN CAHN

SPRAY, METERED; NASAL

MIGRANAL

+ XCEL PHARM

0.5MG/INH

N20148 001 DEC 08, 1997 JUL CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

AP + BIOVAIL

5MG/ML

N20027 001 OCT 24, 1991 JUN CAHN

+

25MG/VIAL

N20027 003 AUG 18, 1995 JUN CAHN

DILTIAZEM HCL

+ GENESIA SICOR PHARMS

10MG/ML

N74894 002 APR 19, 2002 APR NEWA

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

+ BIOVAIL EQ 180MG HCL;5MG

N20507 001 OCT 04, 1996 JUN CAHN

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+ ALLIANCE PHARM 0.92MG/VIAL;0.092MG/VIAL

N21191 001 MAY 31, 2002 MAY NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP AM PHARM PARTNERS 50MG/ML

N40466 001 MAY 28, 2002 MAY NEWA

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

@ GLAXOSMITHKLINE EQ 25MG BASE

N16033 001 JUN DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DEPAKOTE ER

ABBOTT EQ 250MG VALPROIC ACID

N21168 002 MAY 31, 2002 JUL NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

EISAI MEDCL RES 5MG

+ 10MG

N20690 002 NOV 25, 1996 MAY CAHN

N20690 001 NOV 25, 1996 MAY CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL

@ LEDERLE EQ 10MG BASE

N71685 001 JAN 05, 1988 MAY DISC

@ EQ 25MG BASE

N71686 001 JAN 05, 1988 MAY DISC

@ EQ 50MG BASE

N71673 001 JAN 05, 1988 MAY DISC

@ EQ 75MG BASE

N71674 001 JAN 05, 1988 MAY DISC

@ EQ 100MG BASE

N71675 001 JAN 05, 1988 MAY DISC

@ EQ 150MG BASE

N71676 001 JAN 05, 1988 MAY DISC

CREAM; TOPICAL

ZONALON

+ BIOGLAN PHARMS 5%

N20126 001 APR 01, 1994 JUN CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

PERIOSTAT

@ COLLAGENEX EQ 20MG BASE

N50744 001 SEP 30, 1998 JUN DISC

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

+ ABBOTT	2.5MG/ML;EQ 0.05MG BASE/ML	N71982 001	MAY 04, 1988	JUN	CTEC
@ ASTRazeneca	2.5MG/ML;EQ 0.05MG BASE/ML	N72026 001	APR 13, 1989	JUN	DISC

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

@ AYERST	0.03%	N11963 002	JUN	DISC
@	0.06%	N11963 004	JUN	DISC
@	0.25%	N11963 003	JUN	DISC

EDETA TE DISODIUM

INJECTABLE; INJECTION

EDETA TE DISODIUM

AP PHARMAFORCE	150MG/ML	N40437 001	JUL 09, 2002	JUL	NEWA
----------------	----------	------------	--------------	-----	------

EFAVIRENZ

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB	300MG	N21360 001	FEB 01, 2002	FEB	NEWA
+	600MG	N21360 002	FEB 01, 2002	FEB	NEWA

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ WOMEN FIRST HLTHCARE	13.9%	N21145 001	JUL 27, 2000	JUL	CAHN
------------------------	-------	------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

AB BIOVAIL	2.5MG	N18998 005	JUL 26, 1988	MAY	CAHN
AB	5MG	N18998 001	DEC 24, 1985	MAY	CAHN
AB	10MG	N18998 002	DEC 24, 1985	MAY	CAHN
AB +	20MG	N18998 003	DEC 24, 1985	MAY	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

AB BIOVAIL	5MG;12.5MG	N19221 003	JUL 12, 1995	MAY	CAHN
AB +	10MG;25MG	N19221 001	OCT 31, 1986	MAY	CAHN

ENALAPRILAT

INJECTABLE; INJECTION

VASOTEC

AP + BIOVAIL	1.25MG/ML	N19309 001	FEB 09, 1988	MAY	CAHN
--------------	-----------	------------	--------------	-----	------

ENOXACIN

TABLET; ORAL

PENETREX

@ AVENTIS

	200MG	N19616 004	DEC 31, 1991	JUN	DISC
--	-------	------------	--------------	-----	------

⑧ 400MG

N19616 005 DEC 31, 1991 JUN DISC

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

⑧ AVENTIS

90MG/0.6ML

N20164 006 JUN 02, 2000 JUN DISC

EPINEPHRINE

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

⑧ FORREST LABS

1.5MG/AMP

N07942 003 FEB 05, 1999 JUN DISC

⑧

5MG/ML

N07942 001 JUN DISC

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

⑧ MERIDIAN MEDCL TECHN

0.15MG/DELIVERY

N19430 004 AUG 03, 1995 JUN DISC

EPIPEN E Z PEN

⑧ MERIDIAN MEDCL TECHN

0.3MG/DELIVERY

N19430 003 AUG 03, 1995 JUN DISC

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

BIOVAIL PHARMS

EQ 300MG BASE

N20738 004 DEC 22, 1997 JUN CAHN

EQ 400MG BASE

N20738 005 DEC 22, 1997 JUN CAHN

+

EQ 600MG BASE

N20738 006 MAY 27, 1999 JUN CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

BIOVAIL PHARMS

600MG;12.5MG

N21268 001 NOV 01, 2001 JUN CAHN

+

600MG;25MG

N21268 002 NOV 01, 2001 JUN CAHN

EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+ MILLENNIUM PHARMS

2MG/ML

N20718 001 MAY 18, 1998 FEB CAHN

+

75MG/100ML

N20718 002 MAY 18, 1998 FEB CAHN

ERGOLOOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

⑧ NOVARTIS

1MG

N18706 001 JAN 18, 1983 JUN DISC

SOLUTION; ORAL

HYDERGINE

⑧ NOVARTIS

1MG/ML

N18418 001 JUN DISC

ERYTHROMYCIN

GEL; TOPICAL

E-GLADES

AT GLADES PHARMS

2%

N65009 001 MAR 18, 2002 MAR NEWA

JUN DISC

>A>	<u>ESCITALOPRAM OXALATE</u>					
>A>	TABLET; ORAL					
>A>	LEXAPRO					
>A>	FOREST LABS	5MG		N21323 001	AUG 14, 2002	AUG NEWA
>A>		10MG		N21323 002	AUG 14, 2002	AUG NEWA
>A>	+	20MG		N21323 003	AUG 14, 2002	AUG NEWA

JUN DISC

ESTRADIOL
FILM, EXTENDED RELEASE; TRANSDERMAL

JUN DISC

BX	WATSON LABS	0.025MG/24HR	N20655 004	APR 16, 2002	APR NEWA
BX		0.025MG/24HR	N20655 004	APR 05, 2002	MAY CMS1

JUN DISC

AB	USL PHARMA	0.5MG	N40297 001	APR 17, 2002	APR NEWA
AB		1MG	N40297 002	APR 17, 2002	APR NEWA
AB		2MG	N40297 003	APR 17, 2002	APR NEWA

JUN DISC

ESTRADIOL; NORETHINDRONE ACETATE

JUN CAHN

ACTIVELLA					
+ NOVO NORDISK		1MG;0.5MG	N20907 001	NOV 18, 1998	JUN CTNA

JUN CAHN

ESTRADIOL; NORGESTIMATE

JUN CAHN

TABLET; ORAL					
ORTHO-PREFEST					
+ KING PHARMS		1MG;1MG;0.09MG	N21040 001	OCT 22, 1999	MAY CAHN

JUN CAHN

ESTROGENS, CONJUGATED SYNTHETIC A

JUN CAHN

TABLET; ORAL					
CENESTIN					
>A>	DURAMED	0.3MG	N20992 001	JUN 21, 2002	AUG CAHN
>D>	DURAMED PHARM BARR	0.3MG	N20992 001	JUN 21, 2002	AUG CAHN
		0.3MG	N20992 001	JUN 21, 2002	JUL NEWA

FEB CAHN

FEB CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

JUN DISC

TABLET; ORAL-28					
PREMPHASE (PREMARIN; CYCRIN 14/14)					
@ WYETH AYERST		0.625MG;0.625MG;5MG	N20303 002	DEC 30, 1994	JUN DISC
PREMPRO (PREMARIN; CYCRIN)					
@ WYETH AYERST		0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JUN DISC

JUN DISC

ESTROGENS, CONJUGATED; MEPROBAMATE

JUN DISC

TABLET; ORAL					
PMB 200					
@ WYETH AYERST		0.45MG;200MG	N10971 005		JUN DISC
PMB 400					
@ WYETH AYERST		0.45MG;400MG	N10971 003		JUN DISC

MAR NEWA

ETHCHLORVYNOL

CAPSULE; ORAL

PLACIDYL

@ ABBOTT

200MG

N10021 007

JUN DISC

@

500MG

N10021 002

JUN DISC

@

750MG

N10021 010

JUN DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

ALESSE

AB + WYETH AYERST

0.02MG;0.1MG

N20683 001 MAR 27, 1997 MAR CTEC

AB1 +

0.02MG;0.1MG

N20683 001 MAR 27, 1997 MAY CTEC

AVIANE-21

AB1 DURAMED PHARM BARR

0.02MG;0.1MG

N75796 002 APR 30, 2001 MAR CTEC

LESSINA-21

AB2 BARR

0.02MG;0.1MG

N75803 001 MAR 20, 2002 MAR NEWA

LEVLITE

AB2 + BERLEX LABS

0.02MG;0.1MG

N20860 001 JUL 13, 1998 MAR CTEC

PORTIA-21

AB BARR

0.03MG;0.15MG

N75866 001 MAY 23, 2002 MAY NEWA

TABLET; ORAL-28

ALESSE

AB1 WYETH AYERST

0.02MG;0.1MG

N20683 002 MAR 27, 1997 MAR CTEC

AVIANE-28

AB1 DURAMED PHARM BARR

0.02MG;0.1MG

N75796 001 APR 30, 2001 MAR CTEC

LESSINA-28

AB BARR

0.02MG;0.1MG

N75803 002 MAR 20, 2002 MAR NEWA

LEVLITE

AB BERLEX LABS

0.02MG;0.1MG

N20860 002 JUL 13, 1998 MAR CTEC

PORTIA-28

AB BARR

0.03MG;0.15MG

N75866 002 MAY 23, 2002 MAY NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

>D> GENCEPT 0.5/35-21

0.035MG;0.5MG

N72692 001 FEB 28, 1992 AUG CTNA

>D> AB BARR

NORTREL 0.5/35-21

0.035MG;0.5MG

N72692 001 FEB 28, 1992 AUG CTNA

>A> AB

GENCEPT 1/35-21

0.035MG;1MG

N72693 001 FEB 28, 1992 AUG CTNA

>D> AB BARR

NORTREL 1/35-21

0.035MG;1MG

N72693 001 FEB 28, 1992 AUG CTNA

>A> AB

NORTREL 7/7/7

0.035MG;1MG

N72693 001 FEB 28, 1992 AUG CTNA

>A> AB BARR

ORTHO-NOVUM 7/7/7-21

0.035MG,0.035MG,0.035MG;0.5MG,1MG,0

N75478 001 AUG 30, 2002 AUG NEWA

.75MG

>D> + ORTHO MCNEIL PHARM

.75MG

N18985 001 APR 04, 1984 AUG CFTG

>A> AB +

0.035MG,0.035MG,0.035MG;0.5MG,1MG,0

N18985 001 APR 04, 1984 AUG CFTG

.75MG

TABLET; ORAL-28

>D> GENCEPT 0.5/35-28

0.035MG;0.5MG

N72695 001 FEB 28, 1992 AUG CTNA

>D> AB BARR

NORTREL 0.5/35-28

0.035MG;0.5MG

N72695 001 FEB 28, 1992 AUG CTNA

>A> AB

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

GENCEPT 1/35-28

>D>	AB	BARR	0.035MG;1MG	N72696 001	FEB 28, 1992	AUG	CTNA
>D>	AB	NORTREL 1/35-28					
>A>	AB		0.035MG;1MG	N72696 001	FEB 28, 1992	AUG	CTNA
>A>	AB	NORTREL 7/7/7					
>A>	AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75M G,1MG	N75478 002	AUG 30, 2002	AUG	NEWA
		ORTHO-NOVUM 7/7/7-28					
>D>		ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985 002	APR 04, 1984	AUG	CFTG
>A>	AB		0.035MG,0.035MG,0.035MG;0.5MG,1MG,0 .75MG	N18985 002	APR 04, 1984	AUG	CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

ESTROSTEP 21

@ PARKE DAVIS

0.02MG;0.03MG;0.035MG;1MG;1MG;1MG

N20130 001 OCT 09, 1996 JUN DISC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

>A>	+ JOHNSON AND JOHNSON	0.025MG,0.025MG,0.025MG;0.18MG,0.25 MG,0.215MG	N21241 001	AUG 22, 2002	AUG	NEWA
-----	-----------------------	---------------------------------------------------	------------	--------------	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

+ ABBOTT

250MG

N10841 001

JUN CRLD

@

500MG

N10841 003

JUN DISC

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB	NEOSAN PHARMS	300MG	N74929 001	JAN 30, 1998	JUL	CAHN
AB	NEOSAN PHARMS	400MG	N74927 001	OCT 30, 1997	JUL	CAHN
	TABLET, EXTENDED RELEASE; ORAL					
AB	EON	400MG	N75943 001	JUL 26, 2002	JUL	NEWA
AB		500MG	N75943 002	JUL 26, 2002	JUL	NEWA
AB		600MG	N75943 003	JUL 26, 2002	JUL	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

>A>	AP	APOTEX	10MG/ML	N75942 001	AUG 02, 2002	AUG	NEWA
	AP	BAXTER HLTHCARE	10MG/ML	N75799 001	APR 30, 2002	APR	NEWA
		FAMOTIDINE PRESERVATIVE FREE					
	AP	@ APOTHECON	10MG/ML	N75708 001	APR 16, 2001	MAR	WDAG
	AP	BAXTER HLTHCARE	10MG/ML	N75789 001	APR 30, 2002	APR	NEWA

FENOFIBRATE

CAPSULE; ORAL					
FENOFIBRATE (MICRONIZED)					
AB	TEVA	134MG	N75753	002	APR 09, 2002
AB		200MG	N75753	003	APR 09, 2002
TRICOR (MICRONIZED)					
AB	ABBOTT	134MG	N19304	003	JUN 30, 1999
AB	+	200MG	N19304	004	JUN 30, 1999

FENOPROFEN CALCIUM

CAPSULE; ORAL					
NALFON					
AB	+	RANBAXY	EQ 300MG BASE	N17604	002
NALFON 200					
AB	RANBAXY	EQ 200MG BASE	N17604	003	JUN CAHN

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL					
FENTANYL					
AB	ANESTA	EQ 0.1MG BASE	N20195	007	OCT 30, 1995
AB		EQ 0.2MG BASE	N20195	001	OCT 04, 1993
AB		EQ 0.3MG BASE	N20195	002	OCT 04, 1993
AB		EQ 0.4MG BASE	N20195	003	OCT 04, 1993

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL					
FERRISELTZ					
AB	AMERSHAM HLTH	600MG/PACKET	N20292	001	OCT 14, 1997

FLOXURIDINE

INJECTABLE; INJECTION					
FUDR					
AP	+	FAULDING	500MG/VIAL	N16929	001

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION					
FLUDEOXYGLUCOSE F 18					
AB	DOWNSTATE CLINCL	4-40mCi/ML	N20306	001	AUG 19, 1994

FLUDROCORTISONE ACETATE

TABLET; ORAL					
FLORINEF					
AB	+	KING PHARMS	0.1MG	N10060	001
FLUDROCORTISONE ACETATE					
AB	IMPAK LABS	0.1MG	N40431	001	MAR 18, 2002

FLUNISOLIDE

SPRAY, METERED; NASAL					
FLUNISOLIDE					
AB	BAUSCH AND LOMB	0.025MG/SPRAY	N74805	001	FEB 20, 2002
NASALIDE					
AB	+	IVAX RES	0.025MG/SPRAY	N18148	001

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL				
SYNALAR-HP				
@ MEDICIS	0.2%	N16161	002	JUN DISC
SOLUTION; TOPICAL				
FLUONID				
@ ALLERGAN HERBERT	0.01%	N87158	001	MAR 17, 1983 MAY DISC

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL				
TRI-LUMA				
+ HILL DERMAC	0.01%;4%;0.05%	N21112	001	JAN 18, 2002 JAN NEWA

FLUOCINONIDE

CREAM; TOPICAL				
>D> FLUOCINONIDE				
>D> AB TEVA	0.05%	N72490	001	FEB 07, 1989 AUG CTNA
>A> FLUOCINONIDE EMULSIFIED BASE				
>A> AB	0.05%	N72490	001	FEB 07, 1989 AUG CTNA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL				
FLUOXETINE				
AB ALPHAPHARM	EQ 10MG BASE	N75577	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N75577	002	JAN 29, 2002 JAN NEWA
AB BARR	EQ 10MG BASE	N74803	002	JAN 30, 2002 JAN NEWA
AB CARLSBAD	EQ 10MG BASE	N76022	001	JAN 30, 2002 JAN NEWA
AB	EQ 20MG BASE	N76022	002	JAN 30, 2002 JAN NEWA
AB DR REDDYS LABS INC	EQ 10MG BASE	N75465	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N75465	002	JAN 29, 2002 JAN NEWA
AB EON	EQ 10MG BASE	N75807	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N75807	002	JAN 29, 2002 JAN NEWA
AB IVAX PHARMS	EQ 10MG BASE	N75245	002	JAN 31, 2002 JAN NEWA
AB	EQ 20MG BASE	N75245	001	JAN 31, 2002 JAN NEWA
AB MALLINCKRODT	EQ 10MG BASE	N75658	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N75658	002	JAN 29, 2002 JAN NEWA
AB MUTUAL PHARMA	EQ 10MG BASE	N75787	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N75787	002	JAN 29, 2002 JAN NEWA
AB MYLAN	EQ 10MG BASE	N75207	001	JAN 30, 2002 JAN NEWA
AB	EQ 20MG BASE	N75207	002	JAN 30, 2002 JAN NEWA
AB RANBAXY	EQ 10MG BASE	N76165	001	FEB 01, 2002 FEB NEWA
AB	EQ 20MG BASE	N76165	002	FEB 01, 2002 FEB NEWA
AB SIDMAK LABS	EQ 10MG BASE	N76001	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N76001	002	JAN 29, 2002 JAN NEWA
AB SIEGFRIED	EQ 10MG BASE	N75464	001	JAN 30, 2002 JAN NEWA
AB	EQ 20MG BASE	N75464	002	JAN 30, 2002 JAN NEWA
AB TEVA	EQ 10MG BASE	N75452	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N75452	002	JAN 29, 2002 JAN NEWA
AB	EQ 40MG BASE	N75452	003	JAN 29, 2002 JAN NEWA
AB WATSON LABS	EQ 10MG BASE	N75662	001	JAN 29, 2002 JAN NEWA
AB	EQ 20MG BASE	N75662	002	JAN 29, 2002 JAN NEWA
FLUOXETINE HCL				
AB GENEVA PHARMS	EQ 20MG BASE	N75049	002	JAN 29, 2002 JAN NEWA

AB		EQ 40MG BASE	N75049 003	JAN 29, 2002	JAN	NEWA
	SOLUTION; ORAL					
	FLUOXETINE					
AA	ALPHARMA	EQ 20MG BASE/5ML	N75690 001	JAN 31, 2002	JAN	NEWA
AA	MALLINCKRODT	EQ 20MG BASE/5ML	N75920 001	JAN 29, 2002	JAN	NEWA
AA	NOVEX	EQ 20MG BASE/5ML	N75292 001	FEB 07, 2002	FEB	NEWA
AA	PHARM ASSOC	EQ 20MG BASE/5ML	N76015 001	JAN 30, 2002	JAN	NEWA
	FLUOXETINE HCL					
AA	HI TECH PHARMA	EQ 20MG BASE/5ML	N75525 001	JUN 27, 2002	JUN	NEWA
>A>	AA MORTON GROVE	EQ 20MG BASE/5ML	N75514 001	AUG 29, 2002	AUG	NEWA
	TABLET; ORAL					
AB	BARR	EQ 10MG BASE	N75810 001	FEB 01, 2002	FEB	NEWA
AB	DR REDDYS LABS INC	EQ 10MG BASE	N76006 001	JAN 30, 2002	JAN	NEWA
AB	EON	EQ 10MG BASE	N76024 001	JAN 29, 2002	JAN	NEWA
AB	TEVA	EQ 10MG BASE	N75872 001	JAN 29, 2002	JAN	NEWA
AB	ZENITH GOLDLINE	EQ 10MG BASE	N75865 001	FEB 28, 2002	FEB	NEWA
	<u>FLUPHENAZINE ENANTHATE</u>					
	INJECTABLE; INJECTION					
	PROLIXIN ENANTHATE					
@ APOTHECON		25MG/ML	N16110 001		JUN	DISC
	<u>FLUVOXAMINE MALEATE</u>					
	TABLET; ORAL					
	FLUVOXAMINE MALEATE					
AB	+ EON	100MG	N75888 003	NOV 29, 2000	MAY	CRLD
AB	MUTUAL PHARM	25MG	N76125 001	APR 29, 2002	APR	NEWA
AB		50MG	N76125 002	APR 29, 2002	APR	NEWA
AB		100MG	N76125 003	APR 29, 2002	APR	NEWA
	LUVOX					
	@ SOLVAY	25MG	N20243 001	DEC 05, 1994	MAY	DISC
@		50MG	N20243 002	DEC 05, 1994	MAY	DISC
@		100MG	N20243 003	DEC 05, 1994	MAY	DISC
	<u>FOLIC ACID</u>					
	TABLET; ORAL					
	FOLIC ACID					
AA	+ WATSON LABS	1MG	N80680 001		FEB	CAHN
	<u>FOLLITROPIN ALFA/BETA</u>					
	INJECTABLE; INJECTION					
	GONAL-F					
	@ SERONO	37.5 IU/VIAL	N20378 003	MAY 25, 2000	JUN	DISC
	<u>FULVESTRANT</u>					
	INJECTABLE; INTRAMUSCULAR					
	FASLODEX					
+	ASTRAZENECA	50MG/ML	N21344 001	APR 25, 2002	APR	NEWA
	<u>FURAZOLIDONE</u>					
	SUSPENSION; ORAL					
	FUROXONE					
@	SHIRE LABS	50MG/15ML	N11323 002		JUL	DISC

FURAZOLIDONE

TABLET; ORAL
FUROXONE
TABLET; ORAL
④ SHIRE LABS 100MG N11270 002 JUL DISC

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION
NEOSCAN
④ AMERSHAM HLTH 2mCi/ML N17655 001 JUN DISC

GALLIUM NITRATE

INJECTABLE; INJECTION
GANITE
④ GENTA 25MG/ML N19961 002 JAN 17, 1991 JUL CAHN

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS
COPAXONE
+ TEVA 20MG/VIAL N20622 001 DEC 20, 1996 JUN CDFR
INJECTABLE; SUBCUTANEOUS
+ TEVA 20MG/ML N20622 002 FEB 12, 2002 JUN NEWA

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL
GLUCOTROL XL
PFIZER 2.5MG N20329 003 AUG 10, 1999 FEB CRLD
5MG N20329 001 APR 26, 1994 FEB CRLD

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON
④ LILLY EQ 1MG BASE/VIAL N12122 001 JUN DISC

GLYBURIDE

TABLET; ORAL
GLYBURIDE
AB COREPHARMA 1.25MG N76257 001 JUN 27, 2002 JUN NEWA
AB 2.5MG N76257 002 JUN 27, 2002 JUN NEWA
AB 5MG N76257 003 JUN 27, 2002 JUN NEWA

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT
④ FERRING 0.8MG/VIAL N19687 001 OCT 10, 1989 JUL DISC
④ 3.2MG/VIAL N19687 002 OCT 10, 1989 JUN DISC

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL
④ WYETH AYERST EQ 0.5MG BASE/VIAL N18123 003 SEP 30, 1982 JUN DISC

<u>GONADOTROPIN, CHORIONIC INJECTABLE; INJECTION</u>	A.P.L. @ WYETH AYERST	20,000 UNITS/VIAL	N17055 003	JUN DISC	>A> @	>D> AB	5MG 10MG 10MG 20MG 20MG	AUG DISC
CHORIONIC GONADOTROPIN @ STERIS	2,000 UNITS/VIAL		N17016 011	FEB 16, 1990	JUN DISC	>D> AB	HALOPERIDOL GENEVA PHARMS	AUG CRLD
<u>GRANISETRON HYDROCHLORIDE SOLUTION; ORAL</u>	KYTRIL @ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN DISC	>D> AA +	HALDOL ORTHO MCNEIL	AUG DISC
<u>GRISEOFULVIN, MICROCRYSTALLINE TABLET; ORAL</u>	GRISACTIN @ WYETH AYERST	500MG	N60212 001	MAY	DISC	>A> AA +	HALOPERIDOL @ ALPHARMA TEVA	AUG CRLD
<u>GRISEOFULVIN, ULTRAMICROCRYSTALLINE TABLET; ORAL</u>	HYLOREL @ PHARMACIA AND UPJOHN @	165MG 330MG	N62438 001	NOV 17, 1983	MAY DISC		HALOTHANE LIQUID; INHALATION FLUOTHANE @ WYETH AYERST	MAY DISC
<u>GUANADREL SULFATE</u>	TENEX @ NOVARTIS @	10MG 25MG	N18104 001	DEC 29, 1982	JUN DISC		HEPARIN SODIUM INJECTABLE; INJECTION HEP-LOCK @ ELKINS SINN	JUN CRLD
<u>GUANETHIDIINE MONOSULFATE TABLET; ORAL</u>	AB ESP PHARMA AB + @	EQ 10MG SULFATE EQ 25MG SULFATE	N18104 002	DEC 29, 1982	JUN DISC		HEPARIN LOCK FLUSH @ WYETH AYERST @ HEPARIN SODIUM	JUN CRLD
<u>GUANFACINE HYDROCHLORIDE TABLET; ORAL</u>	AB @	EQ 1MG BASE EQ 2MG BASE EQ 3MG BASE	N12329 001	JUN	DISC		2,500 UNITS/ML 20,000 UNITS/ML 1,000 UNITS/ML 2,500 UNITS/ML 5,000 UNITS/ML 5,000 UNITS/0.5ML 7,500 UNITS/ML 10,000 UNITS/ML 20,000 UNITS/ML	JUN CRLD
<u>HALOPERIDOL</u>	>D> AB >A> @	HALDOL ORTHO MCNEIL	N15921 001	OCT 27, 1986	APR CAHN		HEXACHLOROPHENE SOAP; TOPICAL GAMOPHEN @ ARBROOK SPONGE; TOPICAL E-Z SCRUB @ BECTON DICKINSON	JUN DISC
	>D> AB >A> @		N15921 001	NOV 07, 1988	APR CAHN			N06270 003
	>D> AB >A> @		N15921 002	NOV 07, 1988	APR CAHN			N17452 001
	>D> AB + @		N15921 003					JUN DISC
			N15921 004					AUG DISC

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

© SHIRE LABS	EQ 0.2MG BASE/ML	N19836 001	DEC 24, 1991	JUL	DISC
©	EQ 0.5MG BASE/ML	N19836 002	DEC 24, 1991	JUL	DISC
©	EQ 1MG BASE/ML	N19836 003	DEC 24, 1991	JUL	DISC

HYDROCHLOROTHIAZIDE

TABLET; ORAL

ESIDRIX

AB + NOVARTIS	100MG	N11793 009	MAR	CRLD	
HYDROCHLOROTHIAZIDE					
AB VINTAGE PHARMS	25MG	N40412 001	MAR 29, 2002	MAR	NEWA
AB	50MG	N40412 002	MAR 29, 2002	MAR	NEWA
HYDRODIURIL					
© MERCK	25MG	N11835 003	MAR	DISC	
©	50MG	N11835 006	MAR	DISC	
©	100MG	N11835 007	MAR	DISC	

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB EON	12.5MG;10MG	N76262 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;20MG	N76262 002	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N76262 003	JUL 01, 2002	JUL	NEWA
AB GENEVA PHARMS TECH	12.5MG;10MG	N75926 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;20MG	N75926 002	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N75926 003	JUL 01, 2002	JUL	NEWA
AB IVAX PHARMS	12.5MG;10MG	N75776 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;20MG	N75776 002	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N75776 003	JUL 01, 2002	JUL	NEWA
AB MYLAN	12.5MG;10MG	N76113 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;20MG	N76113 002	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N76113 003	JUL 01, 2002	JUL	NEWA
AB PUREPAC PHARM	12.5MG;10MG	N76230 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;20MG	N76230 002	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N76230 003	JUL 01, 2002	JUL	NEWA
AB RANBAXY	12.5MG;10MG	N76007 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;20MG	N76007 002	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N76007 003	JUL 01, 2002	JUL	NEWA
AB TEVA	12.5MG;10MG	N75869 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;20MG	N75869 002	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N75869 003	JUL 01, 2002	JUL	NEWA
AB WATSON LABS	12.5MG;20MG	N76194 001	JUL 01, 2002	JUL	NEWA
AB	12.5MG;10MG	N76194 003	JUL 01, 2002	JUL	NEWA
AB	25MG;20MG	N76194 002	JUL 01, 2002	JUL	NEWA
AB WEST WARD	12.5MG;10MG	N76265 001	JUL 08, 2002	JUL	NEWA
AB	12.5MG;20MG	N76265 002	JUL 08, 2002	JUL	NEWA
AB	25MG;20MG	N76265 003	JUL 08, 2002	JUL	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIRETIC

SCHWARZ PHARMA

12.5MG;15MG

N20729 003 FEB 14, 2002 JUN NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

@ WYETH AYERST

50MG;120MG

N19059 002 JUL 03, 1985 JUN DISC

INDERIDE LA 160/50

@ WYETH AYERST

50MG;160MG

N19059 003 JUL 03, 1985 JUN DISC

INDERIDE LA 80/50

@ WYETH AYERST

50MG;80MG

N19059 001 JUL 03, 1985 JUN DISC

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROPRES 25

@ MERCK

25MG;0.125MG

N11958 002 JUN DISC

HYDROPRES 50

@ MERCK

50MG;0.125MG

N11958 003 JUN DISC

HYDROCORTISONE

TABLET; ORAL

CORTEF

+ PHARMACIA AND UPJOHN

5MG

N08697 003 MAY CRLD

BP +

10MG

N08697 001 MAY CRLD

BP +

20MG

N08697 002 MAY CRLD

HYDROCORTISONE ACETATE

CREAM; TOPICAL

MICORT-HC

+ FERNDALE LABS

2%

N40398 001 MAR 29, 2002 MAR NEWA

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

+ STERIS

25MG/ML

N83128 001 JUN CRLD

HYDROCORTONE

@ MERCK

25MG/ML

N08228 001 JUN DISC

@

50MG/ML

N08228 004 JUN DISC

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

+ FERNDALE LABS

0.1%

N18514 001 MAR 31, 1982 MAR CAHN

LOCOID LIPOCREAM

+ FERNDALE LABS

0.1%

N20769 001 SEP 08, 1997 MAR CAHN

OINTMENT; TOPICAL

LOCOID

+ FERNDALE LABS

0.1%

N18652 001 OCT 29, 1982 MAR CAHN

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

ACHROMYCIN

@ LEDERLE

1.5%;1%

N50272 001

JUN DISC

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

RESERPINE AND HYDROFLUMETHIAZIDE

>D>	BP	PAR PHARM	50MG;0.125MG
>A>	ø		50MG;0.125MG
		SALUTENSIN-DEMI	
		@ SHIRE LABS	25MG;0.125MG

N88907 001	SEP 20, 1985	AUG	DISC
N88907 001	SEP 20, 1985	AUG	DISC
N12359 004		JUL	DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

@ AKORN

1%

N00004 004

JUN DISC

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

@ STERIS

250MG/ML

N17439 002

JUN DISC

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HCL

AA VINTAGE PHARMS

10MG/5ML

N40391 001 APR 10, 2002 APR NEWA

IBUPROFEN

SUSPENSION/DROPS; ORAL

MOTRIN

@ MCNEIL

40MG/ML

N20476 001 MAY 25, 1995 JUN DISC

TABLET; ORAL

@ MCNEIL CONS SPECLT

100MG

N20418 001 NOV 16, 1994 JUN DISC

TABLET, CHEWABLE; ORAL

@ MCNEIL CONS SPECLT

50MG

N20135 001 NOV 16, 1994 JUN DISC

@

100MG

N20135 002 NOV 16, 1994 JUN DISC

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

AP + PHARMACIA AND UPJOHN

5MG/VIAL

N50661 002 SEP 27, 1990 MAY CFTG

@

5MG/VIAL

N50661 002 SEP 27, 1990 JUN DISC

AP +

10MG/VIAL

N50661 001 SEP 27, 1990 MAY CFTG

@

10MG/VIAL

N50661 001 SEP 27, 1990 JUN DISC

AP +

20MG/VIAL

N50661 003 APR 25, 1995 MAY CFTG

@

20MG/VIAL

N50661 003 APR 25, 1995 JUN DISC

IDAMYCIN PFS

AP + PHARMACIA AND UPJOHN

1MG/ML

N50734 001 FEB 17, 1997 MAY CFTG

IDARUBICIN HCL

AP GENSIA SICOR PHARMS

5MG/VIAL

N65037 003 MAY 01, 2002 MAY NEWA

AP

10MG/VIAL

N65037 002 MAY 01, 2002 MAY NEWA

+ AP	10MG/VIAL 20MG/VIAL 20MG/VIAL	N65037 002 MAY 01, 2002 JUN CRLD N65037 001 MAY 01, 2002 MAY NEWA N65037 001 MAY 01, 2002 JUN CRLD
IDARUBICIN HCL PFS AP GENSIA SICOR PHARMS	1MG/ML	N65036 001 MAY 01, 2002 MAY NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

>D>	AM PHARM PARTNERS	1GM/VIAL	N76078 001 MAY 28, 2002 AUG CRLD
>A>	+ + +	1GM/VIAL 1GM/VIAL 3GM/VIAL	N76078 001 MAY 28, 2002 AUG CRLD N76078 001 MAY 28, 2002 MAY NEWA N76078 002 MAY 28, 2002 MAY NEWA

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+ + +	GENSIA SICOR PHARMS GENSIA SICOR PHARMS GENSIA SICOR PHARMS	1GM /20ML(50MG/ML);1GM /10ML(100MG/ML) 3GM /60ML(50MG/ML);1GM /10ML(100MG/ML)	N75874 001 FEB 26, 2002 FEB NEWA N75874 002 FEB 26, 2002 FEB NEWA
-------------	-------------------------------------------------------------------	----------------------------------------------------------------------------------------	----------------------------------------------------------------------

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE

AP + INOCOR @ SANOFI SYNTHELABO	ABBOTT	EQ 5MG BASE/ML	N74616 001 AUG 03, 1998 JUN CRLD
		EQ 5MG BASE/ML	N18700 001 JUL 31, 1984 JUN DISC

INDOCYANINE GREEN

INJECTABLE; INJECTION

CARDIO-GREEN

@ AKORN		50MG/VIAL	N11525 002 JUN DISC
---------	--	-----------	---------------------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB PAR PHARM AB	PAR PHARM	25MG 50MG	N18829 002 AUG 06, 1984 JUL CAHN N18829 001 AUG 06, 1984 JUL CAHN
AB ABLE	CAPSULE, EXTENDED RELEASE; ORAL	75MG	N76114 001 FEB 06, 2002 FEB NEWA
SUPPOSITORY; RECTAL			
INDOCIN			
@ MERCK			
INDOMETHEGAN			
+ G AND W LABS		50MG	N17814 001 AUG 13, 1984 MAY DISC
			N73314 001 AUG 31, 1992 MAY CRLD

INSULIN PORK

INJECTABLE; INJECTION

ILETIN I

@ LILLY		500 UNITS/ML	N17931 001 JUN DISC
---------	--	--------------	---------------------

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION
 CHOLOGRAFIN MEGLUMINE
 @ BRACCO 10.3%

N09321 007

JUN DISC

IODIXANOL

INJECTABLE; INJECTION
 VISIPAQUE 270
 @ AMERSHAM HLTH 55%
 VISIPAQUE 320
 @ AMERSHAM HLTH 65.2%

N20808 001 AUG 29, 1997 JUN DISC

N20808 002 AUG 29, 1997 JUN DISC

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION
 HIPPURAN I 131
 @ MALLINCKRODT 0.25mCi/ML

N16666 001

JUN DISC

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION
 SPECTAMINE
 @ IMP 1mCi/ML

N19432 001 DEC 24, 1987 JUN DISC

IOHEXOL

INJECTABLE; INJECTION
 OMNIPAQUE 210
 @ AMERSHAM HLTH 45.3%
 SOLUTION; URETHRAL
 OMNIPAQUE 70
 @ AMERSHAM HLTH 15.1%

N18956 006 JUN 30, 1989 JUN DISC

N18956 007 JUN 01, 1994 JUN DISC

IOPAMIDOL

INJECTABLE; INJECTION
 IOPAMIDOL
 @ FAULDING 61%
 @ 76%
 ISOVUE-128
 @ BRACCO 26%

N74734 001 DEC 10, 1996 JUL DISC

N74734 002 DEC 10, 1996 JUL DISC

N18735 005 OCT 21, 1986 JUN DISC

IOTHALAMATE SODIUM

INJECTABLE; INJECTION
 CONRAY 325
 @ MALLINCKRODT 54.3%

N17685 001

JUN DISC

IOXILAN

INJECTABLE; INJECTION
 OXILAN-300
 GUERBET 62%
 OXILAN-350
 GUERBET 73%

N20316 001 DEC 21, 1995 JUN CAHN

N20316 002 DEC 21, 1995 JUN CAHN

IPODATE SODIUM

CAPSULE; ORAL

ORAGRAFIN SODIUM

© BRACCO

500MG

N12967 001

JUN DISC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPATROPIUM BROMIDE

AN ROXANE

0.02%

N75867 001 JUL 22, 2002 JUL NEWA

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HCL

© 3M

0.12MG/INH

N10375 004

JUN DISC

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

© 3M

0.08MG/INH

N10375 003

JUN DISC

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

© ALCON

100GM/220ML

N17063 001

JUN DISC

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISMO

AB ESP PHARMA

20MG

N19091 001 DEC 30, 1991 JUL CAHN

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

AB NEOSAN PHARMS

200MG

N75341 001 JUL 27, 1999 JUL CAHN

AB TORPHARM

200MG

N75912 001 JAN 10, 2002 JAN NEWA

KETOPROFEN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

AB MYLAN

100MG

N75679 003 FEB 20, 2002 FEB NEWA

AB

150MG

N75679 002 FEB 20, 2002 FEB NEWA

AB

200MG

N75679 001 FEB 20, 2002 FEB NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP AM PHARM PARTNERS

15MG/ML

N75784 001 JAN 11, 2002 JAN NEWA

AP

30MG/ML

N75784 002 JAN 11, 2002 JAN NEWA

BX +		0.3MG	N21292 012	MAY 31, 2002	MAY	NEWA	AB
	SYNTHROID		N21402 001	JUL 24, 2002	JUL	NEWA	AB
BX	ABBOTT	0.025MG	N21402 002	JUL 24, 2002	JUL	NEWA	AB
BX		0.05MG	N21402 003	JUL 24, 2002	JUL	NEWA	AB
BX		0.075MG	N21402 004	JUL 24, 2002	JUL	NEWA	AB
BX		0.088MG	N21402 005	JUL 24, 2002	JUL	NEWA	AB
BX		0.1MG	N21402 006	JUL 24, 2002	JUL	NEWA	AB
BX		0.112MG	N21402 007	JUL 24, 2002	JUL	NEWA	AB
BX		0.125MG	N21402 008	JUL 24, 2002	JUL	NEWA	AB
BX		0.137MG	N21402 009	JUL 24, 2002	JUL	NEWA	AB
BX		0.15MG	N21402 010	JUL 24, 2002	JUL	NEWA	AB
BX		0.175MG	N21402 012	JUL 24, 2002	AUG	NEWA	AB
>A>	BX	0.2MG	N21402 011	JUL 24, 2002	JUL	NEWA	AB
BX +		0.3MG					
	UNITHROID						>A> AB
AB	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	JUN	CRLD	>A> AB
AB		0.05MG	N21210 002	AUG 21, 2000	JUN	CRLD	>A> AB
AB		0.075MG	N21210 003	AUG 21, 2000	JUN	CRLD	>A> AB
AB		0.088MG	N21210 004	AUG 21, 2000	JUN	CRLD	>A> AB
AB		0.1MG	N21210 005	AUG 21, 2000	JUN	CRLD	>A> AB
AB		0.112MG	N21210 006	AUG 21, 2000	JUN	CRLD	AB
AB		0.125MG	N21210 007	AUG 21, 2000	JUN	CRLD	AB
AB		0.15MG	N21210 008	AUG 21, 2000	JUN	CRLD	AB
AB		0.175MG	N21210 009	AUG 21, 2000	JUN	CRLD	AB
AB		0.2MG	N21210 010	AUG 21, 2000	JUN	CRLD	AB
AB +		0.3MG	N21210 011	AUG 21, 2000	JUN	CRLD	AB
							AB
	<u>LIDOCAINE</u>						AB
	AEROSOL; ORAL						AB
	XYLOCAINE						AB
@ ASTRazeneca		10%	N14394 001		JUN	DISC	AB
FILM, EXTENDED RELEASE; Buccal							AB
LIDOCaine							AB
@ NOVEN		23MG/PATCH	N20575 001	MAY 21, 1996	JUN	DISC	AB
							AB
	<u>LINCOMYCIN HYDROCHLORIDE</u>						AB
	CAPSULE; ORAL						AB
	LINCOCIN						AB
@ PHARMACIA AND UPJOHN		EQ 250MG BASE	N50316 001		JUN	DISC	AB
@		EQ 500MG BASE	N50316 002		JUN	DISC	AB
							AB
	<u>LINEZOLID</u>						AB
	TABLET; ORAL						AB
	ZYVOX						AB
@ PHARMACIA AND UPJOHN		400MG	N21130 001	APR 18, 2000	JUN	DISC	AB
							AB
	<u>LISINOPRIL</u>						AB
	TABLET; ORAL						AB
	LISINOPRIL						AB
AB	EON	2.5MG	N75994 001	JUL 01, 2002	JUL	NEWA	AB
AB		5MG	N75994 002	JUL 01, 2002	JUL	NEWA	AB
AB		10MG	N75994 003	JUL 01, 2002	JUL	NEWA	AB
AB		20MG	N75994 004	JUL 01, 2002	JUL	NEWA	AB

AB		30MG	N75994 005	JUL 01, 2002	JUL	NEWA	
AB		40MG	N75994 006	JUL 01, 2002	JUL	NEWA	
AB	GENEVA PHARMS TECH	2.5MG	N75903 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N75903 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N75903 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N75903 004	JUL 01, 2002	JUL	NEWA	
AB		30MG	N75903 005	JUL 01, 2002	JUL	NEWA	
AB		40MG	N75903 006	JUL 01, 2002	JUL	NEWA	
AB	IVAX PHARMS	2.5MG	N75752 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N75752 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N75752 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N75752 004	JUL 01, 2002	JUL	NEWA	
AB		30MG	N75752 005	JUL 01, 2002	JUL	NEWA	
AB		40MG	N75752 006	JUL 01, 2002	JUL	NEWA	
>A>	AB	LEK PHARM	2.5MG	N75999 001	JUL 01, 2002	AUG	NEWA
>A>	AB		5MG	N75999 002	JUL 01, 2002	AUG	NEWA
>A>	AB		10MG	N75999 003	JUL 01, 2002	AUG	NEWA
>A>	AB		20MG	N75999 004	JUL 01, 2002	AUG	NEWA
>A>	AB		30MG	N75999 005	JUL 01, 2002	AUG	NEWA
>A>	AB		40MG	N75999 006	JUL 01, 2002	AUG	NEWA
AB	MYLAN	2.5MG	N76071 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N76071 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N76071 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N76071 004	JUL 01, 2002	JUL	NEWA	
AB		30MG	N76071 005	JUL 01, 2002	JUL	NEWA	
AB		40MG	N76071 006	JUL 01, 2002	JUL	NEWA	
AB	PAR PHARM	2.5MG	N75743 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N75743 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N75743 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N75743 004	JUL 01, 2002	JUL	NEWA	
AB		30MG	N75743 005	JUL 01, 2002	JUL	NEWA	
AB		40MG	N75743 006	JUL 01, 2002	JUL	NEWA	
AB	PUREPAC PHARM	2.5MG	N76180 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N76180 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N76180 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N76164 001	JUL 01, 2002	JUL	NEWA	
AB		30MG	N76164 002	JUL 01, 2002	JUL	NEWA	
AB		40MG	N76164 003	JUL 01, 2002	JUL	NEWA	
AB	RANBAXY	2.5MG	N75944 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N75944 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N75944 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N75944 004	JUL 01, 2002	JUL	NEWA	
AB		40MG	N75944 005	JUL 01, 2002	JUL	NEWA	
AB	TEVA	2.5MG	N75783 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N75783 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N75783 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N75783 004	JUL 01, 2002	JUL	NEWA	
AB		30MG	N75783 005	JUL 01, 2002	JUL	NEWA	
AB		40MG	N75783 006	JUL 01, 2002	JUL	NEWA	
AB	WATSON LABS	2.5MG	N76059 001	JUL 01, 2002	JUL	NEWA	
AB		5MG	N76059 002	JUL 01, 2002	JUL	NEWA	
AB		10MG	N76059 003	JUL 01, 2002	JUL	NEWA	
AB		20MG	N76059 004	JUL 01, 2002	JUL	NEWA	

AB		30MG	N76059 005	JUL 01, 2002	JUL	NEWA
AB		40MG	N76059 006	JUL 01, 2002	JUL	NEWA
AB	WEST WARD	2.5MG	N76063 001	JUL 01, 2002	JUL	NEWA
AB		5MG	N76063 002	JUL 01, 2002	JUL	NEWA
AB		10MG	N76063 003	JUL 01, 2002	JUL	NEWA
AB		20MG	N76063 004	JUL 01, 2002	JUL	NEWA
AB		40MG	N76063 005	JUL 01, 2002	JUL	NEWA
ZESTRIL						
AB + ASTRazeneca		30MG	N19777 006	JAN 20, 1999	JUL	CFTG

LITHIUM CARBONATE

CAPSULE; ORAL						
LITHIUM CARBONATE						
AB	WEST WARD	300MG	N76243 001	JUN 27, 2002	JUN	NEWA
TABLET, EXTENDED RELEASE; ORAL						
AB	BARR	300MG	N76170 001	JUN 10, 2002	JUN	NEWA
LITHOBID						
AB + SOLVAY		300MG	N18027 001		JUN	CFTG

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL						
MAXAQUIN						
+ PHARMACIA		EQ 400MG BASE	N20013 001	FEB 21, 1992	JUL	CAHN

LORATADINE

TABLET; ORAL						
CLARITIN						
+ SCHERING		10MG	N19658 001	APR 12, 1993	JUL	CTEC

LOVASTATIN

TABLET; ORAL						
LOVASTATIN						
AB	CARLSBAD	10MG	N75991 001	JUN 05, 2002	JUN	NEWA
AB		20MG	N75991 002	JUN 05, 2002	JUN	NEWA
AB		40MG	N75991 003	JUN 05, 2002	JUN	NEWA
TABLET, EXTENDED RELEASE; ORAL						
ALTOCOR						
ANDRX		10MG	N21316 001	JUN 26, 2002	JUL	CAHN
		20MG	N21316 002	JUN 26, 2002	JUL	CAHN
		40MG	N21316 003	JUN 26, 2002	JUL	CAHN
+		60MG	N21316 004	JUN 26, 2002	JUL	CAHN
AURA LABS						
		10MG	N21316 001	JUN 26, 2002	JUN	NEWA
		20MG	N21316 002	JUN 26, 2002	JUN	NEWA
		40MG	N21316 003	JUN 26, 2002	JUN	NEWA
+		60MG	N21316 004	JUN 26, 2002	JUN	NEWA

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL						
LOXITANE C						
@ WATSON LABS		EQ 25MG BASE/ML	N17658 001		JUL	DISC
INJECTABLE; INJECTION						
LOXITANE IM						
@ WATSON LABS		EQ 50MG BASE/ML	N18039 001		JUL	DISC

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

@ BRACCO

3.49MG/GM

N20686 001 DEC 19, 1997 JUN DISC

MASOPROCOL

CREAM; TOPICAL

ACTINEX

@ UNIV AZ CANCER CTR

10%

N19940 001 SEP 04, 1992 JUN DISC

MAZINDOL

TABLET; ORAL

MAZANOR

@ WYETH AYERST

1MG

N17980 002

APR DISC

SANOREX

NOVARTIS

1MG

N17247 001

APR CTEC

@

1MG

N17247 001

JUN DISC

@

2MG

N17247 002

JUN DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

AB + ROCHE

250MG

N19591 001 MAY 02, 1989 FEB CFTG

MEFLOQUINE HCL

AB GENEVA PHARMS TECH

250MG

N76175 001 FEB 20, 2002 FEB NEWA

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB ROXANE

40MG/ML

N75997 001 FEB 15, 2002 FEB NEWA

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

PERGONAL

>D> @ SERONO

75 IU/AMP;75 IU/AMP

N17646 001

AUG CMFD

>A> BX +

75 IU/AMP;75 IU/AMP

N17646 001

AUG CMFD

75 IU/AMP;75 IU/AMP

N17646 001

JUN DISC

@

150 IU/AMP;150 IU/AMP

N17646 002

MAY 20, 1985 JUN DISC

REPRONEX

>D> + FERRING

75 IU/VIAL;75 IU/VIAL

N21047 001

AUG 27, 1999 AUG CRLD

>A> BX

75 IU/VIAL;75 IU/VIAL

N21047 001

AUG 27, 1999 AUG CRLD

+

75 IU/VIAL;75 IU/VIAL

N21047 001

AUG 27, 1999 JUN CRLD

+

150 IU/VIAL;150 IU/VIAL

N21047 002

AUG 27, 1999 JUN CRLD

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HCL

>A> AA CARACO

50MG

N40446 001

AUG 08, 2002 AUG NEWA

>A> AA

100MG

N40446 002

AUG 08, 2002 AUG NEWA

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@ WYETH AYERST

25MG/ML;25MG/ML

N11730 001

JUN DISC

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

@ WYETH AYERST

EQ 15MG BASE/ML

N08248 002

JUN DISC

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

@ NOVARTIS

100MG

N06008 001

JUN DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ GALDERMA LABS

2%;0.01%

N20922 001 DEC 10, 1999 APR CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNEX

AP + BAXTER HLTHCARE

100MG/ML

N19884 001 DEC 30, 1988 MAR CAHN

TABLET; ORAL

+ BAXTER HLTHCARE

400MG

N20855 001 MAR 21, 2002 JUN CAHN

+ BRISTOL MYERS SQUIBB

400MG

N20855 001 MAR 21, 2002 MAR NEWA

MESORIDAZINE BESYLATE

INJECTABLE; INJECTION

SERENTIL

@ NOVARTIS

EQ 25MG BASE/ML

N16775 001

JUN DISC

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

AB WATSON LABS

0.05MG;1MG

N16659 001

JAN CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION

ALUPENT

@ BOEHRINGER INGELHEIM

5%

N17659 001

JUN DISC

METAPROTERENOL SULFATE

AN MORTON GROVE

0.4%

N75586 001 MAY 30, 2002 MAY NEWA

AN

0.6%

N75586 002 MAY 30, 2002 MAY NEWA

METAXALONE

TABLET; ORAL

SKELAXIN

>D>

+ ELAN PHARMS

400MG

N13217 001

AUG CRLD

>A>

400MG

N13217 001

AUG CRLD

+

400MG

N13217 001

JUN CAHN

>A>	+	800MG	N13217 003	AUG 30, 2002	AUG NEWA			
<u>METFORMIN HYDROCHLORIDE</u>								
TABLET; ORAL								
GLUCOPHAGE								
JUN	DISC	AB	BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995	JAN	CFTG
AB		850MG	N20357 002	MAR 03, 1995	JAN	CFTG		
AB	+	1GM	N20357 005	NOV 05, 1998	JAN	CFTG		
METFORMIN HCL								
JUN	DISC	AB	ALPHAPHARM	500MG	N75969 001	JAN 29, 2002	JAN	NEWA
AB		850MG	N75969 002	JAN 29, 2002	JAN	NEWA		
AB		1GM	N75969 003	JAN 29, 2002	JAN	NEWA		
AB	ANDRX PHARMS	500MG	N75961 001	JAN 25, 2002	JAN	NEWA		
AB		850MG	N75961 002	JAN 25, 2002	JAN	NEWA		
AB		1GM	N75961 003	JAN 25, 2002	JAN	NEWA		
JUN	DISC	AB	BARR	500MG	N75971 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75971 002	JAN 25, 2002	JAN	NEWA		
AB		1GM	N75971 003	JAN 25, 2002	JAN	NEWA		
AB	CARACO	500MG	N75967 001	JAN 29, 2002	JAN	NEWA		
APR	CAHN	AB		850MG	N75967 002	JAN 29, 2002	JAN	NEWA
AB		1GM	N75967 003	JAN 29, 2002	JAN	NEWA		
AB	EON	500MG	N75965 001	JAN 25, 2002	JAN	NEWA		
AB		850MG	N75965 002	JAN 25, 2002	JAN	NEWA		
AB		1GM	N75965 003	JAN 25, 2002	JAN	NEWA		
MAR	CAHN	AB	GENEVA PHARMS	500MG	N75985 001	JAN 25, 2002	MAY	CAHN
AB		850MG	N75985 002	JAN 25, 2002	MAY	CAHN		
JUN	CAHN	AB		1GM	N75985 003	JAN 25, 2002	MAY	CAHN
MAR	NEWA	AB	GENEVA PHARMS TECH	500MG	N75985 001	JAN 25, 2002	JAN	NEWA
AB		850MG	N75985 002	JAN 25, 2002	JAN	NEWA		
AB		1GM	N75985 003	JAN 25, 2002	JAN	NEWA		
AB	GENPHARM	500MG	N75973 001	JAN 25, 2002	JAN	NEWA		
AB		850MG	N75973 002	JAN 25, 2002	JAN	NEWA		
JUN	DISC	AB		1GM	N75973 003	JAN 25, 2002	JAN	NEWA
AB	GOLDLINE	500MG	N75972 001	JAN 24, 2002	JAN	NEWA		
AB		625MG	N75972 005	JAN 24, 2002	JAN	NEWA		
AB		750MG	N75972 004	JAN 24, 2002	JAN	NEWA		
AB		850MG	N75972 002	JAN 24, 2002	JAN	NEWA		
JAN	CAHN	AB		1GM	N75972 003	JAN 24, 2002	JAN	NEWA
AB	MUTUAL PHARMA	500MG	N76038 001	FEB 21, 2002	FEB	NEWA		
AB		850MG	N76038 002	FEB 21, 2002	FEB	NEWA		
AB		1GM	N76038 003	FEB 21, 2002	FEB	NEWA		
AB	MYLAN	500MG	N75976 001	JAN 24, 2002	JAN	NEWA		
JUN	DISC	AB		850MG	N75976 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N75976 003	JAN 24, 2002	JAN	NEWA		
MAY	NEWA	AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002	JAN	NEWA
MAY	NEWA	AB		850MG	N76033 002	JAN 24, 2002	JAN	NEWA
AB		1GM	N76033 003	JAN 24, 2001	JAN	NEWA		
AB	TEVA	500MG	N75978 001	JAN 25, 2002	JAN	NEWA		
AB		850MG	N75978 002	JAN 25, 2002	JAN	NEWA		
AB	TORPHARM	500MG	N75984 001	APR 23, 2002	APR	NEWA		
AUG	CRLD	AB		850MG	N75984 002	APR 23, 2002	APR	NEWA
AUG	CRLD	AB		1GM	N75984 003	APR 23, 2002	APR	NEWA
JUN	CAHN	AB	WATSON LABS	500MG	N75979 001	JAN 24, 2002	JAN	NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - AUG 2002

AB		850MG	N75979 002	JAN 24, 2002
AB		1GM	N75979 003	JAN 24, 2002
AB	ZENITH GOLDLINE	500MG	N75975 001	JAN 24, 2002
AB		625MG	N75975 004	JAN 24, 2002
AB		750MG	N75975 005	JAN 24, 2002
AB		850MG	N75975 002	JAN 24, 2002
AB		1GM	N75975 003	JAN 24, 2002

METHADONE HYDROCHLORIDE

SYRUP; ORAL
DOLOPHINE HCL
@ ROXANE 10MG/30ML

N06134 004

METHAMPHETAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
DESOXYN
@ ABBOTT 5MG
@ 10MG
@ 15MG

N05378 004
N05378 003
N05378 005

METHANTHELINE BROMIDE

TABLET; ORAL
BANTHINE
@ SHIRE LABS 50MG

N07390 001

METHOHEXITAL SODIUM

INJECTABLE; INJECTION
BREVITAL SODIUM
+ KING PHARMS 500MG/VIAL
+ 2.5GM/VIAL
+ 5GM/VIAL

N11559 001
N11559 002
N11559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION
FOLEX
+ PHARMACIA AND UPJOHN EQ 50MG BASE/VIAL
+ EQ 100MG BASE/VIAL
METHOTREXATE SODIUM
@ LEDERLE EQ 2.5MG BASE/ML
@ EQ 50MG BASE/VIAL
@ EQ 100MG BASE/VIAL
TABLET; ORAL
AB + CLONMEL HLTHCARE EQ 2.5MG BASE

N87695 002 APR 08, 1983
N87695 003 APR 08, 1983
N11719 004
N11719 003
N11719 006
N08085 002

METHYLDOPA

SUSPENSION; ORAL
ALDOMET
@ MERCK 250MG/5ML

N18389 001

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD
BX + CELLTECH PHARMS 20MG

N21259 001 APR 03, 2001

JAN 24, 2002	JAN	NEWA	<u>METHYLPHENIDATE HYDROCHLORIDE</u>					
JAN 24, 2002	JAN	NEWA	CAPSULE, EXTENDED RELEASE; ORAL					
JAN 24, 2002	JAN	NEWA	RITALIN LA					
JAN 24, 2002	JAN	NEWA	BX NOVARTIS	20MG	N21284 001	JUN 05, 2002	JUN	NEWA
JAN 24, 2002	JAN	NEWA		30MG	N21284 002	JUN 05, 2002	JUN	NEWA
JAN 24, 2002	JAN	NEWA	+ TABLET; ORAL	40MG	N21284 003	JUN 05, 2002	JUN	NEWA
JAN 24, 2002	JAN	NEWA	METHYLPHENIDATE HCL					
JUL	DISC		AB PUREPAC PHARM	5MG	N40321 001	FEB 05, 2002	FEB	NEWA
			AB	10MG	N40321 002	FEB 05, 2002	FEB	NEWA
			AB	20MG	N40321 003	FEB 05, 2002	FEB	NEWA
			TABLET, EXTENDED RELEASE; ORAL					
			CONCERTA					
			+ ALZA	27MG	N21121 004	APR 01, 2002	JUN	NEWA
JUN	DISC		<u>METHYLPREDNISOLONE</u>					
JUN	DISC		TABLET; ORAL					
JUN	DISC		METHYLPREDNISOLONE					
			AB GENEVA PHARMS	4MG	N40194 001	OCT 31, 1997	MAY	CAHN
			<u>METRONIDAZOLE</u>					
			INJECTABLE; INJECTION					
			FLAGYL I.V. RTU IN PLASTIC CONTAINER					
JUL	DISC		AP + GD SEARLE LLC	500MG/100ML	N18353 002		JUL	CAHN
			<u>METRONIDAZOLE HYDROCHLORIDE</u>					
			INJECTABLE; INJECTION					
			FLAGYL I.V.					
FEB	CAHN		+ GD SEARLE LLC	EQ 500MG BASE/VIAL	N18353 001		JUL	CAHN
FEB	CAHN		<u>MICONAZOLE NITRATE</u>					
FEB	CAHN		CREAM, INSERT; TOPICAL, VAGINAL					
			MONISTAT DUAL- PAK					
			@ PERSONAL PRODS	1.2GM;2%	N20968 001	JUN 30, 1999	JUN	DISC
APR 08, 1983	JUN	CRDL	<u>MIDAZOLAM HYDROCHLORIDE</u>					
APR 08, 1983	JUN	CRDL	INJECTABLE; INJECTION					
			MIDAZOLAM HCL					
JUN	DISC		AP ABBOTT	EQ 1MG BASE/ML	N75857 001	JUL 22, 2002	JUL	NEWA
JUN	DISC		AP	EQ 5MG BASE/ML	N75857 002	JUL 22, 2002	JUL	NEWA
JUN	DISC		AP ROSS LABS	EQ 1MG BASE/ML	N75856 001	JUN 13, 2002	JUN	NEWA
			AP	EQ 5MG BASE/ML	N75856 002	JUN 13, 2002	JUN	NEWA
JUL	CAHN		SYRUP; ORAL					
			AA RANBAXY	EQ 2MG BASE/ML	N76058 001	MAR 15, 2002	MAR	NEWA
			AA ROXANE	EQ 2MG BASE/ML	N75873 001	APR 30, 2002	APR	NEWA
		>D>	VERSED					
		>D>	AA + ROCHE	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	AUG	DISC
JUN	DISC	>A>	@	EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	AUG	DISC
		AA +		EQ 2MG BASE/ML	N20942 001	OCT 15, 1998	MAR	CFTG

MIDODRINE HYDROCHLORIDE

TABLET; ORAL						
PROAMATINE						
+ SHIRE LABS	5MG			N19815 002	SEP 06, 1996	JUL CRLD
+	10MG			N19815 003	MAR 20, 2002	JUN NEWA
	10MG			N19815 003	MAR 20, 2002	JUL CRLD
SHIRE PHARM	5MG			N19815 002	SEP 06, 1996	JUN CRLD

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP ABBOTT	EQ 1MG BASE/ML	N75884 001	MAY 28, 2002	MAY	NEWA
AP AM PHARM PARTNERS	EQ 1MG BASE/ML	N75936 001	MAY 28, 2002	MAY	NEWA
AP BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002	MAY	NEWA
AP BEDFORD	EQ 10MG 10/ML (10MG/ML)	N75660 001	MAY 28, 2002	MAY	NEWA
AP	EQ 20MG /20ML (1MG/ML)	N75660 002	MAY 28, 2002	MAY	NEWA
AP	EQ 50MG /50ML (1MG/ML)	N75660 003	MAY 28, 2002	MAY	NEWA
AP ESI LEDERLE	EQ 1MG BASE/ML	N75530 001	MAY 28, 2002	MAY	NEWA
AP FAULDING	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002	MAY	NEWA
>A> AP INT'L MEDICATED	EQ 1MG BASE/ML	N76013 001	AUG 02, 2002	AUG	NEWA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002	MAY	NEWA
AP +	EQ 40MG BASE/200ML	N75885 002	MAY 28, 2002	MAY	NEWA
AP BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002	MAY	NEWA
AP	EQ 40MG BASE/100ML	N75834 002	MAY 28, 2002	MAY	NEWA
AP	EQ 40MG BASE/200ML	N75834 002	MAY 28, 2002	JUN	NEWA
AP ESI LEDERLE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002	MAY	NEWA
MILRINONE LACTOSE IN 5% DEXTROSE					
>A> AP ESI LEDERLE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002	AUG	NEWA
PRIMACOR					
AP + SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987	MAY	CFTG
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994	MAY	CFTG
AP +	EQ 40MG BASE/100ML	N20343 004	AUG 09, 1994	MAY	CFTG
AP +	EQ 40MG BASE/200ML	N20343 004	AUG 09, 1994	JUN	CFTG

MINOCYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

MINOCIN

@ LEDERLE EQ 50MG BASE/5ML

N50445 001

JUN DISC

MISOPROSTOL

TABLET; ORAL

CYTOTEC

AB GD SEARLE LLC	0.1MG	N19268 003	SEP 21, 1990	JUL	CFTG
AB +	0.2MG	N19268 001	DEC 27, 1988	JUL	CFTG
MISOPROSTOL					
AB IVAX PHARMS	0.1MG	N76095 001	JUL 10, 2002	JUL	NEWA
AB	0.2MG	N76095 002	JUL 10, 2002	JUL	NEWA

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ABBOTT

EQ 0.5MG BASE/ML

N20098 002 JAN 22, 1992 JUN DISC

MOMETASONE FUROATE

OINTMENT; TOPICAL

ELOCON

AB + SCHERING 0.1%

MOMETASONE FUROATE

AB CLAY PARK 0.1%

N19543 001 APR 30, 1987 MAR CFTG

N76067 001 MAR 18, 2002 MAR NEWA

MONOCTANOIN

LIQUID; PERfusion, BILIARY

MOCTANIN

@ ETHITEK 100%

N19368 001 OCT 29, 1985 JUN DISC

MONTELUKAST SODIUM

GRANULE; ORAL

SINGULAIR

+ MERCK EQ 4MG BASE/PACKET

N21409 001 JUL 26, 2002 JUL NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

ELAN PHARM	30MG	N21260 001	MAR 20, 2002	MAR	NEWA
	60MG	N21260 002	MAR 20, 2002	MAR	NEWA
	90MG	N21260 003	MAR 20, 2002	MAR	NEWA
+	120MG	N21260 004	MAR 20, 2002	MAR	NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

AB EON	500MG	N75280 001	FEB 25, 2002	FEB	NEWA
AB	750MG	N75280 002	FEB 25, 2002	FEB	NEWA
AB INVAMED	500MG	N75590 001	FEB 25, 2002	FEB	NEWA
AB	750MG	N75590 002	FEB 25, 2002	FEB	NEWA

NAFCILLIN SODIUM

CAPSULE; ORAL

UNIPEN

@ WYETH AYERST EQ 250MG BASE

N50111 001

JUN DISC

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

@ ABBOTT 1.5MG/ML

N20200 001 MAR 12, 1993 JUL DISC

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

@ SANOFI SYNTHELABO 250MG/5ML

N17430 001

JUN DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HCL

MALLINCKRODT	25MG	N76264 001 MAR 22, 2002 MAR NEWA
AB	50MG	N76264 002 MAR 22, 2002 MAR NEWA
+	100MG	N76264 003 MAR 22, 2002 MAR NEWA

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

@ ELAN PHARM

EQ 750MG BASE

N20353 003 JAN 05, 1996 JUN DISC

NEOMYCIN SULFATE

SOLUTION; ORAL

MYCIFRADIN

AA + PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N50285 001 MAY CFTG
@	EQ 87.5MG BASE/5ML	N50285 001 JUN DISC
NEO-FRADIN		
AA PHARMATEK	EQ 87.5MG BASE/5ML	N65010 001 MAY 23, 2002 MAY NEWA
+	EQ 87.5MG BASE/5ML	N65010 001 MAY 23, 2002 JUN CRLD

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

STATROL

@ ALCON

EQ 3.5MG BASE/GM;10,000 UNITS/GM

N50344 002

JUN DISC

SOLUTION/DROPS; OPHTHALMIC

@ ALCON

EQ 3.5MG BASE/ML;16,250 UNITS/ML

N50456 001

JUN DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIASPAN

>D+ KOS	375MG	N20381 001 JUL 28, 1997 AUG DISC
>A@	375MG	N20381 001 JUL 28, 1997 AUG DISC
>D@	500MG	N20381 002 JUL 28, 1997 AUG CMFD
>A+ @	500MG	N20381 002 JUL 28, 1997 AUG CMFD
NIASPAN TITRATION STARTER PACK		
@ KOS	375MG;500MG;750MG	N20381 005 JUL 28, 1997 JUN DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

>D BC + BAYER	90MG	N20198 003 APR 21, 1993 AUG CTEC
>A AB1 +	90MG	N20198 003 APR 21, 1993 AUG CTEC
NIFEDIPINE		
>A AB1 BIOVAIL	90MG	N76070 001 AUG 16, 2002 AUG NEWA

NILUTAMIDE

TABLET; ORAL

NILANDRON

@ AVENTIS PHARMS	50MG	N20169 001 SEP 19, 1996 JUN DISC
+	150MG	N20169 002 APR 30, 1999 JUL CMFD

NISOLDIPINE

TABLET; EXTENDED RELEASE; ORAL

SULAR

+ FIRST HORIZON	10MG	N20356 001	FEB 02, 1995	MAR	CAHN
	20MG	N20356 002	FEB 02, 1995	MAR	CAHN
+	30MG	N20356 003	FEB 02, 1995	MAR	CAHN
+	40MG	N20356 004	FEB 02, 1995	MAR	CAHN
+ WHITEHALL ROBINS	10MG	N20356 001	FEB 02, 1995	FEB	CAHN
	20MG	N20356 002	FEB 02, 1995	FEB	CAHN
+	40MG	N20356 004	FEB 02, 1995	FEB	CAHN

NITISINONE

CAPSULE; ORAL

ORFADIN

R R REGISTRATIONS	2MG	N21232 001	JAN 18, 2002	JAN	NEWA
	5MG	N21232 002	JAN 18, 2002	JAN	NEWA
+	10MG	N21232 003	JAN 18, 2002	JAN	NEWA
SWEDISH ORPHAN	2MG	N21232 001	JAN 18, 2002	MAY	CAHN
	5MG	N21232 002	JAN 18, 2002	MAY	CAHN
+	10MG	N21232 003	JAN 18, 2002	MAY	CAHN

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

+ FIRST HORIZON	25MG/5ML	N09175 001		JAN	CAHN
-----------------	----------	------------	--	-----	------

NITROFURAZONE

CREAM; TOPICAL

FURACIN

@ SHIRE LABS	0.2%	N83789 001		JUL	DISC
OINTMENT; TOPICAL		N05795 001		JUL	DISC
@ SHIRE LABS	0.2%				
NITROFURAZONE					

AT + TARO

0.2%

N86156 001

JUL CRLD

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

@ FIRST HORIZON	0.4MG/SPRAY	N18705 001	OCT 31, 1985	APR	CAHN
@ POHL BOSKAMP	0.4MG/SPRAY	N18705 001	OCT 31, 1985	JUN	CAHN

SPRAY, METERED; SUBLINGUAL

NITROLINGUAL PUMPSPRAY

+ FIRST HORIZON	0.4MG/SPRAY	N18705 002	JAN 10, 1997	APR	CAHN
+ POHL BOSKAMP	0.4MG/SPRAY	N18705 002	JAN 10, 1997	JUN	CAHN

TABLET; SUBLINGUAL

NITROSTAT

PFIZER PHARMS	0.4MG	N21134 002	MAY 01, 2000	JUN	CAHN
---------------	-------	------------	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

AXID

>D AB LILLY	150MG	N19508 001	APR 12, 1988	AUG	CAHN
-------------	-------	------------	--------------	-----	------

AB		150MG	N19508 001	APR 12, 1988	JUL	CFTG
>D>	AB +	300MG	N19508 002	APR 12, 1988	AUG	CAHN
	AB +	300MG	N19508 002	APR 12, 1988	JUL	CFTG
>A>	AB RELIANT PHARMS	150MG	N19508 001	APR 12, 1988	AUG	CAHN
>A>	AB +	300MG	N19508 002	APR 12, 1988	AUG	CAHN
<u>NIZATIDINE</u>						
AB	EON	150MG	N76178 001	JUL 05, 2002	JUL	NEWA
AB		300MG	N76178 002	JUL 05, 2002	JUL	NEWA
AB	GENPHARM	150MG	N75934 001	JUL 09, 2002	JUL	NEWA
AB		300MG	N75934 002	JUL 09, 2002	JUL	NEWA
AB	MYLAN	150MG	N75806 001	JUL 05, 2002	JUL	NEWA
AB		300MG	N75806 002	JUL 05, 2002	JUL	NEWA
AB	WATSON LABS	150MG	N75616 001	JUL 09, 2002	JUL	NEWA
AB		300MG	N75616 002	JUL 09, 2002	JUL	NEWA
AB	ZENITH GOLDLINE	150MG	N75461 001	JUL 08, 2002	JUL	NEWA
AB		300MG	N75461 002	JUL 08, 2002	JUL	NEWA

NORETHINDRONE

TABLET; ORAL

NOR-QD

+ WATSON LABS (UTAH) 0.35MG

N17060 001

MAY CAHN

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

AVENTYL HCL

AA + RANBAXY EQ 10MG BASE/5ML

N14685 001

JUN CAHN

NOVOBIOCIN SODIUM

CAPSULE; ORAL

ALBAMYCIN

@ PHARMACIA AND UPJOHN EQ 250MG BASE

N50339 001

JUN DISC

NYSTATIN

TABLET; ORAL

NILSTAT

@ LEDERLE 500,000 UNITS

N61151 001

JUN DISC

TABLET; VAGINAL

@ LEDERLE 100,000 UNITS

N61325 001

JUL DISC

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

AP + JOHNSON RW 40MG/ML
@ ORTHO MCNEIL PHARM 20MG/MLN20087 003 MAR 31, 1992 JAN CFTG
N20087 002 MAR 31, 1992 JUL DISCOFLOXACIN
AP BEDFORD 40MG/ML

N75762 001 JAN 16, 2002 JAN NEWA

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

SANKYO 5MG
20MG
+ 40MGN21286 001 APR 25, 2002 APR NEWA
N21286 003 APR 25, 2002 APR NEWA
N21286 004 APR 25, 2002 APR NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

>A>	SANOFI	50MG/VIAL	N21492 001	AUG 09, 2002	AUG	NEWA
>A>	+	100MG/VIAL	N21492 002	AUG 09, 2002	AUG	NEWA

OXANDROLONE

TABLET; ORAL

OXANDRIN

BIO TECH GEN	2.5MG	N13718 001	JUN	CRLD
+	10MG	N13718 002	NOV 05, 2001	JUN NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	CARACO	600MG	N75844 001	JAN 03, 2002	JAN	NEWA
AB	IVAX PHARMS	600MG	N75846 001	MAY 13, 2002	MAY	NEWA
AB	TEVA	600MG	N75849 001	JUL 03, 2002	JUL	NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	ABBOTT	6MG/ML	N76131 001	MAY 08, 2002	MAY	NEWA
>A>	AP	NAPRO	N76233 001	AUG 01, 2002	AUG	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	AESGEN	30MG/VIAL	N75594 001	MAY 06, 2002	MAY	NEWA
AP		90MG/VIAL	N75594 002	MAY 06, 2002	MAY	NEWA
AP	AM PHARM PARTNERS	30MG/VIAL	N75773 001	MAY 06, 2002	MAY	NEWA
AP		30MG /10ML(3MG/ML)	N76207 001	MAY 17, 2002	MAY	NEWA
AP		90MG/VIAL	N75773 002	MAY 06, 2002	MAY	NEWA
AP		90MG /10ML(9MG/ML)	N76207 002	MAY 17, 2002	MAY	NEWA
AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAY	CDFR
AP	+	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAY	CDFR
AP	FAULDING	30MG /10ML(3MG/ML)	N75841 001	JUN 27, 2002	JUN	NEWA
AP		60MG /10ML(6MG/ML)	N75841 002	JUN 27, 2002	JUN	NEWA
AP		90MG /10ML(9MG/ML)	N75841 003	JUN 27, 2002	JUN	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAY	CDFR
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAY	CDFR

INJECTABLE; IV (INFUSION)

AP	BEDFORD	30MG /10ML(3MG/ML)	N21113 001	MAR 04, 2002	MAR	NEWA
AP	+	90MG /10ML(9MG/ML)	N21113 002	MAR 04, 2002	MAR	NEWA
AP	GENSIA SICOR PHARMS	30MG /10ML(3MG/ML)	N76153 001	MAR 27, 2002	MAR	NEWA
AP		90MG /10ML(9MG/ML)	N76153 002	MAR 27, 2002	MAR	NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL

COTAZYME

@ ORGANON

30,000Usp UNITS;8,000Usp
UNITS;30,000Usp UNITS

N20580 001 DEC 09, 1996 JUN DISC

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

@ ABBOTT

150MG

N06800 003

JUN DISC

@

300MG

N06800 001

JUN DISC

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

>A>	AP	GENEVA PHARMS	1,000,000 UNITS/VIAL	N65079 001	AUG 30, 2002	AUG	NEWA
>A>	AP		5,000,000 UNITS/VIAL	N65079 002	AUG 30, 2002	AUG	NEWA
>A>	AP		20,000,000 UNITS/VIAL	N65079 003	AUG 30, 2002	AUG	NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PEN-VEE K

@ WYETH AYERST

EQ 125MG BASE/5ML

N60007 001

MAY DISC

@

EQ 250MG BASE/5ML

N60007 002

MAY DISC

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

@ WYETH AYERST

0.25MG/ML

N17048 001

APR DISC

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ JOHNSON AND JOHNSON 100MG

N20193 001 SEP 26, 1996 JUL CAHN

PHENACEMIDE

TABLET; ORAL

PHENURONE

@ ABBOTT

500MG

N07707 001

JUN DISC

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HCL

@ ABLE

200MG;800MG;160MG

N21105 001 JUN 26, 2001 JUN DISC

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA

MIKART

35MG

N89452 001 OCT 30, 1991 MAR CMFD

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HCL

AA

VINTAGE PHARMS

37.5MG

N40377 001 JAN 04, 2002 JAN NEWA

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

@ ALLERGAN 0.12%;0.1%

N07953 001

JUN DISC

PHENYTOIN

SUSPENSION; ORAL

PHENTYTOIN

AB MORTON GROVE 125MG/5ML N40420 001 APR 19, 2002 APR NEWA

PILOCARPINE

DRUG DELIVERY SYSTEM; OPHTHALMIC

OCUSERT PILO-40

@ AKORN 11MG N17548 001

JUN DISC

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

@ AKORN 5MG N17431 001

JUN DISC

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

@ ORGANON 10MG/VIAL N19638 001 JUN 26, 1990 JUN DISC

PODOFILOX

SOLUTION; TOPICAL

CONDYLOX

AT + PADDICK 0.5% N19795 001 DEC 13, 1990 JAN CFTG

PODOFILOX

AT PADDICK 0.5% N75600 001 JAN 29, 2002 JAN NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB ANDRX PHARMS 10MEQ N75604 001 APR 10, 2002 APR NEWA

AB 20MEQ N75604 002 APR 10, 2002 APR NEWA

AB KV PHARM 20MEQ N76044 001 APR 05, 2002 APR NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

BRISTOL MYERS SQUIBB 40MG N19898 004 MAR 22, 1993 MAR CRLD

+ 80MG N19898 008 DEC 18, 2001 MAR NEWA

PREDNICARBATE

CREAM; TOPICAL

DERMATOP

+ DERMIC LABS 0.1% N20279 001 OCT 29, 1993 JUN CAHN

OINTMENT; TOPICAL

+ DERMIC LABS 0.1% N19568 001 SEP 23, 1991 JUN CAHN

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA KV PHARM 15MG/5ML

N40364 001 APR 10, 2002 APR NEWA

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

METIMYD

@ SCHERING 0.5%;10%

N10210 002 SEP 09, 1984 JUL DISC

VASOCIDIN

>D> AT NOVARTIS 0.5%;10%

N88791 001 OCT 05, 1984 AUG CRLD

>A> + 0.5%;10%

N88791 001 OCT 05, 1984 AUG CRLD

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

@ ALCON 0.25%;10%

N87547 001 JUN DISC

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

@ SCHERING 0.5%;10%

N10210 001 JUL DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

AA + ASCENT PEDS EQ 15MG BASE/5ML

N75117 001 DEC 14, 2000 JUL CFTG

PEDIAPRED

AA + CELLTECH PHARMS EQ 5MG BASE/5ML

N19157 001 MAY 28, 1986 JUN CFTG

PREDNISOLONE SODIUM PHOSPHATE

AA MORTON GROVE EQ 5MG BASE/5ML

N75099 001 JUN 28, 2002 JUN NEWA

AA WE PHARMS EQ 15MG BASE/5ML

N75250 001 JUL 12, 2002 JUL NEWA

PREDNISOLONE TEBUGRATE

INJECTABLE; INJECTION

HYDELTRA-TBA

@ MERCK 20MG/ML

N10562 001 JUN DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB VINTAGE PHARMS 5MG

N40256 001 JUL 12, 2002 JUL NEWA

AB 10MG

N40256 002 JUL 12, 2002 JUL NEWA

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

@ XCEL PHARMS 250MG/5ML

N10401 001 JUL DISC

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

@ GLAXOSMITHKLINE EQ 10MG BASE

N11000 001 JUN DISC

+ EQ 10MG BASE

N21019 001 OCT 06, 1999 JUN CRLD

@ EQ 15MG BASE

N11000 002 JUN DISC

+ EQ 15MG BASE

N21019 002 OCT 06, 1999 JUN CRLD

②	EQ 30MG BASE	N11000 003	JUN DISC
---	--------------	------------	----------

PROGESTERONE

INSERT, EXTENDED RELEASE; INTRAUTERINE
PROGESTASERT

② ALZA	38MG	N17553 001	JUN DISC
--------	------	------------	----------

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

SPARINE

② WYETH AYERST	50MG/ML	N10349 006	JUN DISC
----------------	---------	------------	----------

TABLET; ORAL

② WYETH AYERST	25MG	N10348 001	JUN DISC
----------------	------	------------	----------

②	50MG	N10348 002	JUN DISC
---	------	------------	----------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

>A>	AP	GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002	AUG	NEWA
-----	----	---------------------	---------	------------	--------------	-----	------

>A>	AP		50MG/ML	N40454 002	AUG 22, 2002	AUG	NEWA
-----	----	--	---------	------------	--------------	-----	------

SUPPOSITORY; RECTAL
PHENERGAN

AB	+	WYETH AYERST	25MG	N10926 001	FEB	CTEC
----	---	--------------	------	------------	-----	------

PROMETHAZINE HCL

AB		G AND W LABS	25MG	N40428 001	FEB 05, 2002	FEB	NEWA
----	--	--------------	------	------------	--------------	-----	------

SYRUP; ORAL

PHENERGAN FORTIS

AB	+	WYETH AYERST	25MG/5ML	N08381 003	JUN	DISC
----	---	--------------	----------	------------	-----	------

PROPafenone HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HCL

AB		KV PHARM	150MG	N76193 001	FEB 07, 2002	FEB	NEWA
----	--	----------	-------	------------	--------------	-----	------

AB			225MG	N76193 002	FEB 07, 2002	FEB	NEWA
----	--	--	-------	------------	--------------	-----	------

AB			300MG	N76193 003	FEB 07, 2002	FEB	NEWA
----	--	--	-------	------------	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

AA	+	AAI PHARMA	32MG	N10997 001	JUN	CAHN
----	---	------------	------	------------	-----	------

AA	+		65MG	N10997 003	JUN	CAHN
----	---	--	------	------------	-----	------

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

+	NEOSAN PHARMS	50MG/5ML	N16861 001	JUN	CAHN
---	---------------	----------	------------	-----	------

+	AAIPHARMA LLC	100MG	N16862 002	JUN	CAHN
---	---------------	-------	------------	-----	------

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL

② LEDERLE	60MG	N71495 001	DEC 31, 1987	FEB	DISC
-----------	------	------------	--------------	-----	------

⑧		80MG	N70128 001	JUL 30, 1985	MAY	CAHN
⑧		90MG	N71496 001	DEC 31, 1987	FEB	DISC
⑧	PUREPAC PHARM	10MG	N70814 001	NOV 03, 1986	MAY	DISC
⑧		20MG	N70815 001	NOV 03, 1986	MAY	DISC
⑧		40MG	N70816 001	NOV 03, 1986	MAY	DISC
⑧		60MG	N70817 001	NOV 03, 1986	MAY	DISC
⑧		80MG	N70757 001	NOV 03, 1986	MAY	DISC

PYRAZINAMIDE

TABLET; ORAL						
PYRAZINAMIDE						
AB + CLONMEL		500MG	N80157 001		JUL	CAHN

QUINETHAZONE

TABLET; ORAL						
HYDROMOX						
⑧ LEDERLE		50MG	N13264 001		APR	DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL						
ACIPHEX						
⑧ EISAI MEDCL RES		10MG	N20973 001	MAY 29, 2002	JUL	DISC
+		20MG	N20973 002	AUG 19, 1999	MAY	CAHN
+		20MG	N20973 002	AUG 19, 1999	JUL	CMFD
⑧		20MG	N20973 002	AUG 19, 1999	JUN	DISC

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL						
RANITIDINE HCL						
>D> AB GENEVA PHARMS		EQ 300MG BASE	N74655 002	OCT 22, 1997	AUG	CRLD
>A> AB +		EQ 300MG BASE	N74655 002	OCT 22, 1997	AUG	CRLD
ZANTAC 300						
>D> AB + GLAXOSMITHKLINE		EQ 300MG BASE	N20095 002	MAR 08, 1994	AUG	DISC
>A> ⑧		EQ 300MG BASE	N20095 002	MAR 08, 1994	AUG	DISC

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION						
RAPLON						
⑧ ORGANON		100MG/VIAL	N20984 001	AUG 18, 1999	JUN	DISC
⑧		200MG/VIAL	N20984 002	AUG 18, 1999	JUN	DISC

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL						
RIMANTADINE HCL						
>A> AB IMPAX LABS		100MG	N76132 001	AUG 30, 2002	AUG	NEWA

RISEDRONATE SODIUM

TABLET; ORAL						
ACTONEL						
PROCTER AND GAMBLE		30MG	N20835 001	MAR 27, 1998	JUL	CRLD
+		35MG	N20835 003	MAY 25, 2002	JUL	NEWA

RITONAVIR

CAPSULE; ORAL

NORVIR

@ ABBOTT

100MG

N20680 001 MAR 01, 1996 JUN DISC

+

100MG

N20945 001 JUN 29, 1999 JUN CRLD

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

@ ORGANON

10MG/ML

N20214 002 MAR 17, 1994 JUN DISC

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ RANBAXY

50MG

N86101 001 OCT 03, 1983 JUN CAHN

AA +

100MG

N86101 002 OCT 03, 1983 JUN CAHN

SECRETIN

FOR SOLUTION; INTRAVENOUS

SECREFLO

+ CHIRHOCLIN

16UGM/VIAL

N21209 001 APR 04, 2002 APR NEWA

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HCL

AB CLONMEL HLTHCARE

5MG

N75352 001 NOV 30, 1998 JUN CAHN

TABLET; ORAL

>D> AB APOTHECON

5MG

N74672 001 APR 01, 1997 AUG CAHN

AB CLONMEL HLTHCARE

5MG

N74641 001 AUG 02, 1996 APR CAHN

>A> AB SIEGFRIED

5MG

N74672 001 APR 01, 1997 AUG CAHN

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELSUN

>D> AT + ABBOTT

2.5%

N07936 001 AUG CAHN

>A> AT + CHATTEM

2.5%

N07936 001 AUG CAHN

SELENOMETHIONINE, SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

@ CIS

500uCi/ML

N17322 001 JUN DISC

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

@ BRACCO

7.5MG/ML

N20773 001 OCT 29, 1998 JUN DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

+ WYETH AYERST

1MG

N21110 001 AUG 25, 2000 JUN NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

@ B BRAUN

100MG/ML;100MG/ML

N19530 001 DEC 23, 1987 JUN DISC

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPĒ

@ BRACCO

1-150mCi

N10929 003

JUN DISC

SOLUTION; ORAL

@ BRACCO

7-106mCi/BOT

N10929 002

JUN DISC

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ ORPHAN MEDCL

500MG/ML

N21196 001 JUL 17, 2002 JUL NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK

4MG/VIAL

N19721 001 MAY 08, 1995 JUN DISC

@

8MG/VIAL

N19721 002 MAY 08, 1995 JUN DISC

NUTROPIN AQ PEN

BX + GENENTECH

5MG/ML

N20522 002 APR 22, 2002 JUN NEWA

SEROSTIM

BX + SERONO

4MG/VIAL

N20604 003 JUL 25, 1997 JUN CRLD

BX SEROSTIM IN PLASTIC CONTAINER

8.8MG/VIAL

N20604 001 AUG 23, 1996 JUN CRLD

TEV-TROVIN

BX + BIO TECH GEN

5MG/ML

N19774 002 JAN 04, 2002 JUN NEWA

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

@ PHARMACIA AND UPJOHN

EQ 4GM BASE/VIAL

N50347 002

JUN DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

QUELICIN PRESERVATIVE FREE

@ ABBOTT

50MG/ML

N08845 002

JUN DISC

SULFAMETHIZOLE

TABLET; ORAL

THIOSULFIL

@ WYETH AYERST

500MG

N08565 004

JUN DISC

SULFAMETHOXAZOLE

TABLET; ORAL

GANTANOL

@ ROCHE

500MG

N12715 002

MAY CTEC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM PEDIATRIC

@ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML
SEPTRA

N17560 002

APR DISC

AB + MONARCH PHARMS

200MG/5ML;40MG/5ML

N17598 001

APR CRLD

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

@ LILLY 500MG

N00159 001

JUN DISC

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

AB VINTAGE PHARMS 500MG
TABLET, DELAYED RELEASE; ORAL

N40349 001 JAN 11, 2002 JAN NEWA

AZULFIDINE EN-TABS

AB + PHARMACIA AND UPJOHN 500MG
SULFASALAZINE

N07073 002 APR 06, 1983 JAN CFTG

AB VINTAGE PHARMS 500MG

N75339 001 JAN 11, 2002 JAN NEWA

SULFISOXAZOLE ACETYL

SYRUP; ORAL

GANTRISIN

@ ROCHE EQ 500MG BASE/5ML

N09182 002

JUN DISC

SUMATRIPTAN SUCCINATE

TABLET; ORAL

IMITREX

GLAXOSMITHKLINE EQ 50MG BASE
+ EQ 100MG BASE

N20132 003 JUN 01, 1995 JUN CRLD

N20132 001 JUN 01, 1995 JUN CMFD

SUPROFEN

SOLUTION/DROPS; OPHTHALMIC

PROFENAL

@ ALCON 1%

N19387 001 DEC 23, 1988 JUN DISC

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

>D> AB + ASTRAZENECA EQ 20MG BASE
>A> + EQ 20MG BASE

N17970 002 MAR 21, 1994 AUG CTEC

N17970 002 MAR 21, 1994 AUG CTEC

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE; INJECTION

MICROLITE

@ CIS N/A

N18263 001 MAR 25, 1983 JUN DISC

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

@ AMERSHAM HLTH

N/A

N17775 001

JUL DISC

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

@ CADEMA

N/A

N20063 001 JUN 11, 1992 JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

@ MALLINCKRODT

10-60mCi/ML

N17725 001

JUN DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M GENERATOR

@ AMERSHAM HLTH

830-16600mCi/GENERATOR

N17693 001

JUN DISC

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

>D>	NOVARTIS	2MG	N21200 001	JUL 24, 2002	AUG	CPOT
>A>		EQ 2MG BASE	N21200 001	JUL 24, 2002	AUG	CPOT
		2MG	N21200 001	JUL 24, 2002	JUL	NEWA
>D>	+	6MG	N21200 002	JUL 24, 2002	AUG	CPOT
>A>	+	EQ 6MG BASE	N21200 002	JUL 24, 2002	AUG	CPOT
	+	6MG	N21200 002	JUL 24, 2002	JUL	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HCL

>A>	AB	RANBAXY	EQ 1MG BASE	N76021 001	AUG 22, 2002	AUG	NEWA
>A>	AB		EQ 2MG BASE	N76021 002	AUG 22, 2002	AUG	NEWA
>A>	AB		EQ 5MG BASE	N76021 003	AUG 22, 2002	AUG	NEWA
>A>	AB		EQ 10MG BASE	N76021 004	AUG 22, 2002	AUG	NEWA

TERBINAFINE

GEL; TOPICAL

LAMISIL

@ NOVARTIS

1%

N20846 001 APR 29, 1998 JUN DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

BRETHINE

+ AAIPHARMA

1MG/ML

N18571 001

JUL CAHN

+ NEOSAN PHARMS

1MG/ML

N18571 001

FEB CAHN

TABLET; ORAL

AB AAIPHARMA

2.5MG

N17849 001

JUL CAHN

AB +

5MG

N17849 002

JUL CAHN

AB NEOSAN PHARMS

2.5MG

N17849 001

FEB CAHN

AB +	5MG	N17849 002	FEB CAHN
<u>TESTOSTERONE</u>			
	FILM, EXTENDED RELEASE; TRANSDERMAL		
TESTODERM TTS			
BX + ALZA	5MG/24HR	N20791 001	DEC 18, 1997 JAN CTNA
<u>TETRACYCLINE HYDROCHLORIDE</u>			
	FIBER, EXTENDED RELEASE; PERIODONTAL		
ACTISITE			
+ ALZA	12.7MG/FIBER	N50653 001	MAR 25, 1994 FEB CAHN
FOR SOLUTION; TOPICAL			
TOPICYCLINE			
@ SHIRE LABS	2.2MG/ML	N50493 001	JUL DISC
INJECTABLE; INJECTION			
ACHROMYCIN			
@ LEDERLE	250MG/VIAL	N50273 002	JUN DISC
+	500MG/VIAL	N50273 003	JUN CRLD
@	500MG/VIAL	N50273 003	JUL DISC
SUSPENSION; ORAL			
ACHROMYCIN V			
@ LEDERLE	125MG/5ML	N50263 002	APR DISC
SUMYCIN			
+ APOTHECON	125MG/5ML	N60400 001	APR CTEC
TABLET; ORAL			
@ PAR PHARM			
	50MG	N61147 003	MAY CAHN
@	100MG	N61147 002	MAY CAHN
	250MG	N61147 001	MAY CAHN
+	500MG	N61147 004	MAY CAHN
<u>THIETHYLPERAZINE MALATE</u>			
	INJECTABLE; INJECTION		
TORECAN			
@ NOVARTIS	5MG/ML	N12754 002	JUN DISC
<u>THIORIDAZINE</u>			
	SUSPENSION; ORAL		
MELLARIL-S			
@ NOVARTIS	EQ 25MG HCL/5ML	N17923 001	JUN DISC
@	EQ 100MG HCL/5ML	N17923 002	JUN DISC
<u>THIORIDAZINE HYDROCHLORIDE</u>			
	CONCENTRATE; ORAL		
MELLARIL			
>D> AA + NOVARTIS	30MG/ML	N11808 012	AUG DISC
>A> @	30MG/ML	N11808 012	AUG DISC
>D> AA +	100MG/ML	N11808 018	AUG DISC
>A> @	100MG/ML	N11808 018	AUG DISC
THIORIDAZINE HCL			
>D> AA COPLEY PHARM	30MG/ML	N89602 001	NOV 09, 1987 AUG CRLD
>A> AA +	30MG/ML	N89602 001	NOV 09, 1987 AUG CRLD
>D> AA	100MG/ML	N89603 001	NOV 09, 1987 AUG CRLD
>A> AA +	100MG/ML	N89603 001	NOV 09, 1987 AUG CRLD

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL						
THIORIDAZINE HCL						
TABLET; ORAL						
MELLARIL						
>D> AB NOVARTIS	10MG		N11808 003	AUG	DISC	
>A> @	10MG		N11808 003	AUG	DISC	
>D> AB	15MG		N11808 016	AUG	DISC	
>A> @	15MG		N11808 016	AUG	DISC	
>D> AB +	25MG		N11808 006	AUG	DISC	
>A> @	25MG		N11808 006	AUG	DISC	
>D> AB	50MG		N11808 011	AUG	DISC	
>A> @	50MG		N11808 011	AUG	DISC	
>D> AB +	100MG		N11808 009	AUG	DISC	
>A> @	100MG		N11808 009	AUG	DISC	
>D> AB	150MG		N11808 017	AUG	DISC	
>A> @	150MG		N11808 017	AUG	DISC	
>D> AB +	200MG		N11808 015	AUG	DISC	
>A> @	200MG		N11808 015	AUG	DISC	
THIORIDAZINE HCL						
>D> AB GENEVA PHARMS	25MG		N88133 001	AUG 30, 1983	AUG	CRLD
>A> AB +	25MG		N88133 001	AUG 30, 1983	AUG	CRLD
>D> AB	100MG		N88135 001	NOV 20, 1984	AUG	CRLD
>A> AB +	100MG		N88135 001	NOV 20, 1984	AUG	CRLD
>D> AB	200MG		N88137 001	SEP 17, 1986	AUG	CRLD
>A> AB +	200MG		N88137 001	SEP 17, 1986	AUG	CRLD

THIOTEPA

INJECTABLE; INJECTION					
THIOTEPA					
AP AM PHARM PARTNERS	15MG/VIAL		N75698 001	SEP 20, 2001	FEB CAHN

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL					
THIOTHIXENE HCL INTENSOL					
@ ROXANE	EQ 5MG BASE/ML		N73494 001	JUN 30, 1992	JAN DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL					
GABITRIL					
+ CEPHALON	16MG		N20646 003	SEP 30, 1997	JUN CRLD
@	20MG		N20646 004	SEP 30, 1997	JUN DISC

TINZAPARIN SODIUM

INJECTABLE; INJECTION					
INNOHEP					
+ LEO PHARM	20,000 IU/ML		N20484 001	JUL 14, 2000	APR CAHN
+ PHARMION	20,000 IU/ML		N20484 001	JUL 14, 2000	JUL CAHN

TIZANIDINE HYDROCHLORIDE

>A> CAPSULE; ORAL					
>A> ZANAFLEX					
>A> ELAN PHARMS	EQ 2MG BASE		N21447 001	AUG 29, 2002	AUG NEWA

>A>		EQ 4MG BASE	N21447 002	AUG 29, 2002	AUG	NEWA
>A>	+	EQ 6MG BASE	N21447 003	AUG 29, 2002	AUG	NEWA
TABLET; ORAL						
>A>	TIZANIDINE HCL					
AB	DR REDDYS LABS INC	EQ 2MG BASE	N76286 001	JUL 03, 2002	JUL	NEWA
AB		EQ 4MG BASE	N76286 002	JUL 03, 2002	JUL	NEWA
AB	EON	EQ 4MG BASE	N76280 002	JUN 27, 2002	JUN	NEWA
AB	PUREPAC PHARM	EQ 2MG BASE	N76283 001	JUL 12, 2002	JUL	NEWA
AB		EQ 4MG BASE	N76283 002	JUL 12, 2002	JUL	NEWA
AB	TEVA	EQ 2MG BASE	N76284 001	JUL 03, 2002	JUL	NEWA
AB		EQ 4MG BASE	N76284 002	JUL 03, 2002	JUL	NEWA
ZANAFLEX						
>D>	ELAN PHARMS	EQ 2MG BASE	N20397 002	FEB 04, 2000	AUG	CFTG
>A>	AB	EQ 2MG BASE	N20397 002	FEB 04, 2000	AUG	CFTG
	AB +	EQ 4MG BASE	N20397 001	NOV 27, 1996	JUN	CFTG

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	NOVEX	0.3%	N65087 001	FEB 25, 2002	FEB	NEWA
----	-------	------	------------	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

@ ASTRAZENECA	EQ 40MG BASE/ML	N63120 001	OCT 31, 1994	FEB	DISC
@	EQ 40MG BASE/ML	N63122 001	OCT 31, 1994	JAN	DISC

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

@ NOVARTIS	25MG/ML	N06403 005	FEB 22, 1985	JUN	DISC
------------	---------	------------	--------------	-----	------

TOPIRAMATE

TABLET; ORAL

TOPAMAX

+ JOHNSON AND JOHNSON	25MG	N20505 004	DEC 24, 1996	JAN	CAHN
@	50MG	N20505 005	DEC 24, 1996	JAN	CAHN
	100MG	N20505 001	DEC 24, 1996	JAN	CAHN
	200MG	N20505 002	DEC 24, 1996	JAN	CAHN
@	300MG	N20505 003	DEC 24, 1996	JAN	CAHN
@	400MG	N20505 006	DEC 24, 1996	JAN	CAHN

TORSEMIDE

TABLET; ORAL

DEMADEX

AB	ROCHE	5MG	N20136 001	AUG 23, 1993	MAY	CFTG
AB		10MG	N20136 002	AUG 23, 1993	MAY	CFTG
AB +		20MG	N20136 003	AUG 23, 1993	MAY	CFTG
AB		100MG	N20136 004	AUG 23, 1993	MAY	CFTG

TORSEMIDE

AB	TEVA	5MG	N76110 001	MAY 14, 2002	MAY	NEWA
AB		10MG	N76110 002	MAY 14, 2002	MAY	NEWA
AB		20MG	N76110 003	MAY 14, 2002	MAY	NEWA

AB		100MG	N76110 004	MAY 14, 2002	MAY	NEWA
----	--	-------	------------	--------------	-----	------

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HCL

AB	ABLE	50MG	N75963 001	JUL 03, 2002	JUL	NEWA
AB	ASTA	50MG	N75974 001	JUL 12, 2002	JUL	NEWA
AB	CARACO	50MG	N75964 001	JUN 19, 2002	JUN	NEWA
AB	COREPHARMA	50MG	N76003 001	JUN 20, 2002	JUN	NEWA
AB	EON	50MG	N75968 001	JUN 25, 2002	JUN	NEWA
AB	MALLINCKRODT	50MG	N75983 001	JUN 25, 2002	JUN	NEWA
AB	MUTUAL PHARM	50MG	N76100 001	JUN 20, 2002	JUN	NEWA
AB	MYLAN	50MG	N75986 001	JUN 21, 2002	JUN	NEWA
AB	PUREPAC PHARM	50MG	N75960 001	JUN 19, 2002	JUN	NEWA
AB	SIDMAK LABS	50MG	N75982 001	JUL 01, 2002	JUL	NEWA
AB	TEVA	50MG	N75977 001	JUN 19, 2002	JUN	NEWA
AB	TORPHARM	50MG	N75981 001	JUL 10, 2002	JUL	NEWA
AB	WATSON LABS	50MG	N75962 001	JUN 24, 2002	JUN	NEWA
	ULTRAM					
+ AB	JOHNSON AND JOHNSON	50MG	N20281 002	MAR 03, 1995	FEB	CAHN
	@	100MG	N20281 001	MAR 03, 1995	FEB	CAHN
AB +	ORTHO MCNEIL PHARM	50MG	N20281 002	MAR 03, 1995	JUN	CTEC

TREPROSTINIL SODIUM

INJECTABLE; SUBCUTANEOUS

REMODULIN

	UNITED THERAP	1MG/ML	N21272 001	MAY 21, 2002	MAY	NEWA
		2.5MG/ML	N21272 002	MAY 21, 2002	MAY	NEWA
		5MG/ML	N21272 003	MAY 21, 2002	MAY	NEWA
+		10MG/ML	N21272 004	MAY 21, 2002	MAY	NEWA

TRETINOIN

GEL; TOPICAL

RETIN-A

AB +	JOHNSON AND JOHNSON	0.01%	N17955 001		JUN	CTFG
AB	SPEAR PHARMS	0.01%	N75589 001	JUN 11, 2002	JUN	NEWA

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

	@ FUJISAWA HLTHCARE	1MG	N11161 009		JUL	DISC
	@	2MG	N11161 004		JUL	DISC
	@	8MG	N11161 011		JUL	DISC

KENACORT

>D>	BP	BRISTOL MYERS SQUIBB	8MG	N11283 010		AUG	CTEC
>A>	+		8MG	N11283 010		AUG	CTEC

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

KENALOG-10

	APOTHECON	10MG/ML	N12041 001		JUN	CRLD
	KENALOG-40					

MAY NEWA TRIAMCINOLONE ACETONIDE
 INJECTABLE; INJECTION
 KENALOG-40
 BP + APOTHECON 40MG/ML N14901 001 JUN CRLD

JUL NEWA TRIAMCINOLONE ACETONIDE
 @ PARNELL 3MG/ML N19503 001 OCT 16, 1987 JUN DISC

JUL NEWA SPRAY, METERED; NASAL
 TRI-NASAL
 JUN NEWA @ MURO 0.05MG/SPRAY N20120 001 FEB 04, 2000 JUN DISC

JUN NEWA TRIAMCINOLONE DIACETATE
 SYRUP; ORAL
 ARISTOCORT
 JUN NEWA @ FUJISAWA HLTHCARE 2MG/5ML N11960 004 JUL DISC

JUL NEWA TRIFLUOPROMAZINE HYDROCHLORIDE
 INJECTABLE; INJECTION
 VESPRIN
 JUN NEWA @ APOTHECON 10MG/ML N11325 004 JUN DISC

FEB CAHN @ 20MG/ML N11325 001 JUN DISC

JUN CTEC TRILOSTANE
 CAPSULE; ORAL
 MODRASTANE
 JUN CTEC @ BIOENVISION 30MG N18719 002 DEC 31, 1984 JUN CAHN
 @ 60MG N18719 001 DEC 31, 1984 JUN CAHN

MAY NEWA TRIMETHADIONE
 CAPSULE; ORAL
 TRIDIONE
 MAY NEWA @ ABBOTT 300MG N05856 005 JUN DISC

MAY NEWA SOLUTION; ORAL
 @ ABBOTT 200MG/5ML N05856 002 JUN DISC

JUN CFTG TRIMETHOBENZAMIDE HYDROCHLORIDE
 CAPSULE; ORAL
 TIGAN
 JUN NEWA + KING PHARMS 300MG N17531 006 DEC 13, 2001 JAN NEWA

JUN NEWA INJECTABLE; INJECTION
 TRIMETHOBENZAMIDE HCL
 @ STERIS 100MG/ML N87939 001 DEC 28, 1982 FEB DISC

JUL DISC TRIMETHOPRIM
 TABLET; ORAL
 TRIMPEX
 AUG CTEC >D> AB ROCHE 100MG N17952 001 AUG DISC

AUG CTEC >A> @ 100MG N17952 001 AUG DISC

JUN CRLD TRIOXSALEN
 TABLET; ORAL
 TRISORALEN
 JUN CRLD @ ICN 5MG N12697 001 JUN DISC

TRIPELENNAMINE CITRATE

ELIXIR; ORAL

PBZ

© NOVARTIS

EQ 25MG HCL/5ML

N05914 004

JUN DISC

TRIPELENNAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

© NOVARTIS

100MG

N10533 001

JUN DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

TABLET; VAGINAL

SULTRIN

© ORTHO MCNEIL PHARM

184MG;143.75MG;172.5MG

N05794 002

JUN DISC

UREA, C-13

FOR SOLUTION; ORAL

PYLORI-CHEK BREATH TEST

© ALIMENTERICS

100MG/VIAL

N20900 001 FEB 04, 1999 JUL DISC

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

BX + FERRING 75 IU/VIAL

N21289 001 MAY 06, 2002 MAY NEWA

INJECTABLE; SUBCUTANEOUS

FERTINEX

BX + SERONO 75 IU/AMP

N19415 005 AUG 23, 1996 MAY CTEC

©

150 IU/AMP

N19415 004 AUG 23, 1996 JUN DISC

URSODIOL

CAPSULE; ORAL

ACTIGALL

© WATSON PHARMS

150MG

N19594 001 DEC 31, 1987 FEB CAHN

AB + 300MG

N19594 002 DEC 31, 1987 FEB CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALTREX

© GLAXOSMITHKLINE

EQ 500MG BASE

N20487 001 JUN 23, 1995 MAR DISC

©

EQ 1GM BASE

N20487 002 JUN 23, 1995 MAR DISC

VALSARTAN

CAPSULE; ORAL

DIOVAN

© NOVARTIS

80MG

N20665 001 DEC 23, 1996 JUN DISC

©

160MG

N20665 002 DEC 23, 1996 JUN DISC

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

© ORGANON

20MG/VIAL

N18776 003 JAN 03, 1992 JUN DISC

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
EFFEXOR XR

WYETH AYERST EQ 37.5MG BASE
EQ 150MG BASE

N20699 001 OCT 20, 1997 MAY CRLD
N20699 004 OCT 20, 1997 MAY CRLD

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN

AB + ELAN DRUG	120MG
AB +	180MG
AB +	240MG
+	360MG

N19614 001 MAY 29, 1990 APR CAHN
N19614 003 JAN 09, 1992 APR CAHN
N19614 002 MAY 29, 1990 APR CAHN
N19614 004 MAY 10, 1996 APR CAHN

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ AAIPHARMA EQ 50,000 UNITS BASE/ML

N06823 001 JUL CAHN

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

+ PFIZER 200MG/VIAL

N21267 001 MAY 24, 2002 MAY NEWA

TABLET; ORAL

PFIZER 50MG

N21266 001 MAY 24, 2002 MAY NEWA

+

200MG

N21266 002 MAY 24, 2002 MAY NEWA

XENON, XE-127

GAS; INHALATION

XENON XE 127

@ MALLINCKRODT

5mCi/VIAL

N18536 001 OCT 01, 1982 JUN DISC

@

10mCi/VIAL

N18536 002 OCT 01, 1982 JUN DISC

XYLOSE

POWDER; ORAL

XYLOSE

@ LYNE

25GM/BOT

N18856 001 MAR 26, 1987 JUL DISC

ZILEUTON

TABLET; ORAL

ZYFLO

+ ABBOTT

300MG

N20471 001 DEC 09, 1996 JUN CRLD

@

300MG

N20471 001 DEC 09, 1996 JUL DISC

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER

EQ 20MG BASE/ML

N20919 001 JUN 21, 2002 JUN NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

+ ASTRAZENECA

5MG

N21231 002 SEP 17, 2001 JUN NEWA

PRESCRIPTION DRUG PRODUCT LIST - 22ND EDITION
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - AUG 2002

2-1

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL
ACETAMINOPHEN
COREPHARMA 650MG

N76200 001 MAR 19, 2002 MAR NEWA

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CONTAC 12 HOUR
@ GLAXOSMITHKLINE 8MG;75MG
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE
@ CENT PHARMS 8MG;75MG

N18099 001 JAN DISC
N18809 001 MAY 07, 1984 FEB DISC

CIMETIDINE

TABLET; ORAL
CIMETIDINE
TORPHARM 200MG

N74948 002 JUL 26, 2002 JUL NEWA

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE
TORPHARM 10MG

N75610 001 MAR 12, 2002 MAR NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL
MUCINEX
ADAMS LABS 600MG

N21282 001 JUL 12, 2002 JUL NEWA

IBUPROFEN

TABLET; ORAL
IBUPROFEN
PERRIGO 200MG

N75995 001 MAR 14, 2002 MAR NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL
ADVIL COLD AND SINUS
WYETH CONS 200MG;30MG
SUSPENSION; ORAL
CHILDREN'S ADVIL COLD
WYETH CONS 100MG/5ML;15MG/5ML
TABLET; ORAL
IBUPROFEN AND PSEUDOEPHEDRINE HCL
PHARM FORM 200MG;30MG

N21374 001 MAY 30, 2002 MAY NEWA

N21373 001 APR 18, 2002 APR NEWA

N75588 001 APR 08, 2002 APR NEWA

INSULIN PURIFIED PORK

INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN
@ NOVO NORDISK 100 UNITS/ML

N18381 001 FEB DISC

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION
VELOSULIN BR
+ NOVO NORDISK 100 UNITS/ML

N21028 001 JUL 19, 1999 JUN CMS2

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

NPH PURIFIED PORK ISOPHANE INSULIN

@ NOVO NORDISK 100 UNITS/ML

N18623 001

FEB DISC

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

@ NOVO NORDISK 100 UNITS/ML

N18383 001

FEB DISC

NO AUG

KETOPROFEN

TABLET; ORAL

KETOPROFEN

PERRIGO 12.5MG

N75364 001 FEB 07, 2002 FEB NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL

LOPERAMIDE HCL AND SIMETHICONE

>A> PERRIGO 2MG;125MG

N76029 001 AUG 30, 2002 AUG NEWA

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

CLAY PARK 5%

N75737 001 MAR 15, 2002 MAR NEWA

NOVEX 5%

N75839 001 OCT 01, 2001 MAR CTNA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

>A> DR REDDYS LABS INC EQ 200MG BASE

N75168 001 JUL 28, 1998 AUG CAHN

>D> PAR PHARM EQ 200MG BASE

N75168 001 JUL 28, 1998 AUG CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

SUDAFED 12 HOUR

+ WARNER LAMBERT 120MG

N73585 001 OCT 31, 1991 MAY CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

>A> PERRIGO EQ 75MG BASE

N76195 001 AUG 30, 2002 AUG NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

FEB DISC

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST '02

FEB DISC

NO AUGUST 2002 APPROVALS

FEB NEWA

AUG NEWA

MAR NEWA

MAR CTNA

AUG CAHN

AUG CAHN

MAY CAHN

AUG NEWA

**This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.**

Orphan Products Designations and Approvals List

August 2002

autologous tumor-derived TN Oncophage	Treatment of metastatic	Antigenics, Inc. 34 Commerce Way Woburn MA 01702 DD 7/11/2002 MA
cells produced using the TN	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem	Aastrom Biosciences P.O. Box 376 Ann Arbor MI 48106
Decitabine TN	Treatment of sickle	DD 7/10/2002 MA
G17DT Immunogen TN	Treatment of adenocarcinoma of the	SuperGen, Inc. 4140 Dublin Blvd., Dublin CA 94568 DD 9/9/2002 MA
G17DT Immunogen TN	Treatment of gastric	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776 DD 7/10/2002 MA
human TN	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776 DD 7/18/2002 MA
interferon TN Actimmune	Treatment of idiopathic pulmonary fibrosis	Protein Therapeutics, 9040 S. Rita Road Suite 1100 Tucson AZ 85747 DD 9/16/2002 MA
Lintuzumab TN Zamyl	Treatment of acute myelogenous leukemia	InterMune, Inc. 3280 Bayshore Brisbane CA 94005 DD 9/12/2002 MA
		Protein Design Labs, 34801 Campus Drive Fremont CA 94555 DD 9/9/2002 MA

Orphan Products Designations and Approvals List
August 2002

N-acetylcysteine TN	Treatment of acute	William M. Lee, MD, University of Texas 5323 Harry Hines Blvd Dallas TX 75390-9151 DD 9/9/2002 MA
polyinosinic-pol ycytidilic acid TN Poly-ICLC	As an adjuvant to smallpox vaccination	Ribopharm, Inc. 3203 Cleveland Ave., Washington DC DD 8/2/2002 MA
recombinant human monoclonal TN Mycograb	Treatment of invasive	NeuTec Pharma plc 2dn floor, Clinical Central Manchester M139WL, UK DD 9/16/2002 MA
recombinant human TN	Treatment of acute intermittent porphyria	HemeBiotech A/S Roskildevej 12C 3400 Hillerod Denmark DD 9/9/2002 MA
rubitecan TN	Treatment of pediatric patients infected with human immunodeficiency	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 virus and acquired Dublin CA 94568 DD 7/17/2002 MA

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2002 ADDITIONS

PRESCRIPTION AND DRUG PRODUCTS
PATENT AND EXCLUSIVITY DATA
P&D and P&D represent Pediatric Exclusivity

L-V

APPN/PROD	INGREDIENT NAME; TRADE NAME	PATENT	NUMBER	EXPIRES	CODE	EXCLUS
*PEP and PPD represent Pediatric Exclusivity						
018731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR	M-12	JUN 19, 2004	W	W	JUN 19, 2005
018731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR	PPD	JAN 19, 2005	W	W	JUN 19, 2004
020954 001	BUSULFAN; BUSULFEX	5430057	SEP 30, 2013	U-263 ODE	PEB 04,	2006
020838 002	CANDESARTAN CILEXETIL; ATACAND	5266329	NOV 05, 2002	U-457	U-264 PEP	AUG 04,
020838 003	CANDESARTAN CILEXETIL; ATACAND	555148*PPD	NOV 24, 2015	U-264 NDF	PEB 04,	2002
019881 001	BUTOCONAZOLE NITRATE; GYNAZOLE-1	5430057	SEP 30, 2013	U-263 ODE	PEB 04,	2006
020838 004	CANDESARTAN CILEXETIL; ATACAND	555148*PPD	NOV 24, 2015	U-264 PEP	PEB 04,	2006
020838 001	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04, 2012	U-3	U-3	5196444
020838 002	CANDESARTAN CILEXETIL; ATACAND	5196444	JUN 04, 2012	U-3	U-3	5196444
020838 003	CANDESARTAN CILEXETIL; ATACAND	4551148	NOV 05, 2002	U-3	U-3	5196444
019881 002	BUTOCONAZOLE NITRATE; GYNAZOLE-1	5266329	NOV 05, 2002	U-457	U-264 PEP	AUG 04,
020998 003	CELECOXIB; CELEBREX	5958915	OCT 14, 2016	U-284 DEC 23, 2002	I-284 DEC 31, 2003	5563165 NOV 30, 2013
019835 001	CETIRIZINE HYDROCHLORIDE; ZYTRC	5760068	JUN 02, 2015	U-19 I-338 OCT 17, 2004	NCF DEG 31, 2003	5760068 NOV 30, 2013
019835 002	CETIRIZINE HYDROCHLORIDE; ZYTRC	4525358*PPD	DEC 25, 2007	U-299	U-299	4525358 JUN 02, 2015
020346 001	CETIRIZINE HYDROCHLORIDE; ZYTRC	4525358	JUN 25, 2007	U-2007	U-2007	4525358 DEC 09, 2007
020822 001	CITRALOPRAM HYDROBROMIDE; CELEXA	4670444	DEC 09, 2003	U-223	U-223	4670444 DEC 09, 2003
020822 002	CITRALOPRAM HYDROBROMIDE; CELEXA	4525358*PPD	DEC 25, 2007	U-2007	U-2007	4525358 DEC 25, 2007
020822 003	CITRALOPRAM HYDROBROMIDE; CELEXA	4525358	JUN 25, 2007	U-2007	U-2007	4525358 JUN 25, 2007
020369 001	CIPROLOXACIN HYDROCHLORIDE; CLOXAN	4525358*PPD	DEC 25, 2007	U-2007	U-2007	4525358*PPD DEC 25, 2007
020822 001	CIPROLOXACIN HYDROCHLORIDE; CLOXAN	4525358	JUN 25, 2007	U-2007	U-2007	4525358 JUN 25, 2007
021046 001	CITRALOPRAM HYDROBROMIDE; CELEXA	4525358	JUN 25, 2007	U-2007	U-2007	4525358 JUN 25, 2007
020822 003	CITRALOPRAM HYDROBROMIDE; CELEXA	4525358	JUN 25, 2007	U-2007	U-2007	4525358 JUN 25, 2007
021141 001	COLLESVELAM HYDROCHLORIDE; MELCHOL	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
021145 001	COLLESVELAM HYDROCHLORIDE; MELCHOL	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
021165 001	DESLOTRADATINE HYDROCHLORIDE; CLARINEX	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
021312 001	DESOGESTEROL; KARVIA	6100274	JUL 07, 2019	U-2019	U-2019	6100274 JUL 07, 2019
021168 001	DIVALPROEX SODIUM; DEPAKOTE ER	5780740	JUL 30, 2013	U-2013	U-2013	5780740 JUL 30, 2013
020690 001	DONEPPEZIL HYDROCHLORIDE; ARICEPT	5798091	AUG 25, 2015	U-458	U-458	5798091 AUG 25, 2015
020690 002	DONEPPEZIL HYDROCHLORIDE; ARICEPT	5798091	AUG 24, 2015	U-458	U-458	5798091 AUG 24, 2015
021027 001	DOXERACLIFEROL; HECTROL	5707980	AUG 17, 2014	U-278	U-278	5707980 AUG 17, 2014
02098 001	DROSOPHENONE; YASMIN	56238695	APR 06, 2019	U-321	U-321	56238695 APR 06, 2019
020972 001	EFAVIRENZ; SUSTIVA	6238695	APR 06, 2019	U-321	U-321	6238695 APR 06, 2019
020972 002	EFAVIRENZ; SUSTIVA	6238695	APR 06, 2019	U-321	U-321	6238695 APR 06, 2019
020718 001	EPITIFIBATIDE; INTEGRILIN	5112861	MAY 12, 2009	U-453	U-453	5112861 MAY 12, 2009
020718 002	EPITIFIBATIDE; INTEGRILIN	5968902	JUN 02, 2015	U-453	U-453	5968902 JUN 02, 2015
021223 001	ESCITALOPRAM OXALATE; LEXapro	5747447	MAY 05, 2015	U-453	U-453	5747447 MAY 05, 2015
021223 002	ESCITALOPRAM OXALATE; LEXapro	5968902	JUN 02, 2015	U-453	U-453	5968902 JUN 02, 2015
020796 001	ENTACAPONE; COMTAN	5446194	AUG 29, 2012	U-1	U-1	5446194 AUG 29, 2012
020972 003	EFAVIRENZ; SUSTIVA	6238695	APR 06, 2019	U-321	U-321	6238695 APR 06, 2019
021098 001	DROSOPHENONE; YASMIN	5569652	OCT 29, 2013	U-1	U-1	5569652 OCT 29, 2013
021098 002	DROSOPHENONE; YASMIN	5707980	AUG 17, 2014	U-278	U-278	5707980 AUG 17, 2014
021027 002	DOXERACLIFEROL; HECTROL	56238695	APR 06, 2019	U-321	U-321	56238695 APR 06, 2019
020862 001	DONEPEZIL HYDROCHLORIDE; ARICEPT	5707980	AUG 17, 2014	U-278	U-278	5707980 AUG 17, 2014
020690 003	DONEPEZIL HYDROCHLORIDE; ARICEPT	5798091	AUG 25, 2015	U-458	U-458	5798091 AUG 25, 2015
021168 002	DIVALPROEX SODIUM; DEPAKOTE ER	4988731	JAN 29, 2008	NP	NP	4988731 JAN 29, 2008
021168 003	DIVALPROEX SODIUM; DEPAKOTE ER	4913906	APR 03, 2007	NP	NP	4913906 APR 03, 2007
021165 002	DESMETHYLPHENIDATE HYDROCHLORIDE; PROCALBIN	6355656	DEC 04, 2015	PC	PC	6355656 DEC 04, 2015
021278 001	DESMETHYLPHENIDATE HYDROCHLORIDE; PROCALBIN	6355656	DEC 04, 2015	PC	PC	6355656 DEC 04, 2015
021278 003	DESMETHYLPHENIDATE HYDROCHLORIDE; PROCALBIN	6355656	DEC 04, 2015	PC	PC	6355656 DEC 04, 2015
021191 001	DIMYRISTOYL LECITHIN; MAGNET	6280740	JUL 30, 2013	NCE	NCE	6280740 JUL 30, 2013
021278 002	DESMETHYLPHENIDATE HYDROCHLORIDE; PROCALBIN	6355656	DEC 04, 2015	PC	PC	6355656 DEC 04, 2015
021278 004	DESMETHYLPHENIDATE HYDROCHLORIDE; PROCALBIN	6355656	DEC 04, 2015	PC	PC	6355656 DEC 04, 2015
021165 001	DESLORATADINE; CLARINEX	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
021312 001	DESOGESTEROL; CLARINEX	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
075863 001	DESOGESTEROL; KARVIA	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
021176 001	COLLESVELAM HYDROCHLORIDE; MELCHOL	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
021176 002	COLLESVELAM HYDROCHLORIDE; MELCHOL	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
021176 003	COLLESVELAM HYDROCHLORIDE; MELCHOL	6433026	JUN 10, 2014	U-2014	U-2014	6433026 JUN 10, 2014
*PEP and PPD represent Pediatric Exclusivity						

*PEP and PPD represent Pediatric Exclusivity DATA
PATENT AND EXCLUSIVITY DATA
PRESCRIPTION AND OTC DRUG PRODUCT

APPL/PROD	NUMBER	INGREDIENT NAME; TRADE NAME		PATENT/PED	EXCL USE	EXCLUS EXCLES	CODE	EXPIRES	
		NUMBER	PATENT						
*PED and PED represent Pediatric Exclusivity									
021323 003	ESCITALOPRAM OXALATE;LEXapro	NP	AUG 14, 2005	APR 05, 2005	I-351	APR 16, 2003	I-254	AUG 16, 2003	
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	NOV 03, 2019	6428810	MAY 25, 2018	6369085	MAY 25, 2011	5227169	MAY 17, 2011	
020655 001	ESTRADIOL;ALORA	6428810	NOV 03, 2019	6369085	MAY 25, 2018	6369085	I-351	APR 05, 2005	
020655 002	ESTRADIOL;ALORA	I-366	PED	PED	PED	PED	I-351	APR 05, 2005	
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	I-366	PED	PED	PED	PED	NP	AUG 14, 2005	
020538 006	ESTRADIOL;VIVELLE-DOT	I-254	AUG 16, 2003	I-254	AUG 16, 2003	I-254	I-254	AUG 16, 2003	
020538 007	ESTRADIOL;VIVELLE-DOT	I-254	AUG 16, 2003	I-254	AUG 16, 2003	I-254	I-254	AUG 16, 2003	
020538 008	ESTRADIOL;VIVELLE-DOT	I-254	AUG 16, 2003	I-254	AUG 16, 2003	I-254	I-254	AUG 16, 2003	
021241 001	ETHINODIENYL BSTRAIDIOL;ORTHO TRI-CYCLEN LO	I-359	JUN 21, 2005	I-359	JUN 21, 2005	I-359	I-359	JUN 21, 2005	
020992 001	ESTROGENS; CONJUGATED SYNTHETIC A;GENESTIN	I-112	NP	4616066	SEP 26, 2015	6214815	JUL 09, 2019	6214815	SEP 26, 2015
020538 003	FENOFIBRATE;FENOPIBRATE (MICRONI	PC	OCT 28, 2002	PC	OCT 28, 2002	PC	OCT 28,	PC	SEP 15, 2002
075753 002	FENOFIBRATE;FENOPIBRATE (MICRONI	PC	SEP 15, 2002	PC	SEP 15, 2002	PC	SEP 15,	PC	SEP 15, 2002
075442 002	FLBECANIIDE ACETATE;FLBECANIIDE ACETATE	PC	OCT 28, 2002	PC	OCT 28, 2002	PC	OCT 28,	PC	SEP 15, 2002
075442 003	FLBECANIIDE ACETATE;FLBECANIIDE ACETATE	PC	OCT 28,	PC	OCT 28,	PC	OCT 28,	PC	SEP 15, 2002
018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC	I-362	JUL 29, 2005	I-362	JUL 29, 2005	I-362	JUL 29,	I-362	SEP 15, 2002
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	I-362	JUL 29, 2005	I-362	JUL 29, 2005	I-362	JUL 29,	I-362	SEP 15, 2002
018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	I-362	JUL 29, 2005	I-362	JUL 29, 2005	I-362	JUL 29,	I-362	SEP 15, 2002
018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC	I-362	JUL 29, 2005	I-362	JUL 29, 2005	I-362	JUL 29,	I-362	SEP 15, 2002
018936 007	FLUOXETINE HYDROCHLORIDE;PROZAC	I-362	JUL 29, 2005	I-362	JUL 29, 2005	I-362	JUL 29,	I-362	SEP 15, 2002
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	I-362	JUL 29, 2005	I-362	JUL 29, 2005	I-362	JUL 29,	I-362	SEP 15, 2002
020974 008	FLUOXETINE HYDROCHLORIDE;PROZAC	I-362	JUL 29, 2005	I-362	JUL 29, 2005	I-362	JUL 29,	I-362	SEP 15, 2002
020121 001	FLUOXETINE HYDROCHLORIDE;SARAFEM	D-75	JUN 12, 2005	D-75	JUN 12, 2005	D-75	JUN 12,	D-75	SEP 15, 2002
021345 001	FLUOXETINE HYDROCHLORIDE;SARAFEM	D-76	MAY 23, 2005	D-76	MAY 23, 2005	D-76	MAY 23,	D-76	SEP 15, 2002
021129 001	GABAPEPTIN;NEURONIN	I-354	MAY 24, 2005	I-354	MAY 24, 2005	I-354	MAY 24,	I-354	SEP 15, 2002
020882 001	GABAPEPTIN;NEURONIN	5084479	JAN 02, 2010	5084479	JAN 02, 2010	5084479	JAN 02,	5084479	SEP 15, 2002
020235 003	GABAPEPTIN;NEURONIN	5084479	JAN 02, 2010	5084479	JAN 02, 2010	5084479	JAN 02,	5084479	SEP 15, 2002
021061 001	GATIPLOXACIN;TEQUIN	5880283	DEC 05, 2015	5880283	DEC 05, 2015	5880283	DEC 05,	5880283	SEP 15, 2002
021062 001	GATIPLOXACIN;TEQUIN	NCE	DEC 17,	NCE	DEC 17,	NCE	DEC 17,	NCE	SEP 15, 2002
020305 001	GRANISTERON HYDROCHLORIDE;KTRIL	4344949	OCT 03, 2002	4344949	OCT 03, 2002	4344949	OCT 03,	4344949	SEP 15, 2002
020125 001	HYDROCHLOROTHIAZIDE;ACCURTEC	4743450	DEC 24,	4743450	DEC 24,	4743450	DEC 24,	4743450	SEP 15, 2002
020125 002	HYDROCHLOROTHIAZIDE;ACCURTEC	4743450	DEC 24,	4743450	DEC 24,	4743450	DEC 24,	4743450	SEP 15, 2002
020125 003	HYDROCHLOROTHIAZIDE;ACCURTEC	4743450*	PED APR 03,	4743450*	PED APR 03,	4743450*	PED APR 03,	4743450*	PED APR 03,
020125 004	HYDROCHLOROTHIAZIDE;AVALIDE	4344949	OCT 03, 2002	4344949	OCT 03, 2002	4344949	OCT 03,	4344949	SEP 15, 2002
020758 001	HYDROCHLOROTHIAZIDE;DIOLAN HCT	5270317	SEP 30,	5270317	SEP 30,	5270317	SEP 30,	5270317	SEP 15, 2002
020758 002	HYDROCHLOROTHIAZIDE;DIOLAN HCT	6294197	JUN 18,	6294197	JUN 18,	6294197	JUN 18,	6294197	SEP 15, 2002
020818 001	HYDROCHLOROTHIAZIDE;DIVAN HCT	6294197	JUN 18,	6294197	JUN 18,	6294197	JUN 18,	6294197	SEP 15, 2002
020387 001	HYDROCHLOROTHIAZIDE;HYZABAR	5138069	AUG 11,	5138069	AUG 11,	5138069	AUG 11,	5138069	SEP 15, 2002
020387 002	HYDROCHLOROTHIAZIDE;HYZABAR	5138197	OCT 06,	5138197	OCT 06,	5138197	OCT 06,	5138197	SEP 15, 2002
020387 003	HYDROCHLOROTHIAZIDE;HYZABAR	5138075	SEP 04,	5138075	SEP 04,	5138075	SEP 04,	5138075	SEP 15, 2002
020387 004	HYDROCHLOROTHIAZIDE;HYZABAR	5153197	PED APR 06,	5153197	PED APR 06,	5153197	PED APR 06,	5153197	SEP 15, 2002
020387 005	HYDROCHLOROTHIAZIDE;HYZABAR	5608075	MAR 04,	5608075	MAR 04,	5608075	MAR 04,	5608075	SEP 15, 2002
020387 006	HYDROCHLOROTHIAZIDE;HYZABAR	5153197	OCT 06,	5153197	OCT 06,	5153197	OCT 06,	5153197	SEP 15, 2002
020387 007	HYDROCHLOROTHIAZIDE;HYZABAR	5138069	AUG 11,	5138069	AUG 11,	5138069	AUG 11,	5138069	SEP 15, 2002
020387 008	HYDROCHLOROTHIAZIDE;HYZABAR	5138069*	PED FEB 11,	5138069*	PED FEB 11,	5138069*	PED FEB 11,	5138069*	SEP 15, 2002
020387 009	HYDROCHLOROTHIAZIDE;HYZABAR	5138069	PED FEB 11,	5138069	PED FEB 11,	5138069	PED FEB 11,	5138069	SEP 15, 2002
020387 010	HYDROCHLOROTHIAZIDE;HYZABAR	5138069	PED FEB 11,	5138069	PED FEB 11,	5138069	PED FEB 11,	5138069	SEP 15, 2002

*PED and PED represent Pediatric Exclusivity
PATENT AND EXCLUSIVITY DATA
PRESCRIPTION AND OTC DRUG PRODUCT

APP/PROD	NUMBER	INGREDIENT NAME, TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXCLUSES	CODE	CODE EXPRIES	EXCLUS EXCLUSES	PATENT
*PDD and PED represent Pediatrictic Exclusivity								
020729 003	020729 001	HYDROCHLOROTHIAZIDE;UNNITRIC	IBUPROFEN;ADVIL COL	NP	AUG 01, 2003	PBD OCT 01, 2004	PC OCT 05, 2002	4743450
>ADD>	075874 001	IPOSFAMIDE;IPOSFAMIDE/MESSNA KIT	4396598 DEC 30, 2002	U-31	4396598 DEC 30, 2002	U-29	4396598 DEC 30, 2002	4396598 DEC 30, 2002
>ADD>	075874 002	IPOSFAMIDE;IPOSFAMIDE/MESSNA KIT	4396598 DEC 30, 2002	U-31	4396598 DEC 30, 2002	U-29	4396598 DEC 30, 2002	4396598 DEC 30, 2002
>ADD>	075874 003	IPOSFAMIDE;IPOSFAMIDE/MESSNA KIT	5071643*PED JUN 10, 2008	5071643*PED JUN 10, 2008	5071643*PED JUN 10, 2008	5360615*PED JUN 10, 2009	5360615*PED JUN 10, 2009	5360615*PED JUN 10, 2008
>ADD>	020716 001	HYDROCODONE BITARTRATE;VICOCOPROFEN	6348216 JUN 10, 2007	4743450 FEB 24, 2007	4743450 FEB 24, 2007	6348216 JUN 10, 2007	6348216 JUN 10, 2007	6348216 JUN 10, 2007
>ADD>	021374 001	IBUPROFEN;ADVIL COL AND SINUS	5071643 DEC 10, 2008	5071643 DEC 10, 2008	5071643 DEC 10, 2008	5360615 DEC 10, 2008	5360615 DEC 10, 2008	5360615 DEC 10, 2008
>ADD>	021373 001	IBUPROFEN;CHILDRN'S ADVIL COL	NP AUG 01, 2003	NP AUG 01, 2003	NP AUG 01, 2003	PC OCT 05, 2002	PC OCT 05, 2002	4396598 DEC 30, 2002
021373 002	021373 002	IBUPROFEN;CHILDRN'S ADVIL COL	4396598 DEC 30, 2002	U-31	4396598 DEC 30, 2002	U-29	4396598 DEC 30, 2002	4396598 DEC 30, 2002
>ADD>	019710 002	IOVERSOL;OPTIRAY 240	4396598 DEC 30, 2002	U-30	4396598 DEC 30, 2002	U-29	4396598 DEC 30, 2002	4396598 DEC 30, 2002
>ADD>	019710 003	IOVERSOL;OPTIRAY 350	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	4396598 DEC 30, 2002
>ADD>	019710 004	IOVERSOL;OPTIRAY 300	4396598 DEC 30, 2002	U-29	4396598 DEC 30, 2002	U-28	4396598 DEC 30, 2002	4396598 DEC 30, 2002
>ADD>	019710 005	IOVERSOL;OPTIRAY 320	4396598 DEC 30, 2002	U-464	4396598 DEC 30, 2002	U-465	4396598 DEC 30, 2002	4396598 DEC 30, 2002
>ADD>	020757 001	IRBESARTAN;AVAPRO	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	4396598 DEC 30, 2002
020757 002	020757 003	IRBESARTAN;AVAPRO	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	4396598 DEC 30, 2002
020757 001	020757 001	IRBESARTAN;AVAPRO	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	U-62	4396598 DEC 30, 2002	4396598 DEC 30, 2002
020564 001	020564 001	KETROLAC TROMEETHAMINE;ACULAIR PRESERVATIVE	M-16 FEB 08, 2005					
019700 001	019700 001	KETROLAC TROMEETHAMINE;ACULAIR PRESERVATIVE	5047407 NOV 17, 2009	NS D-2	5047407*PED MAY 17, 2010	NS D-2	5047407*PED MAY 17, 2010	5047407 NOV 17, 2009
020966 001	020966 001	ITRACONAZOLE;SPORANOX	6407079 JUN 18, 2019	6407079 JUN 18, 2019	6407079 JUN 18, 2019	PED NOV 02, 2005	PED NOV 02, 2005	PEB 08, 2005
020657 001	020657 001	ITRACONAZOLE;SPORANOX	6407079 JUN 18, 2019	6407079 JUN 18, 2019	6407079 JUN 18, 2019	PEB 08, 2005	PEB 08, 2005	PEB 08, 2005
020657 002	020657 002	ISOTRETINOIN;ACUTANE	M-12 MAY 02, 2005	M-12 MAY 02, 2005	M-12 MAY 02, 2005	M-16 FEB 08, 2005	M-16 FEB 08, 2005	M-16 FEB 08, 2005
018662 003	018662 003	ISOTRETINOIN;ACUTANE	PEB NOV 02, 2005					
018662 004	018662 004	ISOTRETINOIN;ACUTANE	PEB NOV 02, 2005					
020966 001	020966 001	KETROLAC TROMEETHAMINE;ACULAIR PRESERVATIVE	M-16 FEB 08, 2005					
020564 003	020564 003	LAMIVUDINE;EBIVIR	D-2 JUN 24, 2005					
020564 001	020564 001	LAMIVUDINE;EBIVIR	5278201 JAN 11, 2011					
021088 001	021088 001	LEUPROLIDE ACETATE;VADUR	OCT 03, 2008					
020837 003	020837 003	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5733950 NOV 08, 2011					
021379 001	021379 001	LEUPROLIDE ACETATE;ELIGARD	NP JUL 24, 2005					
021343 001	021343 001	LEUPROLIDE ACETATE;ELIGARD	503743 FEB 12, 2010					
020406 002	020406 002	LANSPORAZOLE;PREVACID	5599552 FEB 04, 2014					
021343 002	021343 002	LANSPORAZOLE;PREVACID	503743 FEB 12, 2010					
021343 003	021343 003	LEVOPLAQUIN;LEVAGUIN	I-357 APR 08, 2003					
020634 001	020634 001	LEVOPLAQUIN;LEVAGUIN	I-357 APR 08, 2003					
020634 002	020634 002	LEVOPLAQUIN;LEVAGUIN IN DEXTROSE	I-357 APR 08, 2003					
020635 001	020635 001	LEVOPLAQUIN;LEVAGUIN IN DEXTROSE	I-357 APR 08, 2003					
020635 002	020635 002	LEVOPLAQUIN;LEVAGUIN IN DEXTROSE	I-357 APR 08, 2003					
020635 003	020635 003	LEVOPLAQUIN;LEVAGUIN IN DEXTROSE	I-357 APR 08, 2003					
021342 001	021342 001	LEVOCARNITINE;CARNITOR	6429230 JAN 18, 2011					
021342 002	021342 002	LEVOCARNITINE;CARNITOR	633569 JAN 05, 2010					
021342 003	021342 003	LEVOPLOXAQUIN;LEVAGUIN	I-357 APR 08, 2003					
021342 004	021342 004	LEVOPLOXAQUIN;LEVAGUIN	I-357 APR 08, 2003					
021342 005	021342 005	LEVOTHYROXINE SODIUM;LEVO-T	I-357 APR 08, 2003					
021342 006	021342 006	LEVOTHYROXINE SODIUM;LEVO-T	I-357 APR 08, 2003					
021342 007	021342 007	LEVOTHYROXINE SODIUM;LEVO-T	I-357 APR 08, 2003					
021342 008	021342 008	LEVOTH						

APP#/PROD	INGREDIENT NAME; TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXPIRES	CODE	EXCLUS EXPIRES	NUMBER	PATENT AND OTC DRUG PRODUCT		PRESCRIPTION AND EXCLUSIVITY DATA	*PED and PED represent Pediatric Exclusivity
							PATENT	PED		
020386 002	LOSARTAN POTASSIUM; COZART	5153197 OCT 06, 2009	U-3						LOSARTAN POTASSIUM; COZART	
020386 003	LOSARTAN POTASSIUM; COZART	5138069 AUG 11, 2009							LOSARTAN POTASSIUM; COZART	
021249 001	LOVASTATIN; ADVICOR	5608075 MAR 04, 2014							LOVASTATIN; ADVICOR	
021249 002	LOVASTATIN; ADVICOR	5138069*PED FEB 11, 2010							LOVASTATIN; ADVICOR	
021249 003	LOVASTATIN; ADVICOR	6406715 OCT 31, 2017	U-450						LOVASTATIN; ADVICOR	
021316 001	LOVASTATIN; ALTOCOR	6129930 SEP 20, 2013	U-448						LOVASTATIN; ALTOCOR	
021316 002	LOVASTATIN; ALTOCOR	6406715 OCT 31, 2017	U-450						LOVASTATIN; ALTOCOR	
021316 003	LOVASTATIN; ALTOCOR	6129930 SEP 20, 2013	U-448						LOVASTATIN; ALTOCOR	
021316 004	LOVASTATIN; ALTOCOR	6406715 MAR 27, 2017	U-456						LOVASTATIN; ALTOCOR	
019643 001	LOVASTATIN; MEVACOR	6080428 MAY 27, 2017	U-447						LOVASTATIN; MEVACOR	
019643 002	LOVASTATIN; MEVACOR	6406715 OCT 31, 2017	U-450						LOVASTATIN; MEVACOR	
019643 003	LOVASTATIN; MEVACOR	6129930 SEP 20, 2013	U-448						LOVASTATIN; MEVACOR	
019643 004	LOVASTATIN; MEVACOR	6406715 MAR 27, 2017	U-450						LOVASTATIN; MEVACOR	
020652 001	MANGAPODIPIR TRISODIUM; TESLASCAN	4933456 NOV 27, 2011							MANGAPODIPIR TRISODIUM; TESLASCAN	
076175 001	MEFLOQUINE HYDROCHLORIDE; MEFLOQUINE HCl								MEFLOQUINE HYDROCHLORIDE; MEFLOQUINE HCl	
020938 002	MELOXICAM; MOBIC	5916595 MAR 23, 2018	U-456						MELOXICAM; MOBIC	
020922 001	MEGUNITOL; SOLAGE	6080778 DEC 12, 2017	U-456						MEGUNITOL; SOLAGE	
020855 001	MESNA; MESNA	6353029 AUG 24, 2020							MESNA; MESNA	
013217 001	METFORMIN HYDROCHLORIDE; SKELAXIN	6407128 DEC 03, 2021	U-189						METFORMIN HYDROCHLORIDE; SKELAXIN	
020357 001	METFORMIN HYDROCHLORIDE; GLUCOPHAG								METFORMIN HYDROCHLORIDE; GLUCOPHAG	
020357 002	METFORMIN HYDROCHLORIDE; GLUCOPHAG								METFORMIN HYDROCHLORIDE; GLUCOPHAG	
020357 003	METFORMIN HYDROCHLORIDE; GLUCOPHAG								METFORMIN HYDROCHLORIDE; GLUCOPHAG	
020357 004	METFORMIN HYDROCHLORIDE; GLUCOPHAG								METFORMIN HYDROCHLORIDE; GLUCOPHAG	
020357 005	METFORMIN HYDROCHLORIDE; GLUCOPHAG								METFORMIN HYDROCHLORIDE; GLUCOPHAG	
021121 004	METHYLPHENIDATE HYDROCHLORIDE; CONCERTA	4519801 JUL 12, 2002							METHYLPHENIDATE HYDROCHLORIDE; CONCERTA	
021259 001	METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	4612008 SEP 16, 2003	U-372						METHYLPHENIDATE HYDROCHLORIDE; METADATE CD	
021284 002	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	4783337 SEP 16, 2003							METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	
021284 003	METHYLPHENIDATE HYDROCHLORIDE; REMERON	5082668 SEP 16, 2003							METHYLPHENIDATE HYDROCHLORIDE; REMERON	
020415 001	MIRTAZAPINE; REMERON	NP JUN 07, 2005							MIRTAZAPINE; REMERON	
020415 002	MIRTAZAPINE; REMERON	NP JUN 07, 2005							MIRTAZAPINE; REMERON	
020415 003	MIRTAZAPINE; REMERON	NP JUN 07, 2005							MIRTAZAPINE; REMERON	
020415 004	MIRTAZAPINE; REMERON	NP JUN 07, 2005							MIRTAZAPINE; REMERON	
020415 005	MIRTAZAPINE; REMERON	NP JUN 07, 2005							MIRTAZAPINE; REMERON	
020762 001	MOMETAZONE HYDROCHLORATE; NASONE	W M-18 APR 09, 2005							MOMETAZONE HYDROCHLORATE; NASONE	
019297 001	MOMETAZONE HYDROCHLORATE; NOVANTONE	W M-18 APR 09, 2005							MOMETAZONE HYDROCHLORATE; NOVANTONE	
021260 001	MORPHINE SULFATE; AVINZA	NP JUN 17, 2005							MORPHINE SULFATE; AVINZA	
021260 002	MORPHINE SULFATE; AVINZA	NP JUN 17, 2005							MORPHINE SULFATE; AVINZA	
021260 003	MORPHINE SULFATE; AVINZA	NP JUN 17, 2005							MORPHINE SULFATE; AVINZA	
021260 004	MORPHINE SULFATE; AVINZA	NP JUN 17, 2005							MORPHINE SULFATE; AVINZA	
020152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	NP JUN 17, 2005							NEFAZODONE HYDROCHLORIDE; SERZONE	
020152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	NP JUN 17, 2005							NEFAZODONE HYDROCHLORIDE; SERZONE	
>ADD2>										
>ADD2>										

A-10

APP#/PROD NUMBER
 INGREDIENT NAME, TRADE NAME
 PATENT/PED EXCL USE EXPATENTS
 NUMBER EXPATENTS CODE CODES
 EXCLUSUS EXCLUSUS EXCLUSUS
 *PED and PED represent Pediatric Exclusivity
 PATENT AND EXCLUSIVITY DATA
 PRESCRIPTION AND OTC DRUG PRODUCT

PRESCRIPTION AND OTC DRUG PRODUCT							PATENT AND EXCLUSIVITY DATA			*PED and PED represent Pediatrictc Exclusivity							
APPL/PROD	NUMBER	INGREDIENT NAME, TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXCLES	CODE	CODE	EXCLES	EXCLES	NUMBER	INGREDIENT NAME, TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXCLES	CODE	CODE	EXCLES	EXCLES	
020710 001	PAROXETINE HYDROCHLORIDE, PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	5872132	MAY 19, 2015	I-261	MAY 17, 2002	5789449*PED JUN 06, 2009	U-285	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431
020710 002	PAROXETINE HYDROCHLORIDE, PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	5872132	MAY 19, 2015	I-261	MAY 17, 2002	5789449*PED JUN 06, 2009	U-285	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431
020885 001	PAROXETINE HYDROCHLORIDE, PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	5872132	MAY 19, 2015	I-261	MAY 17, 2002	5789449*PED JUN 06, 2009	U-285	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431
020885 002	PAROXETINE HYDROCHLORIDE, PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	5872132	MAY 19, 2015	I-261	MAY 17, 2002	5789449*PED JUN 06, 2009	U-285	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431
020885 003	PAROXETINE HYDROCHLORIDE, PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	5872132	MAY 19, 2015	I-261	MAY 17, 2002	5789449*PED JUN 06, 2009	U-285	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431
020885 004	PAROXETINE HYDROCHLORIDE, PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	5872132	MAY 19, 2015	I-261	MAY 17, 2002	5789449*PED JUN 06, 2009	U-285	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431	6121291*PED SEP 17, 2017	U-431

A-15

PRESCRIPTION AND OTC DRUG PRODUCT							PATENT AND EXCLUSIVITY DATA			*PED and PED represent Pediatrictc Exclusivity							
APPL/PROD	NUMBER	INGREDIENT NAME, TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXCLES	CODE	CODE	EXCLES	EXCLES	NUMBER	INGREDIENT NAME, TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXCLES	CODE	CODE	EXCLES	EXCLES	
020710 001	PAROXETINE HYDROCHLORIDE, PAXIL	4721723	DEC 29, 2006	I-261	MAY 17, 2002	5872132	MAY 19, 2015	I-345	DEC 14, 2004	5900423	MAY 19, 2015	I-345	DEC 14, 2004	5900423	MAY 06, 2009	U-285	PED NOV 17, 2002

A-14

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

A-16

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

A-17

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723 4839177 5422123 5789449 5872132 5900423 6063927 6080759 6121291 6133289 6172233 4721723*PED 4839177*PED 5422123*PED 5789449*PED 5872132*PED 5900423*PED 6063927*PED 6080759*PED 6121291*PED 6133289*PED 6172233*PED 5075445 6423722 6423722*PED 6352998 6352998*PED 6303640 6303640 6303640 4346227 5180589 5030447 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	DEC 29, 2006 JUN 13, 2006 JUN 06, 2012 JAN 06, 2009 MAY 19, 2015 MAY 19, 2015 APR 23, 2019 MAY 19, 2015 MAR 17, 2017 MAY 19, 2015 JAN 15, 2018 JUN 29, 2007 DEC 13, 2006 DEC 06, 2012 JUL 06, 2009 NOV 19, 2015 NOV 19, 2015 OCT 23, 2019 NOV 19, 2015 SEP 17, 2017 NOV 19, 2015 JUL 15, 2018 SEP 24, 2010 JUN 26, 2018 DEC 26, 2018 OCT 26, 2015 APR 26, 2016 AUG 09, 2016 AUG 09, 2016 AUG 09, 2016 OCT 20, 2005 JUL 09, 2008 JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009	I-358 PED	FEB 12, 2005 AUG 12, 2005		
		U-286					
		U-286					
		U-286					
		U-286					
		U-286					
		U-286					
		U-286					
		U-286					
		U-425					
		U-425					
		U-425					
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-335	PED	DEC 09, 2003			
		PED	JUL 18, 2003				
		PED	JUL 18, 2003				
		PED	AUG 10, 2003				
		PED	JUN 18, 2005				
		PED	JUL 18, 2003				
		PED	JUN 18, 2005				
		I-281	JUN 09, 2003				
		I-304	JAN 18, 2003				
		I-287	FEB 10, 2003				
		I-286	JAN 18, 2003				
		D-51	JAN 18, 2003				
		D-70	DEC 18, 2004				
		U-					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227 5030447 5180589 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	OCT 20, 2005 JUL 09, 2008 JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009	U-335	I-286 I-304 I-287 U-335 D-51 D-70 U-335 U-335	PED PED PED PED JUN 09, 2003 JAN 18, 2003 FEB 10, 2003 JAN 18, 2003 JAN 18, 2003 DEC 18, 2004 DEC 09, 2003 JUL 18, 2003	JUN 18, 2005 JUL 18, 2003 JUN 18, 2005 JUN 18, 2005 JAN 18, 2003 AUG 10, 2003 JUN 18, 2005 JUL 18, 2003 JUN 18, 2005 JUL 18, 2003 JUL 18, 2003 JUN 18, 2005 JUN 18, 2005 DEC 18, 2004 DEC 18, 2004 JUN 18, 2005 JUN 09, 2003 DEC 09, 2003 JAN 18, 2003 JUL 18, 2003 JAN 18, 2003 JUL 18, 2003 I-286 I-287 I-287 I-304	PED PED PED PED PED PED PED PED PED PED PED PED PED PED NS D-70 PED U-335 I-281 D-51 U-335 I-286 I-287 I-287 I-304
019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227 5030447 5180589 5622985 4346227*PED 5180589*PED 5622985*PED 5030447*PED	OCT 20, 2005 JUL 09, 2008 JUL 09, 2008 APR 22, 2014 APR 20, 2006 JAN 09, 2009 OCT 22, 2014 JAN 09, 2009	U-335	PED D-70 PED U-335 I-281 D-51 U-335 I-286 I-287 I-287 I-304	JUN 18, 2005 DEC 18, 2004 JUN 18, 2005 JUN 18, 2005 JUN 09, 2003 JAN 18, 2003 DEC 09, 2003 JAN 18, 2003 JUL 18, 2003 JUL 18, 2003 FEB 10, 2003 AUG 10, 2003 JAN 18, 2003 JUL 18, 2003 DEC 18, 2004 DEC 18, 2004 JUN 18, 2005 JUN 09, 2003 DEC 09, 2003 JAN 18, 2003 JUL 18, 2003 JAN 18, 2003 JUL 18, 2003 I-286 I-287 I-287 I-304	JUL 18, 2003 JUL 18, 2003	
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949 4743450 5684016 5747504 4344949*PED 4743450*PED 5684016*PED 5747504*PED 4344949 4743450	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005 APR 03, 2003 AUG 24, 2007 MAY 04, 2015 OCT 10, 2005 OCT 03, 2002 FEB 24, 2007	U-3	U-210 U-210 U-210 U-210 U-3 U-210 U-210 U-210 U-210 U-3	U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210	U-3	
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949 4743450 5684016 5747504 4344949*PED 4743450*PED 5684016*PED 5747504*PED 4344949 4743450	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005 APR 03, 2003 AUG 24, 2007 MAY 04, 2015 OCT 10, 2005 OCT 03, 2002 FEB 24, 2007	U-3	U-210 U-210 U-210 U-210 U-3 U-210 U-210 U-210 U-210 	U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210	U-3	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL CODE	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949 4743450 5684016 5747504 4344949*PED 4743450*PED 5684016*PED 5747504*PED 4344949 4743450	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005 APR 03, 2003 AUG 24, 2007 MAY 04, 2015 OCT 10, 2005 OCT 03, 2002 FEB 24, 2007	U-3	U-210 U-210 U-210 U-210 U-3 U-210 U-210 U-210 U-210 U-3	U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210	U-3
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949 4743450 5684016 5747504 4344949*PED 4743450*PED 5684016*PED 5747504*PED 4344949 4743450	OCT 03, 2002 FEB 24, 2007 NOV 04, 2014 APR 10, 2005 APR 03, 2003 AUG 24, 2007 MAY 04, 2015 OCT 10, 2005 OCT 03, 2002 FEB 24, 2007	U-3	U-210 U-210 U-210 U-210 U-3 U-210 U-210 U-210 U-210 U-3	U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210 U-210	U-3
020973 001	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U-385	NCE	AUG 19, 2004	
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5045552	SEP 03, 2008	U-385	I-346	FEB 12, 2005	
020903 001	RIBAVIRIN;REBETOL	4418068	APR 03, 2003	6177074	NOV 01, 2016	U-454	
020599 001	RILUZOLE;RILUTEK	6177074*PED	MAY 01, 2017	5527814	JUN 18, 2013	U-454	
>ADD>	020835 003 RISEDRONATE SODIUM;ACTONEL	5994329 6015801	JUL 17, 2018 JUL 17, 2018	U-353 U-353	NCE I-292	MAR 27, 2003 APR 14, 2003	
>ADD>	020272 001 RISPERIDONE;RISPERDAL	5298520	JUN 29, 2012	5298520	I-291	APR 14, 2003	
>ADD>	020272 002 RISPERIDONE;RISPERDAL	5298520	JUN 29, 2012	5298520	D-73	MAY 17, 2005	
>ADD>	020272 003 RISPERIDONE;RISPERDAL	5298520	JUN 29, 2012	5298520	D-74	MAY 17, 2005	
>ADD>	020272 004 RISPERIDONE;RISPERDAL	5298520	JUN 29, 2012	5298520	M-15	MAR 03, 2005	
>ADD>	020272 005 RISPERIDONE;RISPERDAL	5298520	JUN 29, 2012	5298520	M-15	MAR 03, 2005	
>ADD>	020272 007 RISPERIDONE;RISPERDAL	5298520	JUN 29, 2012	5298520	M-15	MAR 03, 2005	
>ADD>	020272 008 RISPERIDONE;RISPERDAL	5298520	JUN 29, 2012	5298520	M-15	MAR 03, 2005	
>ADD>	020588 001 RISPERIDONE;RISPERDAL	5691374	MAY 18, 2015	5691374	M-15	MAR 03, 2005	
>ADD>	020864 001 RIZATRIPTAN BENZOATE;MAXALT	5691374	MAY 18, 2015	5691374	M-15	MAR 03, 2005	
>ADD>	020864 002 RIZATRIPTAN BENZOATE;MAXALT	5691374	MAY 18, 2015	5691374	M-15	MAR 03, 2005	
>ADD>	020865 001 RIZATRIPTAN BENZOATE;MAXALT-MLT	5691374	MAY 18, 2015	5691374	M-15	MAR 03, 2005	
>ADD>	020865 002 RIZATRIPTAN BENZOATE;MAXALT-MLT	5691374	MAY 18, 2015	5691374	M-15	MAR 03, 2005	
>ADD>	021042 001 ROFECOXIB;VIOXX	5691374	MAY 18, 2015	5691374	M-15	MAR 03, 2005	
>ADD>	021042 002 ROFECOXIB;VIOXX	6063811	MAY 06, 2017	6063811	I-353	APR 11, 2005	
>ADD>	021042 003 ROFECOXIB;VIOXX	6063811	MAY 06, 2017	6063811	I-353	APR 11, 2005	
>ADD>		5691374	MAY 18, 2015	5691374	I-353	APR 11, 2005	
>ADD>		6063811	MAY 06, 2017	6063811	I-353	APR 11, 2005	

Prescription AND OTC Drug Product									
PATENT AND EXCLUSIVITY DATA									
*PED and PED represent Pediatrictic Exclusivity									
APP/PROD	INGREDIENT NAME; TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXPIRES	CODE	CODE	EXCLUS	EXCLUS EXPIRES	CODE	CODE
NUMBER									
021209 001	SECRETIN; SECRELLO	6008228	JUN 06, 2015						
021209 002	SERTRALINE HYDROCHLORIDE;ZOLOPT	5789449	JAN 06, 2009	U-460 I-355	MAY 16, 2005	U-461			
021209 003	SERTRALINE HYDROCHLORIDE;ZOLOPT	5744501	JAN 06, 2009	U-460 I-355	MAY 16, 2005	U-461			
021209 004	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 005	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 006	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED JUN 30, 2006	U-12					
021209 007	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518*	PED JUN 30, 2006	U-12					
020828 001	SACQUINAVIR;PORTVASE	6352717	NOV 16, 2019	I-348	MAR 22, 2005				
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007				
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007				
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007				
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007				
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007				
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007				
020658 008	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007	4452808	DEC 07, 2007				
021052 001	ROFECOXIB;VIOMAX	5691374	MAY 18, 2015	I-353	APR 11, 2005	U-266			
021052 002	ROFECOXIB;VIOMAX	6063811	MAY 06, 2017	U-266	I-353 APR 11, 2005	U-266			
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	6063811	MAY 06, 2017	U-266	I-353 APR 11, 2005	U-266			
021052 002	ROFECOXIB;VIOMAX	5691374	MAY 06, 2017	U-266	I-353 APR 11, 2005	U-266			
021052 003	ROFECOXIB;VIOMAX	5691374	MAY 06, 2017	U-266	I-353 APR 11, 2005	U-266			
021052 004	ROFECOXIB;VIOMAX	5691374	MAY 06, 2017	U-266	I-353 APR 11, 2005	U-266			
021052 005	ROFECOXIB;VIOMAX	5691374	MAY 06, 2017	U-266	I-353 APR 11, 2005	U-266			
021209 001	SERTRALINE HYDROCHLORIDE;ZOLOPT	5789449	JAN 06, 2009	U-460 I-355	MAY 16, 2005	U-461			
021209 002	SERTRALINE HYDROCHLORIDE;ZOLOPT	5744501	JAN 06, 2009	U-460 I-355	MAY 16, 2005	U-461			
021209 003	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 004	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 005	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 006	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518*	PED JUN 30, 2006	U-12					
021209 007	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 008	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 009	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 010	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518*	PED JUN 30, 2006	U-12					
021209 011	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 012	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 013	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 014	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 015	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 016	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 017	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 018	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 019	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 020	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 021	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 022	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 023	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 024	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 025	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 026	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 027	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 028	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 029	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 030	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 031	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 032	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 033	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 034	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 035	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 036	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 037	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 038	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 039	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 040	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 041	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 042	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 043	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 044	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 045	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 046	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 047	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 048	SERTRALINE HYDROCHLORIDE;ZOLOPT	4536518	DEC 30, 2005	U-12					
021209 049	SERTRALINE HYDROCHLORIDE;ZOLOPT	5248699*	PED FEB 13, 2013	U-12					
021209 050									

APP#/PROD	INGREDIENT NAME; TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXCLES	CODE	CODE	EXPIRES	NUMBER
*PED and PED represent Pediatric Exclusivity							
021272 002	TREPROSТИNIL SODIUM;REMODULIN	5153222 OCT 06, 2009	U-455 NCE ODE	MAY 21, 2009	OCT 06, 2009	U-455 NCE ODE	5153222
021272 003	TREPROSТИNIL SODIUM;REMODULIN	5153222 OCT 06, 2009	U-455 NCE ODE	MAY 21, 2009	OCT 06, 2009	U-455 NCE ODE	5153222
021289 001	VALPOLITROPIN;RAVELLE	4957924 JUN 23, 2009	NP	MAY 06, 2005	JUN 23, 2009	NP	4957924
020550 001	VAMILCYCLOVIR HYDROCHLORIDE;VALTREX	6107302 JAN 19, 2016	5879706 JAN 19, 2016	JUN 23, 2009	6107302 JAN 19, 2016	5879706 JAN 19, 2016	4957924
020550 002	VAMILCYCLOVIR HYDROCHLORIDE;VALTREX	5879706 JAN 19, 2016	5879706 JAN 19, 2016	JUN 23, 2009	5879706 JAN 19, 2016	5879706 JAN 19, 2016	6107302
021283 001	VAMILSARTAN;DIOVAN	4957924 JUN 23, 2009	5879706 JAN 19, 2016	NP	5879706 JAN 19, 2016	4957924 JUN 23, 2009	4957924
020665 002	VAMILSARTAN;DIOVAN	5633272 FEB 13, 2015	5633272 FEB 13, 2015	U-462	5633272 FEB 13, 2015	5633272 FEB 13, 2015	5633272
021341 002	VAMILDECOXB1;BEXTRA	5633272 FEB 13, 2015	5633272 FEB 13, 2015	U-462	5633272 FEB 13, 2015	5633272 FEB 13, 2015	5633272
>ADD>	021283 003	VAMILSARTAN;DIOVAN	6294197 JUN 18, 2017	U-3 I-365 AUG 14, 2005	6294197 JUN 18, 2017	U-3 I-365 AUG 14, 2005	6294197
>ADD>	020665 001	VAMILSARTAN;DIOVAN	6294197 JUN 18, 2017	U-3 I-365 AUG 14, 2005	6294197 JUN 18, 2017	U-3 I-365 AUG 14, 2005	6294197
>ADD>	021283 002	VAMILSARTAN;DIOVAN	5399578 MAR 21, 2017	I-365 AUG 14, 2005	5399578 MAR 21, 2017	I-365 AUG 14, 2005	5399578
>ADD>	020699 001	VENIPAPAXINE HYDROCHLORIDE;EFFEXOR XR	6419958 MAR 20, 2017	U-459	6419958 MAR 20, 2017	U-459	6419958
>ADD>	020699 002	VENIPAPAXINE HYDROCHLORIDE;EFFEXOR XR	6403120 MAR 20, 2017	U-459	6403120 MAR 20, 2017	U-459	6403120
>ADD>	020699 003	VENIPAPAXINE HYDROCHLORIDE;EFFEXOR XR	6419958 MAR 20, 2017	U-459	6419958 MAR 20, 2017	U-459	6419958
>ADD>	021119 001	VERTEPORFIN;VISUDYNE	4883790 JAN 20, 2007	U-459	4883790 JAN 20, 2007	U-459	4883790
>ADD>	020388 001	VINORELBINE TARTRATE;NAVELINE	4307100 JUL 08, 2002	2002	4307100 JUL 08, 2002	2002	4307100
>ADD>	021119 004	VENIPAPAXINE HYDROCHLORIDE;EFFEXOR XR	6403120 MAR 20, 2017	U-459	6403120 MAR 20, 2017	U-459	6403120
>ADD>	020699 004	VENIPAPAXINE HYDROCHLORIDE;EFFEXOR XR	6419958 MAR 20, 2017	U-459	6419958 MAR 20, 2017	U-459	6419958
>ADD>	021119 002	VERTEPORFIN;VISUDYNE	4883790 JAN 20, 2007	U-459	4883790 JAN 20, 2007	U-459	4883790
>ADD>	020388 004	VINORELBINE TARTRATE;NAVELINE	4307100 JUL 08, 2002	2002	4307100 JUL 08, 2002	2002	4307100
>ADD>	021266 001	VORICONAZOLE;VFLNZA	NCE MAY 24, 2007	2007	NCE MAY 24, 2007	2007	NCE
>ADD>	021266 002	VORICONAZOLE;VFEND	NCE MAY 24, 2007	2007	NCE MAY 24, 2007	2007	NCE
>ADD>	021267 001	ZANAMIVIR;RELenza	NCE MAY 24, 2007	2007	NCE MAY 24, 2007	2007	NCE
>ADD>	020919 001	ZIPRASTIDONE MESYLATE;GEODON	NCE FEB 05, 2006	2006	NCE FEB 05, 2006	2006	NCE
>ADD>	020825 001	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE JUN 21, 2005	2005	NCE JUN 21, 2005	2005	NCE
>ADD>	020825 002	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE MAY 27, 2019	2019	NCE MAY 27, 2019	2019	NCE
>ADD>	020825 003	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE MAY 27, 2019	2019	NCE MAY 27, 2019	2019	NCE
>ADD>	020825 004	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE APR 01, 2017	2017	NCE APR 01, 2017	2017	NCE
>ADD>	020825 001	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE MAR 02, 2007	2007	NCE MAR 02, 2007	2007	NCE
>ADD>	020825 002	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE MAR 26, 2007	2007	NCE MAR 26, 2007	2007	NCE
>ADD>	020825 003	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE APR 27, 2019	2019	NCE APR 27, 2019	2019	NCE
>ADD>	020825 004	ZIPRASTIDONE HYDROCHLORIDE;GEODON	NCE MAY 27, 2019	2019	NCE MAY 27, 2019	2019	NCE
>ADD>	021223 001	ZOLEDRONIC ACID;ZOMETA	NCE NOV 14, 2012	2012	NCE NOV 14, 2012	2012	NCE
>ADD>	021231 001	ZOMETRIPtan;ZOMIG-ZMT	NCE NOV 25, 2002	2002	NCE NOV 25, 2002	2002	NCE
>ADD>	020789 001	ZONISAMIDE;ZONERGAN	NCE U-438	2002	NCE U-438	2002	NCE

APP#/PROD	INGREDIENT NAME; TRADE NAME	PATENT/PED EXCL USE	EXCLUS EXCLES	CODE	CODE	EXPIRES	NUMBER
*PED and PED represent Pediatric Exclusivity							
021272 002	TREPROSТИNIL SODIUM;REMODULIN	5153222 OCT 06, 2009	U-455 NCE ODE	MAJ 21, 2009	OCT 06, 2009	U-455 NCE ODE	5153222

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 22ND EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

- W** EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.3 OF SUPPLEMENT WAIVED EXCLUSIVITY

REFERENCES NEW DOSING SCHEDULE

- D-71 EIGHT WEEK DOSING REGIMEN
- D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
- D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)

NEW INDICATION

- I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
- I-349 ACUTE CORONARY SYNDROME
- I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
- I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
- I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
- I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
- I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
- I-355 PREMENSTRUAL DYSPHORIC DISORDER
- I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
- I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
- I-358 TREATMENT OF PANIC DISORDER
- I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
- I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE

- I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
- I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
- I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
- I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
- I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

MISCELLANEOUS EXCLUSIVITY CODES

- M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
- M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
- M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
- M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
- M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
- M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME

PATENT USE CODES

- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY
- U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
- U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE
- U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
- U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
- U-444 METHOD OF TREATING
- U-445 USE AS AN ANTIMYCOTIC AGENT
- U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
- U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
- U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
- U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
- U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
- U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
- U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
- U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
- U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
- U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
- U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
- U-458 METHOD OF USE OF IMAGENT

- U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
 - U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
 - U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
-
- U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
 - U-463 VENOGRAPHY
 - U-464 PERIPHERAL ARTERIOGRAPHY
 - U-465 CT IMAGING OF THE HEAD

New 22nd Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

22nd EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code

* 8392

**Charge your order.
It's easy!**



Yes, enter my subscription as follows:

Subscriptions of APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, ADP, and the monthly Cumulative Supplements, for \$105.00 per year.

The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change.
International customers please add 40%.

For privacy protection, check the box below:

Do not make my name available to other mailers.

Please choose method of payment:

Check payable to Superintendent of Documents
 GPO Deposit Account 11111111-1

VISA or MasterCard

1111111111111111

Company or personal name

Additional address/attention line

Street address

City, State, ZIP Code

(_____) Daytime phone including area code

Purchase Order No. (optional)

(Credit card expiration date)

(Authorizing Signature)

Thank you for your order!

(10/01)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954

To FAX your charge order, call (202) 512-2250.

To charge your subscription call (202) 512-1800.

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90039 1216

RM301.45 .A66 2002 Aug. suppl.

Approved drug products with
therapeutic equivalence
C:355661 M:174736 O:12937927

Library Use Only

LIBRARY

ST. LOUIS COLLEGE OF PHARMACY
4588 PARKVIEW PL.
ST. LOUIS, MO. 63110

